{
    "0aac921d-b930-4a9f-9f90-507374f67828": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in NCT02953860 receive more mg of Enzalutamide than Fulvestrant over the course of the study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "e523e906-8df2-4e85-9fa2-7d44040a1318": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in NCT02953860 receive less mg of Enzalutamide than Fulvestrant on a weekly basis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "dd7ea690-88e7-4f64-bdd9-44203bffc673": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in NCT01830933 do not receive any extra medication for the study, whereas in NCT01224678 they are given an oral medication.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "f0e1981f-3863-4387-b2df-50ec395ff7bc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in NCT01830933 and NCT01224678 are administered daily oral medication.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "e3ebe653-1692-4107-a6ce-5ba91347a021": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of NCT01224678 resulted in a lower percentage in Mammographic Density than intervention 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "b7af90cd-02e4-4580-a4dc-112feee6cd2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of NCT01224678 resulted in a lower percentage in tumor diameter than intervention 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "44ded43e-6653-4dac-92de-0efa60572c07": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "NCT03283553 and NCT01646346 do not use topical medications in their studies.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "52e97d06-6844-4529-a182-4ec9cc74ab73": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "NCT03283553 and NCT01646346 both use irradiation techniques in their studies.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5cdf894f-284c-41e0-9279-1e7c57d26bbe": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Statement": "NCT03283553 has two cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0554f48f-1f40-4f3c-90af-c089369a0921": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Secondary_id": "NCT02679755",
        "Statement": "NCT03283553 and NCT03283553 have a different number of cohorts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3e743213-38d0-4d84-bb41-591e1fe8b7ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "Every patient in the Palbociclib+Letrozole Australia Cohort of NCT02679755 experienced Treatment-Emergent Adverse Events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            14,
            15,
            16,
            17,
            8,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e7747d41-e7f2-4188-a9ea-703ef424901c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "More patients in the Palbociclib+Letrozole Australia Cohort of NCT02679755 experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            8,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "1ea004ba-6e38-4784-9df5-4b76ea04d36f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in NCT01325207 and NCT02429427 experienced a variety of cardiac problems. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "50166cde-8249-4504-8b55-667f358207b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in NCT01325207 and NCT02429427 experienced serious eye disorders.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "33bda260-15a8-4e13-8652-cbb3fbba2ee4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50 x 109/l are not eligible for NCT02429427",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "d22e9d15-40e8-4342-aec2-7704d8b84646": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50,0000 x 109/l are not eligible for NCT02429427",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "17804c3d-3a64-47b5-aff3-a55de177d84c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "NCT01432886 is testing for the DLT of its interventions, whereas NCT02336737 is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "b37365e7-d3df-4a69-949b-59d4dbae5cc5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "NCT01432886 is testing for the DLT of its interventions, whereas NCT02336737 is evaluating the dose limiting toxicity for SentiMag and SiennaXP. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3c8e98ec-20c0-45c2-86cd-defcb9479dcd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "None of the patients in either cohort of NCT01432886 experienced DLT.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "4c17068b-c2dd-4dbb-8fa5-0ff1085d0e76": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "One of the patients in cohort 2 of NCT01432886 experienced neutropenia persisting for more than 7 days.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "f1bc5ac7-a3d0-4594-9d53-7e5132882913": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "11 patients in NCT03165955 suffer from a liver disease, 0 in NCT00912340.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "eb85cc52-e096-4e7e-abb8-7eec2cbb8462": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "2 patients in NCT03165955 suffer from DVT, 0 in NCT00912340.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3edfe22b-e1de-41c4-b382-1e7f4baad099": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "More patients in cohort 2 of NCT00912340 suffered from Pleural effusions than in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "2cf20f74-cfbd-402e-ad44-78aefba7dab6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "Less patients in cohort 2 of NCT00912340 had an unusual amount of fluid around the lungs than in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "12349e00-487a-4f36-a701-e4a84f77dd74": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia was the most common adverse event for patients in cohort 1 of NCT01427933.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "153c9ba8-4888-4bb7-90d3-8bf7f8fc9cc7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia affected the majority of patients in cohort 1 of NCT01427933.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "c96c7266-b52d-4626-a07a-e85fab536cb4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 1 of NCT00828074, than in cohort 1 of NCT00810797.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            8
        ]
    },
    "85e97baa-9579-42ef-a71a-652c2b3de936": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 2 of NCT00828074, than in cohort 1 of NCT00810797.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            13,
            21
        ]
    },
    "4e46fb0f-7226-4d6b-a7ec-3012466207c0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher percentage of cohort 1 of NCT00828074 showed signs of fever, compared to cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "adf2f0e7-92b9-40c1-93c4-b499e01aafd9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher number of cohort 2 participants from NCT00828074 experienced fever, compared to cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "2a09758f-505e-4019-ab12-ee5d10f3c4ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in NCT01300351 showed signs of poor liver function.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "90df60ed-a964-4432-a55d-ef7e332700b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in each cohort of NCT01300351 showed signs of poor liver function.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "d7dc3ead-bd42-4a38-9fe0-f9bf115a59db": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "Less than a quarter of participants in NCT01365845 had radiation dermatitis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "58717623-f213-4eb6-a64b-b2fa54dc4cf0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "More than 18 participants in NCT01365845 had radiation dermatitis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "eac406b9-3eea-4608-a4ba-0f7174ab7b9e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "None of the patients in NCT01565499 were recorded as having heart related adverse events, whereas many patients in NCT01234402 experienced several different heart related issues.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "a9749c96-7975-4465-b2f3-544864bd11f3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "Some of the patients in NCT01565499 were recorded as having heart related adverse events, whereas many patients in NCT01234402 experienced several different breathing related issues.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "1f4e5c52-f225-41cb-962c-88f0f75a7271": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "NCT01234402 more than 6 different types of cardiac related adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            13,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "b5bcd9ce-c271-46a2-9208-e65a8067714a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "NCT01234402 at least 8 different types of cardiac related adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            13,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "c6ba6991-7e38-4025-a13a-47d8e340fcff": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Statement": "57% of patients in cohort 1 of NCT00723125 had Pathological Complete Response Rates at Surgery.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "fae7bef5-0e47-4d53-8142-f4c4b68dc2dc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Secondary_id": "NCT00617942",
        "Statement": "57% of patients in cohort 1 of NCT00723125 had Pathological Complete Response Rates at Surgery, compared to 60% in cohort 1 of NCT00617942.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1765e523-eb49-41a3-a970-ab55a30ebd18": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "NCT00617942 had a lower total percentage of patients experiencing adverse events compared to NCT00388726.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "4450f58e-1193-422c-a9cb-09effe71c805": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "NCT00388726 had a lower total number of patients experiencing adverse events compared to NCT00617942.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "37abbec9-0580-4450-af22-b1589d4d1d51": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for NCT00388726.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11,
            12,
            13
        ]
    },
    "7d95fbb7-8273-416b-b41b-06ad5191651f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for NCT00388726.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            11,
            12,
            13
        ]
    },
    "c93580b7-da5e-4ffb-a21b-c847f814f89e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients over 6 months pregnant cannot take part in either NCT00193180 or NCT00570323",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            8,
            18
        ]
    },
    "9adb3813-993b-4c85-897b-0138ae330d24": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients with a womb cannot take part in either NCT00193180 or NCT00570323.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "4d4ef1b5-127b-474c-bd56-d590ac56267c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from Cirrhosis cannot take part in NCT00193180.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            8,
            16
        ]
    },
    "5352f5f2-9cad-42dd-96ac-b9141ddeee9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for NCT00193180.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            8,
            16
        ]
    },
    "ffa537c8-bd14-4b5a-a017-46bf518ea821": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with a positive FISH result are eligible for NCT00392392, but not for NCT00971737.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "9444b625-d96f-4afe-84a4-27f6b950975e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with tumors overexpressing HER-2 are eligible for NCT00392392, but not for NCT00971737.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "8dafa80f-c66d-48dd-89d2-2e865d50d6dc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "NCT00392392 records two different types of pain in its adverse events, in the abdomen and chest area, NCT00503906 does not record any types of pain in its participants. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "156e29af-be08-4546-882b-78419f459d15": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "NCT00392392 records two different types of pain in its adverse events, in the cranial and foot area, NCT00503906 does not record any types of pain in its participants. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "6b47d37b-2532-45fc-ba0a-852d4b42a442": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in NCT00503906 where all equally prevalent, whereas in NCT01142661, progression of disease was reported as the most common event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "97130e8d-3f14-42f8-92dd-93617993980f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in NCT00503906 where all equally prevalent, whereas in NCT01142661, alcohol poisoning was reported as the most common event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "794ceb3e-d9bf-41e1-bdc0-7377a380d1bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "NCT01142661 does not accept patients with grade 1 alopecia.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17,
            19
        ]
    },
    "3edcf8c7-3348-485d-8ade-fb995fece900": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "NCT01142661 accepts patients with grade  3 neuropathy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17,
            19
        ]
    },
    "732cbaf2-0999-442a-8a8b-a569e0f5d027": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined  human epidermal growth factor receptor 2 expression cannot be accepted by either NCT02244580 or NCT01901146.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "695cc7c7-8bed-4660-a2c3-ef2933de4acf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined estrogen receptor status can be accepted by both NCT02244580 and NCT01901146.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5,
            7
        ]
    },
    "7c975907-8319-4e23-9928-09c9af3740a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of NCT01901146 recorded more instances of Neutropenic fever than Cohort 1 of NCT00209092.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "c284cf89-d7c5-49be-a97b-ce74b5b9c292": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of NCT01901146 recorded the same number of instances of Neutropenic fever as Cohort 1 of NCT00209092.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "2a4fc547-804c-4313-ba38-068a15f6d806": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for NCT00209092, but not for NCT00631852.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "26f62dfd-5aca-42d1-9d5c-3bba614b5f99": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a Histologically confirmed breast cancer would be accepted for NCT00209092 and NCT00631852.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3fa4aa52-2aa9-4d65-a049-2463fb34c9ff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Statement": "Patients with hemophilia are excluded from NCT00631852.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            19
        ]
    },
    "65477d00-f4ac-4279-b3a6-2068a3ed5959": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Secondary_id": "NCT00193037",
        "Statement": "Patients may be forced to take part in NCT00193037 and NCT00631852, even against their consent, as long as it is in their best interests.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ],
        "Secondary_evidence_index": [
            0,
            9
        ]
    },
    "aed11fa0-0a3c-4a69-9720-c4b336b8d35d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "None of the patients in Cohort 1 of NCT00193037 suffered from Hypotension.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "3ce8051e-19db-4658-8cfd-bfe0268102cf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "10 of the patients in Cohort 1 of NCT00193037 suffered from Hypotension.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "521e564c-eba3-4e10-8fe0-d340b6973f23": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "NCT00244933 does not monitor the occurrence of Hemoglobin C Disease in its adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "f5b0bc6a-7558-480a-983d-387c744f7497": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "NCT00244933 monitors the occurrence of anemia in its adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1b53e336-271d-41b8-b6c7-8f1357a9e092": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in NCT00924352 had abnormally low red blood cells, white blood cells, and platelets.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ]
    },
    "03c2caa8-0361-463e-9a1a-97edd62c43ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in NCT00924352 had abnormally low levels of AST, ALT and ANC.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1005c2a6-c3c2-45bc-bf27-dee992fc8045": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in NCT00382018 and NCT03012477, only a single one suffered from sepsis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "5acc2e2e-30aa-4b2b-a48f-f327f93839cb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in NCT00382018 and NCT03012477, only 1.56% suffered from sepsis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "eff2f962-2da7-42cc-8116-770b2977ee42": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in NCT03012477 experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "8f37a248-34c0-417c-9068-9a2f158f176f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in NCT03012477 experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "0aa83991-c0ba-4efd-ae03-862e75cf1eed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both NCT00083174 and NCT00190671 was 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "aa2de070-2e8e-4fc1-9438-21998d8e0474": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both NCT00083174 and NCT00190671 was 39.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "4aa40358-6de1-4c2f-8403-3570e8e69431": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In NCT00190671 cohort 2 had more patients with Leukopenia than cohort 1, whereas in NCT00455533 cohort 1 had more than cohort 2. Cohort 2 of NCT00190671 had the highest proportion of patients with leukopenia.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            14,
            19
        ],
        "Secondary_evidence_index": [
            0,
            3,
            12,
            15
        ]
    },
    "36fe281f-d918-4e58-9f70-2c02ae49f964": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In NCT00190671 cohort 2 had more patients with Leukopenia than cohort 1, whereas in NCT00455533 cohort 1 had more than cohort 2. Cohort 1 of NCT00190671 had the highest proportion of patients with leukopenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            14,
            19
        ],
        "Secondary_evidence_index": [
            0,
            3,
            12,
            15
        ]
    },
    "6b5878d7-47a1-4981-b7ca-d22c90488b81": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both NCT00767520 and NCT00455533 there was only one case of sudden and unexpected death, in cohort 1 of NCT00767520.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "0c351290-9f18-427e-8b12-16f7c6300e85": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both NCT00767520 and NCT00455533 there was only one case of pregnancy, in cohort 1 of NCT00767520.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "4d9eb15f-f455-40ec-8f37-f763c993be8a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of NCT00767520 reported the same number of patients vomiting during the trial.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "7c681188-ebe5-4b7f-a221-af2c4a48472f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of NCT00767520 reported the same precentage of patients vomiting during the trial.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            13,
            18
        ]
    },
    "5e1e4c4e-5188-4205-b3cd-2c546cf4c289": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in NCT00107276 had adverse events, in comparison almost 10% patients in cohort 1 of NCT00232505  experienced an adverse event, and more than 30% of those in cohort 2 of NCT00232505 had adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            8,
            9
        ]
    },
    "3a3face6-75a9-49a8-8588-d0bd5bc84aad": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in NCT00107276 had adverse events, in comparison almost 10% patients in cohort 1 of NCT00232505  experienced an adverse event, and less than a 1/3 of those in cohort 2 of NCT00232505 had adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            8,
            9
        ]
    },
    "63c5e013-0d07-4bb1-ae7e-a28706084b8e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were no instances of patients with abnormal heart rates in NCT00232505.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b7a693f9-d6ce-4dde-b80c-a778e711be57": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were 2 instances of patients with Atrial tachycardia in NCT00232505.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "16280bdc-aea0-48c8-883d-6b4293727920": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "No cases of Anaphylaxis occurred in either NCT01234337 or NCT00217672.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7fdf2bef-44c8-4f9f-bb8a-f6affe182149": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "More than 2 cases of Anaphylaxis occurred in either NCT01234337 or NCT00217672.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "d92b2518-5fd1-4246-bf19-7036b08ddab9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "NCT00217672 had a higher occurrence rate of fistula enterovesical than NCT00110084.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "5968c32f-1d06-4048-87c8-2163a691acbe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "NCT00217672 had three times the occurence rate of fistula enterovesical as NCT00110084.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "a5533945-257a-4458-84c2-9a1bd62a2f3e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "NCT00110084 and NCT01961544 both reported cases of sepsis in their patients.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            12
        ]
    },
    "545ba87a-d0fa-4460-971d-f22dea2779aa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "NCT00110084 and NCT01961544 both reported cases of Pseudomonal sepsis in their patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            12
        ]
    },
    "fcc04a37-e06a-4cf4-ab29-0776f0b87ef0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "NCT01961544 reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8,
            9
        ]
    },
    "4eba9574-64c2-4e18-aed4-8ffb14345e1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "NCT01961544 reported a combined total of 3 cases of Pericardial effusion, Asthenia and Gastritis in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            8,
            9
        ]
    },
    "bf9d619d-3443-45f4-9ddc-1edccf525d56": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "One patient in NCT00258960 experienced a grade 4 adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "8bbad562-56eb-403e-81ce-66260c66d4e6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "4 patients in NCT00258960 experienced a grade 3 or above adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "ccc9c496-2346-4efc-8238-644e9d3f9e9e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in NCT02600923.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8,
            9
        ]
    },
    "71c11b3a-128d-42d3-a2f0-8643fb61c070": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Cataracts cannot be included in NCT02600923.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "4731d46e-815f-4db0-83a6-9a0c7affccf7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in NCT01582971, participants must be aware of where they are, and what day it is.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "6555085a-f549-4b5a-8577-fe89a1190b88": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in NCT01582971, participants must have 20/20 vision and a hiistologically confirmed, measurable, invasive breast carcinoma.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "6f05e7c4-38cb-4f46-b1ec-6c2c7cc3362e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are excluded from NCT00635050.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "5c149bbd-2807-41c6-a071-77b7f76e7101": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are included in NCT00635050.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "262dc12b-569d-44fc-8e30-087b40ce84f2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "NCT00618826 and NCT02040857 only record 4 of the same adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            8,
            10,
            5
        ],
        "Secondary_evidence_index": [
            0,
            9,
            3,
            6,
            11
        ]
    },
    "0221a2ca-da78-4204-b227-1d2df387db4d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "NCT00618826 and NCT02040857 only record 2 of the same adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            8,
            10,
            5
        ],
        "Secondary_evidence_index": [
            0,
            9,
            3,
            6,
            11
        ]
    },
    "5a8da078-2ea2-463c-8ff4-3c762df33289": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "All genders are eligible for NCT02040857.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "5f05f874-82c5-4d5d-99a2-e8e1ead8eb3b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "Only men and postmenopausal women are eligible for NCT02040857.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "0152168e-ec04-4aaa-8ad8-274c7acdc260": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T2 N1 M0 breast carcinoma are eligible for NCT03004534.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8
        ]
    },
    "83e468a3-6a58-46a8-8522-eb84a293cdce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T4 N1 M0 breast carcinoma are eligible for NCT03004534.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8
        ]
    },
    "0d143cd0-4231-4716-ad30-21f313922abf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "NCT00266110 and NCT00879086 have entirely different adverse event reports.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "5342c4cd-f2bf-4a25-ac8d-7d108a9309ff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "NCT00266110 had a much higher rate of adverse events than NCT00879086.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "f8f0ad0f-a276-4a9c-aec1-bce9d6f19ef3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of NCT00879086 had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            4,
            5,
            14,
            17,
            18,
            19
        ]
    },
    "56c712c7-72e9-4359-8967-b17b49c0b419": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of NCT00879086 had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 8 more cases of Leukopenia than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            4,
            5,
            14,
            17,
            18,
            19
        ]
    },
    "e4ff608a-23b1-4b88-9261-e1fe944acf0f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with ER-positive tumours are eligible for NCT00721409 but not for NCT02413320.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "f8fdb12f-f812-4cbf-9b0a-7cb7500e7090": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with HER2 negative tumours are eligible for NCT00721409 but not for NCT02413320",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "1799d698-27b7-49eb-910b-461d42e5494d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for NCT02413320.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "a3e08434-1df0-411e-87c9-8b6814570247": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 that have recieved chemotherapy in the last 4 weeks , are eligible for NCT02413320.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "557334b3-65b6-47dc-ac86-b85e1b2df673": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "NCT00087152 recorded less patients with nausea than NCT00203502.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "68092f62-24f6-4ce9-aa65-f6b108992f0e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "NCT00087152 recorded half as many patients vomiting as NCT00203502.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "6ad57bee-fb7b-4dda-8d9d-4e22253c20f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Every single patient in NCT00203502 experienced at least 1 adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "f3e81644-18fa-44bf-b43a-473b0efa6dce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Less than 30% of patients in NCT00203502 experienced at least 1 adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "df2d292c-4a8c-46ae-b576-b61d89a5013f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in both NCT00093145 and NCT00703326.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10
        ]
    },
    "f392b6d5-d4f0-4898-a7ff-96bb2249881b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in NCT00703326, but not  NCT00093145.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10
        ]
    },
    "0054139c-1309-4b17-b8f3-6cb58edb6de7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for NCT00274768 and NCT00703326.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            7,
            8
        ]
    },
    "1ad25b99-5069-4ead-840b-c149a3b988d1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for NCT00274768 and NCT00703326.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            7,
            8
        ]
    },
    "be4300f0-1042-402a-bfe7-8bd61a7d3942": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with stage 4 cancer are eligible for NCT00654836 and NCT00274768.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            2
        ]
    },
    "db17222d-94cd-4423-86f7-e878dbd093ad": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with at most stage 3 cancer are eligible for NCT00654836 and NCT00274768.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61
        ]
    },
    "f5aff83c-f069-412f-abf3-336c3ab2d2ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for NCT00654836.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            5
        ]
    },
    "08d7d871-c27c-4b1c-ae5b-0da6bc478629": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for NCT00654836.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            5
        ]
    },
    "16206999-4c9d-4879-aff5-2e9469210209": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either NCT00662129 or NCT03097653.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            4,
            5,
            6
        ]
    },
    "315444a0-b77e-4755-b3fc-a3557de47d7a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with stable angina cannot be included in either NCT00662129 or NCT03097653.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67,
            68,
            69,
            70,
            71,
            72
        ]
    },
    "b0f98a58-ed1d-46b8-8629-e057fa1ed2d9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00b3, ANC <  1,700/mm\u00b3 and Hemoglobin between 11 to 18 grams per deciliter are eligible for NCT00662129.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18,
            22,
            23,
            24
        ]
    },
    "9aa76a7b-3831-47bd-a53b-985b301407bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00b3, ANC <  1,700/mm\u00b3 and Hemoglobin between 4 to 5 grams per deciliter are eligible for NCT00662129.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            22,
            23,
            24
        ]
    },
    "705e8a81-47ad-4e81-b0a4-40a3734e9e29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T2 N1 M0 adenocarcinoma of the breast are eligible for NCT00005957.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c4aa10aa-67d3-4647-a499-9955b7a5caea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T4 N3 M0 adenocarcinoma of the breast are eligible for NCT00005957.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3be38d10-3515-4762-96f7-1f1d6b1266b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were no cases of Intracranial hemorrhage in NCT02370238.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "8ce59c8e-be8f-4449-bc17-34e002e2517e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were 2 cases of Angina in NCT02370238.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "5d2f36b4-ec0d-4651-a953-a07ed9f7ec54": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "NCT00423917 and NCT00082641 both report cases of confusion in their patient cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "208ef833-2276-4bf1-aadc-016c9b74a5dc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "NCT00423917 and NCT00082641 both report cases of confusion in all their patient cohorts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            15
        ]
    },
    "7dfdb95e-e40e-49f0-b7f0-8ebfc344d132": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in NCT00082641 suffered from impaired mobility.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            14
        ]
    },
    "72e47588-872d-4b40-b999-45dabeee380c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in NCT00082641 suffered from a life threatening bone fracture.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f3307f09-9ee4-49ba-b81a-921b2a6505c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of NCT00075764 is low Hemoglobin levels.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "286367b6-d960-4165-8bf4-6542e0dff9a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of NCT00075764 is Neutropenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "fc78a0d3-9fd6-4fb4-898f-be5a26b477e5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of NCT01269346 and Cohort 1 of NCT01597193 both have less than 30% occurrence of adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3d9b3923-20e6-4790-b05c-bc9f313dd918": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of NCT01269346 and Cohort 1 of NCT01597193  have the same total number of adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "19896375-6270-4672-b56d-724e685c4dac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in NCT01597193.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "239a3c23-6403-4972-a337-cf113e49a4f2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in NCT01597193.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ]
    },
    "04eea2b8-b0fd-4a4c-8052-4fd3e0701734": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in NCT02650193, but can be entered into NCT00656669, as long as they do not have uncontrolled Hypertension.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "7732cdab-bc73-474e-aa08-6ebc327cac39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in NCT02650193, but can be entered into NCT00656669, even if they have uncontrolled Hypertension.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "e9def556-8337-493a-8760-a720548ece4b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "NCT00656669 did not record any adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "b668b570-c37c-42d1-b756-2a836017add6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "NCT00656669 recorded 23 adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "3337ee11-155f-4e73-a35e-6d1740503a3c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for NCT00372424 and NCT00041067.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "bf656171-f972-4f94-8688-1db9d7530ec2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for NCT00372424, but excluded from NCT00041067.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "2b1125ee-435f-46b2-88aa-d4fe48c25b9c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive tumors may be eligible for NCT01273896 or NCT00041067.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            15,
            16,
            17,
            7,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            7,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            7,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42
        ]
    },
    "2b2c91a8-4f7b-41bd-a4a9-bede02275246": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for NCT01273896 or NCT00041067.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42
        ]
    },
    "70197c0f-f679-4686-9a76-568667b3ea19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of NCT01273896.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            8
        ]
    },
    "39bbdb5d-cb29-4747-b2f4-c27c2e75c377": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of NCT01273896.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            8
        ]
    },
    "2900a720-fc43-41d3-aed1-df3ecfc6ad34": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were no cases of Multi-Organ Failure in both cohort 1 of NCT00454805 and cohort 1 of NCT00499122.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "5711683c-bf99-493a-b05c-bd39da2dd9f9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were several cases of Multi-Organ Failure in both cohort 1 of NCT00454805 and cohort 2 of NCT00499122.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e9508d65-98e0-47b1-b184-c83d1bc4f018": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In NCT00454805 there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "e5311c73-b003-4d97-a53a-645548e74e65": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In NCT00454805 there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8,
            14,
            22
        ]
    },
    "d068c98c-1f3a-48a8-a579-bdc4e3484430": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Elizabeth has HER2 positive breast cancer, she is eligible for NCT00033514.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "afb6dc8e-53d8-4987-8df6-fe59e8a58eac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Mark has HER2 positive breast cancer, he is eligible for NCT00033514.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8d54adc2-0a74-428b-bf58-6f146e778436": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable breast cancer, she is eligible for both NCT01644890 and NCT00996632.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f6dcc90d-d6cc-4dcd-a1d6-4e9c53a28a65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable non-metastatic breast cancer, she is eligible for both NCT01644890 and NCT00996632.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f8fc9c8d-8d8d-4606-8dfa-8074c6d9ef58": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout NCT01644890, one patient developed issues with their vision.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "356c5d38-09d7-4e29-bfb9-b1dc1592d797": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout NCT01644890, one patient in cohort 1 developed issues with their vision.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "aefbd0ae-5638-47d9-8f3d-e54378affc80": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 15 patients in cohort 1 of NCT01298193 experienced adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "32218bab-f147-43ec-83ea-aab147109d3e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 20% of  patients in cohort 1 of NCT01298193 experienced adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "29024429-e5f5-4d3a-8807-4863e3dca69f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of NCT00003830 was Anaphylaxis, which affected less than 1% of patients.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "1ae5e65f-e886-419c-a316-d1b47cd9be4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of NCT00003830 was Anaphylaxis, which affected more than 10 patients in total.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e15cbf81-ddb2-467f-be8b-105628824f95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for NCT00009945.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "21ad8303-a37f-4ec8-9187-c833ffe60b53": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for NCT00009945.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "ebaf2dfb-13cf-4ae0-b35a-a3d31bb402c4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for NCT01313039 or NCT01031446, due to potential harm to the nursing infant from the study interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            19
        ]
    },
    "bba17791-e75c-418d-8884-d5a6b513c725": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for NCT01313039 or NCT01031446, due to potential harm to the father from the study interventions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            19
        ]
    },
    "6d9d8753-2973-4516-92cb-a28ddf7c86bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in NCT01031446.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "31c1c410-1a5c-452b-9064-49c4101cd419": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This will not prevent her from participating in NCT01031446.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5
        ]
    },
    "aa35c8c4-420c-469b-970c-495cf594d617": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for NCT00411788 for the next month.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18,
            33
        ]
    },
    "66ffe6cc-957a-450b-9f4a-602b5a9658e8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for NCT00411788 next Tuesday.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            33
        ]
    },
    "02e85abb-03ab-4415-9be1-b3fb9e8c012e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "1 patient in NCT00093808 developed an eating disorder, there were no cases of this happening in NCT01310231.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "b25c5b21-067f-44c6-aaee-0f604aab921a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "19.57% of patients in NCT00093808 developed an eating disorder, there were no cases of this happening in NCT01310231.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "adfcfb1f-0de5-44a3-bff3-f549cb68e650": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "NCT00093808 and NCT00394082 reported the same number of dehydrated patients during the studies.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            11
        ]
    },
    "d4ae3299-7506-4076-9d8d-2225732780b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "NCT00093808 and NCT00394082 reported the same percentage of dehydrated patients during the studies.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            11
        ]
    },
    "4a6f4c69-751e-4bfe-b4e9-3738b0202c93": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "NCT00394082 recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in NCT01033032.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "13046ec7-0516-42d6-9bd1-ab1bbb3d4c3b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "NCT00394082 recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in NCT01033032.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "501bd69c-daf6-48bd-ace9-f62d98d27442": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in NCT01033032 was one single case of pleural effusion.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "93b0e20d-6db4-4f3e-ba56-b1385563050b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in NCT01033032 was one single case of spinal fracture.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "c2fd9257-bcd3-49fa-a06c-4286a69ecd38": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from NCT02878057.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "b64c772e-1064-448d-8a53-9e1e0badaad5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from NCT02878057.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "ac9cefa1-13e2-43b6-9b36-50f8da136f71": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is excluded from NCT00859651.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "28bae50d-1ae1-4be3-97b8-3464a89149e6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 7 years prior, but has been disease-free for 5 years., she is excluded from NCT00859651.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "f01b7476-e615-4240-a3c0-1de8a29a66a7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for NCT02165605",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            3
        ]
    },
    "47ecff94-f8db-4d6f-a8dd-d67adf89c105": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for NCT02165605, due to her age.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3
        ]
    },
    "92bba641-6b98-461d-aaae-d67996427182": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over half a year to participate in NCT03511378.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "36dba932-bede-43af-b556-97ba518c6132": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over a year to participate in NCT03511378.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "9f5d1aeb-3ab6-4d14-abb0-0cb71a2ff5c7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in NCT00432172 occurred in patients from cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "60746db4-49bf-44a0-b2a3-5a5b9852aa2d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in NCT00432172 were cardiac related.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "48244d5c-afcb-41d7-8eb7-2c6eaca0f508": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "NCT00623233 recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in NCT01525589.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "1cecd949-fe23-4f71-92b3-5ce51830af11": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "More patients with a Low Platelet Count where found in NCT00623233 than in NCT01525589.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "453206a5-4941-4a97-83d8-40ec00ff594d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for NCT01525589.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "bdb891bb-3a3d-4af3-8b60-8dddcf8c736d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for NCT01525589.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "f3ec19cd-d9ac-4d9b-be9c-7697ab9e9ce2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for NCT00633750.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            4,
            10
        ]
    },
    "2c4d761c-6cfc-4e97-a13c-126c5cbe22a5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for NCT00633750.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            4,
            10
        ]
    },
    "63553fa8-3d72-4b2a-aae5-1a95ac271f1d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There is only 1 adverse event in NCT02481050 that occurred more than once.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "c4fa4156-c75e-4e81-991b-0a21d910ecde": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There are no adverse events in NCT02481050 that occurred more than once.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "448799fc-dfbd-4ab9-87ad-01dc455a39cb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There was 1 case of night blindness in NCT00066573, and 0 in NCT01091454.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "b207840e-74fb-4a32-8c24-96e3a6ba265f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There were 0 cases of night blindness in NCT00066573, and 1 in NCT01091454.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "2642c463-77a2-4566-b271-0204ca8f26c5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and vomiting in NCT01091454 than NCT00054275.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "e0ebf930-6b5b-4c35-9aa0-b734433a6375": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and Leukopenia in NCT01091454 than NCT00054275.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "3755027b-50c3-4fb7-bafe-adab06f034a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in NCT00054275.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            33,
            35
        ]
    },
    "065e3986-886b-4478-87d0-a14513329048": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in NCT00054275.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            33,
            35
        ]
    },
    "9f0bd7e9-00c7-4c28-88e1-75c972b875c9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from NCT00004092.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ]
    },
    "6636ac8a-c2b0-4504-bb2d-8abde78749b2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in NCT00004092.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ]
    },
    "25e93a98-aed8-497e-9701-43ab17146307": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells in lymph nodes above the collarbone cannot enter NCT00093795.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "a3caa6da-46e0-4847-b8e0-dba7e442cfc5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells that have metastasised into less than 3 lymph nodes, with at least one larger than 2mm, cannot enter NCT00093795.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "006556aa-f0ef-4513-85a4-fd39f6c79e52": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from NCT02010021.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            11
        ]
    },
    "05c2469d-fec7-4059-83b3-321d9af2747d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently had an oophorectomy,they are excluded from NCT02010021.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            11
        ]
    },
    "a07b10b6-7c17-47c9-a040-64de2fe7f86e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of Pneumopathy in either NCT02402764 or NCT00490646.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "ab8882e5-26a8-4cfb-9dee-f0cf457c2eb8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of extravasation in either NCT02402764 or NCT00490646.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "00a61c8e-e5e5-473a-8a35-23a7c9598be9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of NCT00490646 had 25% more patients experiencing adverse events than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "2cbf7a32-cd38-4f9b-b6bd-615eb8b5c927": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of NCT00490646 had 25% more patients experiencing Cholecystitis than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "224cd9e8-3696-45d1-8d72-8c9afd2561ff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of deteriorating mental health in NCT00323479 than NCT03078751.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "704b140f-6afe-4ef8-851c-09cc26116326": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of Pulmonary embolisms in NCT00323479 than NCT03078751.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "0903f799-8ef8-4f03-b1a1-097b553968a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 1 of NCT03078751 reported one case of AML.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "70bb3509-68b5-498f-8f73-f35d8e46cc88": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 2 of NCT03078751 reported one case of AML.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "953d3371-9232-415b-8dcf-dda3a4a2be86": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "NCT01086605 and NCT00570921 do not record any of the same adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "b735cfd6-4b64-4971-b358-0a7b3719788c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "NCT01086605 and NCT00570921 both record cases of Cholecystitis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "83f972b2-63c2-4598-ab7f-4e9f18666e8e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 2 of NCT00274456, but none in cohort 1 of NCT00570921.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            13,
            14,
            15,
            3,
            4,
            5,
            19,
            20,
            21,
            22,
            10,
            11,
            25
        ]
    },
    "7c5574a0-2552-493b-adfc-3c1dcd86ec4d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 1 of NCT00274456, but none in cohort 1 of NCT00570921.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f79c474d-5164-49d7-84a7-6f0e6b6fb723": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 14 cases of neutropenia related adverse events in NCT00274456 across both cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            3,
            4,
            5,
            19,
            20,
            21,
            22,
            10,
            11,
            25
        ]
    },
    "a1b79627-3f3e-43fc-a569-cc27f0513274": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 7 cases of Gastritis in NCT00274456 across both cohorts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            3,
            4,
            5,
            19,
            20,
            21,
            22,
            10,
            11,
            25
        ]
    },
    "ed156586-bf02-4119-baab-c43eea79def8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in NCT02291913 suffered from an inflammation of the esophagus.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "3c6575f7-51db-4be9-bf0d-25e2699d242a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in NCT02291913 suffered from an inflammation of the liver.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "06f5588d-54c9-4535-bf7b-944961d1f225": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Oesophageal adenocarcinoma were recorded in NCT02001974.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "43e8a727-c024-42a4-9851-e7f70ff138b3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Metastasis to the CNS were recorded in NCT02001974.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e870ee9b-7169-436c-ba66-77fba8f49afc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and bone marrow to participate in NCT01617668.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8,
            9,
            10
        ]
    },
    "f8d6954b-4409-4fb7-91d2-df057582f405": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and ovaries to participate in NCT01617668.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "b4e6ae6f-d059-4e6e-bec1-7506f1b35bd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from NCT00675259 but included in NCT01875367.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            15,
            18
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "73fc53c0-e898-4e1f-9c25-c8a0e8df7e8b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from NCT00675259 and NCT01875367.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            15,
            18
        ],
        "Secondary_evidence_index": [
            0,
            15
        ]
    },
    "eeda3b9a-16c8-4b44-a72f-2ed89659e76d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "One patient in NCT01875367 suffered a cerebral infarction.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "fbc6f042-1ebd-48aa-bb78-92933b056c44": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "More than 3 patients in NCT01875367 had a common cold.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "4d963e2a-9248-421d-a308-abcdf68abf16": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed metatases in the CNS are excluded from both NCT00428922 and NCT00630032.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "8941d738-aaab-4adf-895a-fdeb2b9b8ba8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed bone metatases are excluded from both NCT00428922 and NCT00630032.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "6f9ad8f6-906a-4d50-a6dc-fcf7f422d097": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either NCT00428922 or NCT00499083.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            26
        ]
    },
    "ba3eb597-3474-4b37-bab5-f9cb84ea7a74": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either NCT00428922 or NCT00499083.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            26
        ]
    },
    "93d4eb38-f5a3-4bf0-9ac4-a3de547bfd47": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both NCT03045653 and NCT00499083, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            10,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cf44c4ec-75b0-4dee-9cd8-6df8ee535c68": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both NCT03045653 and NCT00499083, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            10,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3e121d07-cb72-4b18-8c31-a1723da95446": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 3 weeks prior, she is not elgible for NCT03045653.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            6
        ]
    },
    "15f99944-99f9-4d13-a36d-0a5fd9f0fc2c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 2 months prior, she is not elgible for NCT03045653.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            6
        ]
    },
    "70d7da3a-7763-4732-88c2-e64d240ba603": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "Neither of the cohorts in NCT00003782 had more than 5% of patients experiencing side effects.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            11,
            12
        ]
    },
    "8e5d1e01-5b41-4d7a-bd52-1f6866a63ba0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "One of the cohorts in NCT00003782 had more than 5% of patients experiencing side effects.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            11,
            12
        ]
    },
    "e36154ce-c35a-4612-839d-2a93d10841b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of NCT00591851.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6,
            7,
            8
        ]
    },
    "35ec37be-211a-4926-b289-0df5717c70c7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different cardiac adverse events recorded in cohort 1 of NCT00591851.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "a8baef9f-a548-4f4b-a978-6ef49b9e33d9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Diarrhea was the most common adverse event in cohort 1 of NCT00820872.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "1f3a33b3-2aef-4c70-89a7-18d86eaf0ad5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Hyperglycemia was the most common adverse event in cohort 1 of NCT00820872.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "a1ffe499-812e-4bb5-b7a6-0832bb853a75": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "NCT00320541 recorded more cardiac related adverse events than NCT01629615.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "83a1ba84-c3c5-4189-bca0-9ddd786f712c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "NCT00320541 recorded more cardiac related adverse events than NCT01629615.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "730dd995-12e2-419b-bf2b-cece43827a0f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of NCT00320541 recorded three times as many cases of Leukopenia as cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            13,
            17
        ]
    },
    "e912ac09-e994-43b8-b49d-9ec471e8f96e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of NCT00320541 recorded 10% more cases of Leukopenia than cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            13,
            17
        ]
    },
    "822e7511-1bd8-4ddb-bbdc-3168a56f647d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "NCT01166763 only recorded three types of adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "74f6f606-072a-40cf-8c10-333515098156": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "NCT01166763 recorded 4 life-threatening adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "69428346-9731-48aa-bf47-788fdcf1db36": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from NCT00553410 as it would prevent prevent prolonged follow-up.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "1cf9904f-a7fe-45de-b7ed-4f33a6c515b4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from NCT00553410 due to her age.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "04c9a107-138b-4788-bd0f-f14d5c92fa39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed  estrogen receptor-positive breast cancer is elgible for both NCT02806544 and NCT00605267.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "557a936e-2c28-4a25-a461-9600b2e03fb5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed PR positive breast cancer is elgible for both NCT02806544 and NCT00605267.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f775a820-d4c0-4336-8186-8b01720e3098": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Men are not eligible for NCT00605267.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d991560b-c975-4a1a-bdd8-466e02ecbe91": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Only men can be eligible for NCT00605267.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "39f41183-9fcc-40e5-9dda-660d7610b32d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "NCT00468585 did not record any skin infections in their patients.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "26b8048c-235b-4a88-b1a3-82d3e29a694d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "NCT00468585 recorded several skin infections in their patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "bd5e77eb-55a8-4285-ae85-bc6a73805c00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "NCT00693719 recorded less than 5 different Adverse Events .",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8561dd19-a189-4014-a729-fd370746d4a1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "NCT00693719 recorded less than 3 different Adverse Events .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "59b7615c-b170-4113-abb3-75c067bba0c8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for NCT00754845.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3
        ]
    },
    "dfed3126-34b3-4c55-9bcc-c5127eebf8a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for NCT00754845.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3
        ]
    },
    "b5f0c803-9b0f-4187-aa2e-982782037a08": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "African American patients are eligible for both NCT02673918 and NCT01042938.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "c425152d-9d28-4356-ba37-46f0bbc3c762": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "Only White and Asian patients are eligible for both NCT02673918 and NCT01042938.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "18e9da2d-b76c-470b-a39e-7d41587caed7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Only patients capable of understanding english are eligible for NCT01042938.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11
        ]
    },
    "87d7de9a-4a0a-4cea-a077-750a7755f5b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Patients must be english to participate in NCT01042938.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "2496c72e-e9ef-4e1b-8b1c-c39e207b9a2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 1 of NCT01671319 fainted.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "986edf2c-745d-4c03-9e02-68918651dacd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 2 of NCT01671319 fainted.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "abe599aa-ee39-48e5-ad83-6e0ec8188f7a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in NCT00871858 was diagnosed with a Clear cell renal cell carcinoma.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "b67fd716-5075-49f3-858d-ece04ac72f4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in cohort 1 of NCT00871858 was diagnosed with a Clear cell renal cell carcinoma.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "fc971741-4539-44af-ad7f-575002bb0a9b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "NCT02366130 and NCT01262027 have entirely different adverse event profiles.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a77d7eb0-5b73-4070-b0c2-372b5fadad4d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "NCT02366130 reported more than 10 times the number of patients experiencing adverse events as NCT01262027 .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "437c3ccc-8fb8-4aba-a16c-c6dd19adca15": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "Less than 5% of patients in NCT01262027 suffered an adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fcbf1f5d-2d74-459d-ae73-f6b598a00887": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "More than 1 patient in NCT01262027 suffered an adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "bdcfcf18-e684-445f-94a5-85065fff174b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A higher number of patients in NCT00965523 suffured from infection compared to those in NCT01463007.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c9f6f8ce-98ec-4e50-a1cf-906b2ef84c3a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A significantly higher proportion of patients in NCT00965523 suffured from infection compared to NCT01463007.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2d8c1fac-e222-4b4e-b6f1-3047509a7add": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in NCT00965523 where Infection and Stomatitis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2d1c678d-b579-4ad7-859a-1206ff14528a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in NCT00965523 where Infection and Stomatitis, affecting a total of 14 patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "83542cf3-ba27-4778-862f-1964db483428": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of NCT00068341 experienced febrile neutropenia than in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "06f2b60e-b46a-48e2-a1b6-a821df7769dd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of NCT00068341 experienced death progressive disease  than in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "e020aaac-a272-4bdd-b88d-11a0b03c5d9b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of NCT00063570 had a platlet deficiency, and none of the patients in cohort 2 were constipated. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "a9542f51-0e4b-48af-9157-4b1c2b5b49fb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of NCT00063570 had a platlet deficiency, and none of the patients in cohort 2 had Pyrexia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "6aad4bde-4a92-40d3-807f-2b20c9476ee0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever exceeding 39\u00b0C are excluded from NCT02018458 but may be included in NCT00895414.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "ff98f605-98ae-466a-bebc-e53593e84e9b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever below thirty eight degrees Celsius may be included in NCT00895414 and NCT02018458.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            25,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "c5694e77-796f-4562-8683-8ecb3d9a315c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Certain drinks are banned for patients undertaking NCT00895414.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "751fc567-2d75-45f0-aca7-8a7a4c0b3533": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Orange juice is banned for patients undertaking NCT00895414.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8
        ]
    },
    "3bb42201-71ef-4bc6-931a-0a18cf90d737": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have AST, ALP and ALT < 1.5 ULN to participate in NCT02988986.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            20
        ]
    },
    "4f337c8e-3543-486d-9bfc-fbb64ab70dc7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have either AST or ALT < 1.5 ULN to participate in NCT02988986.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            20
        ]
    },
    "53fdf8ef-8c66-44d6-a530-babf4b7373c2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with pacemakers or stents may be allowed to participate in NCT00562718 at their physician's discretion.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ]
    },
    "a83bb2a5-b03d-444b-90c2-f2b94e1c1a19": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with breast implants are always excluded from NCT00562718.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ]
    },
    "8c96725d-37ce-43ac-b928-808e3b5eb177": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in NCT02321527.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "bd47dd4c-3a7f-44bc-8bdd-f718ea6555a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of more than 70mm are included in NCT02321527.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "1bd0f68b-f4fa-48a8-89c3-3aeb5d604755": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with significantly elevated blood pressure in cohort 1 of NCT01332630, than in cohort 1 of NCT00121134.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "5ca20e13-507d-47ff-906d-bcb10dad6db4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with hypotension in cohort 1 of NCT01332630, than in cohort 1 of NCT00121134.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "de742956-bbf5-48a6-932a-a37621aa044b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "NCT00121134 requires participants to have undergone PTR.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "9e3c79cb-1d1a-49d4-89b1-dfeafb887b66": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "NCT00121134 requires participants to have a primary tumor > 5cm in longest dimension. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "c9ec01ef-f7f2-416e-8a02-849f263b67fe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with irrational fear of confined spaces are not elligible for NCT01823991.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            19
        ]
    },
    "69d6eed5-d93b-4691-8538-6147c90e7833": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for NCT01823991.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            19
        ]
    },
    "5eaeba64-48a8-46b3-b528-62ae5204e568": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Left ventricular ejection fraction > 50% is required for participation in NCT00331630.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ]
    },
    "b6b3adbf-c4a6-4899-b490-4935dc840e85": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Men with Left ventricular ejection fraction > 50% are excluded from participating in NCT00331630.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            9
        ]
    },
    "f037a8a6-005c-4c60-ba3e-4aef1e611b37": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from NCT02732119.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            14
        ]
    },
    "ef2e154d-f9c1-40c2-81fd-c5e556833fa5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark complained he had a racing heart twice in the last month and he is therefore excluded from NCT02732119.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            14
        ]
    },
    "89b13a33-5d2b-4248-9025-a80e75c8193d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with implantable cardioverter defibrillators are excluded from NCT02635737.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ]
    },
    "39dbf58b-5778-489b-84af-5dcf7e551684": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with ICDs may be eligible for NCT02635737.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ]
    },
    "2a5d3b0d-f7eb-436e-b5e0-8b57f8d6f517": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with non-measurable diseases are only eligible for phase I of NCT01105312.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "4adaab61-c1d4-4313-86d5-689d0d890501": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with measurable diseases are only eligible for phase 2 of NCT01105312.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "dc501679-ad2f-4917-b0a1-1d6bfece550b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "NCT00127205 and NCT01740323 accept patients in the same age range.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16,
            17
        ]
    },
    "b3320eda-8d00-42d0-b725-224830577328": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "NCT00127205 and NCT01740323 only accept 18 year olds.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16,
            17
        ]
    },
    "a2fb4b80-b6cf-4a0e-9f87-fc841c7a0178": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in NCT00127205 suffer from dysfunctions with ventricular contractions than ventricular relaxations.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            17,
            18
        ]
    },
    "4c0c4424-276e-4fed-ad82-6bec3d3c400b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in NCT00127205 suffer from dysfunctions with ventricular contractions than ventricular systole.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            17,
            18
        ]
    },
    "38fb86bc-8c35-4cd4-94d0-9a6949b3c292": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Sam has recently received a liver transplant, he is not eligible for NCT00418028, but is eligible for NCT00293540.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "4c42340a-4a62-49bd-a32b-2d33e66815d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for NCT00418028, but is eligible for NCT00293540.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            10
        ],
        "Secondary_evidence_index": [
            3,
            4
        ]
    },
    "42f13130-433c-4650-9732-a3541f46e9bd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for NCT00293540.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "332f8c27-c053-48b4-a05a-302b2b4bf650": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for NCT00293540, because they do not produce oestrogen.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "043efc5a-0a38-474b-bc18-1fbf5b18d883": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in NCT01276041 suffered from oedema in their limbs, compared to patients in NCT00796978.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "4f206295-4737-492a-b1e9-074394520876": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in cohort 1 of NCT01276041 suffered from oedema in their limbs, compared to patients in cohort 2 of NCT00796978.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "8e262eec-2930-4881-894b-4fe2551dbb1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Statement": "1 patient in NCT01276041 died in an event not associated with a specifc CTCAE term.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "062a0854-4979-4abe-8c91-002980c5ae0b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Secondary_id": "NCT00688909",
        "Statement": "0 patients in NCT01276041 or NCT00688909 died.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "f7098fb5-f80d-4564-87d3-067d5d643bb9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in NCT00688909 and NCT00129376 did not suffer from any of the same adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "9ea8ecf5-e774-49a0-90f5-f2edfdfb3913": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in both NCT00688909 and NCT00129376 suffered from Pulmonary embolisms.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "848b0ea7-4144-4eb3-a25e-486bc26a73a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "A single patient in NCT00129376 experienced a clinically significant inflammation of the back of the throat.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "63704d5f-9c67-4555-87b9-d050cf764362": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "More than 2% of patients in NCT00129376 experienced a clinically significant inflammation of the back of the throat.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "0f4e665c-f5ac-4b69-97d2-dbd27eec127a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Statement": "Women of any age can participate in NCT01783444.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e3cc3dcf-4d74-4144-aa84-3e47602ed0ad": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03136367",
        "Statement": "Women of any age can participate in NCT01783444 or NCT03136367.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "baa2fecd-d262-4e54-b19b-a1db7628cde2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients which have been assigned as female at birth are eligible for NCT00129935 and NCT03136367.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7
        ],
        "Secondary_evidence_index": [
            18,
            38
        ]
    },
    "f35525f6-ff17-46a5-b9c5-5a7fe3b74bbc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients who identify as female are eligible for NCT00129935 and NCT03136367.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7
        ],
        "Secondary_evidence_index": [
            18,
            38
        ]
    },
    "1e7eadbb-0bcc-4350-8778-9d4cb2ced5ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were more cases of embolisms in cohort 2 of NCT00129935 than cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "ed0ee466-f01c-4c0f-86e6-c7140892fa2b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were 80% more cases of embolisms in cohort 2 of NCT00129935 than cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "048d284a-4e75-4005-bcae-52db7a25502c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The overall most frequent adverse event in NCT00930930 was Dehydration.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "30f8993d-849d-45f6-867d-0f1b5884403a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The most frequent adverse event in cohort 1 of NCT00930930 was lymphopenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "0685ec0c-2d37-4eeb-a96b-ad859f3f0fa9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "NCT01989676 only records cardiovasuclar adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "2eeb1181-f015-4bb1-8a84-5d8e86e65c3a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "NCT01989676 only records GI adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "83835835-e54f-4062-b60b-2de723fdd069": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from NCT00821886.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            20,
            33
        ]
    },
    "b9d147ac-6320-4b0a-84f4-fbe5a83ec182": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for NCT00821886.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            20,
            33
        ]
    },
    "ad66f8b0-586e-474e-9231-fbe4392f529d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "HIV+ Patients are excluded from both NCT00458237 and NCT00880464.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            14,
            18
        ],
        "Secondary_evidence_index": [
            12,
            26
        ]
    },
    "373dc849-e47d-4d22-bb85-8c72b4fbe319": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "Patients with AIDS are eligible for both NCT00458237 and NCT00880464.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            14,
            18
        ],
        "Secondary_evidence_index": [
            12,
            26
        ]
    },
    "00e1a365-9a8b-4628-a822-c0fe753a5a67": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have recently undergone External beam radiation therapy are eligible for NCT00458237.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "aab1aa24-adf0-443c-b817-3a715288efcd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for NCT00458237.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            12,
            21
        ]
    },
    "7c730740-419f-4407-849c-d40f319a0114": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with a Karnofsky status of 94% are eligible for NCT00295867.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            16
        ]
    },
    "2f76e6c7-a752-4499-a021-664887563a20": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with an ECOG score between 3-5 are eligible for NCT00295867.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "7e25918c-1d87-493c-86e7-01344cd2dbc7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of NCT00014222 reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded none.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "4026f0bc-9b04-4912-849d-067a6c49b36f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of NCT00014222 reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "6895bc98-925e-43f4-971d-44ba45a57eee": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both NCT00834678 and NCT01593020.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            18
        ],
        "Secondary_evidence_index": [
            23
        ]
    },
    "0c6bed67-b9cb-43b7-b2e6-693e436407c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both NCT00834678 but eligible for NCT01593020.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            18
        ],
        "Secondary_evidence_index": [
            23
        ]
    },
    "d54bf1dd-473e-4d7f-a730-efbba6082e37": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients must have a white blood cell count above 1,500/mm\u00b3 to participate in NCT00834678.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ]
    },
    "f55c5be2-d62b-42ef-8699-7bc7df1cf9d8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients with lymphopenia can participate in NCT00834678.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18
        ]
    },
    "ca0b2201-75a7-4317-abd0-739edf7683ff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her husband for 31 years, she is eligible for NCT02721147.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6
        ]
    },
    "8743badd-98f4-474c-89b8-27b95f50f394": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her boyfriend for 2 months, she is eligible for NCT02721147.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            6
        ]
    },
    "04801ab7-0f79-4038-a7ac-1a742f1eae09": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with both type 1 and 2 Diabetes are not suitable for NCT00723398.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            9
        ]
    },
    "70d721ac-7c0a-4d60-915a-c995eb034f60": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with diabetes insipidusare not suitable for NCT00723398.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1c452f84-1ecd-4b9c-a364-d73e6c9e3a21": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Statement": "All cancer stages are accepted for NCT03190083.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "797d5cce-bf83-439a-8757-c5188dc7c8e4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Secondary_id": "NCT01805089",
        "Statement": "All cancer stages are accepted for NCT03190083 and NCT01805089.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "70ffdfd8-6d81-4f14-8545-486a9c4963e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "Patients with Lactiferous duct carcinomas are eligible for NCT01805089.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "d31e65f1-ad08-4329-979b-f04ca91a9b26": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "pre-menopausal patients with Lactiferous duct carcinomas are eligible for NCT01805089.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3
        ]
    },
    "6cafd542-8f9e-453e-a554-1b2d97d6d59e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 weeks prior are eligible for NCT01073865.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "3a508066-d9a9-4fa3-975d-214890f6c036": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for NCT01073865.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "1a01b82e-a9ee-4621-bca1-cd796baffba7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multi-focal breast cancer cannot be accepted for NCT00945061.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "5171d668-475c-4faa-91f8-9dc11e2c974b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multicentric breast cancer can be accepted for NCT00945061.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "1b6d752d-cbc9-4991-ad05-755a759d1686": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with tumors underexpressing HER2 are excluded from NCT00944047, but may be included in NCT00228943.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "82679cc3-82d5-45bd-aed2-5d1ccb1d23f4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with HER2 positive tumors are excluded from NCT00944047, but may be included in NCT00228943.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "0774e93f-a750-4dbd-9677-6454d196ee99": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically depressed patients are not able to participate in NCT00228943.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9
        ]
    },
    "99c31581-542a-4409-872c-5647bb345d57": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically anxious patients are not able to participate in NCT00228943.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9
        ]
    },
    "95ddd9a3-84af-418a-aff1-a8e971733923": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have cancer that can be felt by touch to be eligible for NCT02550210.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "7d21b575-aeda-443e-aa33-d789db2e8d80": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have ductal carcinoma, that can be felt by touch to be eligible for NCT02550210.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "0341f9f7-b143-4422-abf2-9f9f6bb44391": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "One case of hematolysis was recorded in NCT00265759, none in NCT00866905.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            5,
            6,
            21,
            22,
            23,
            24,
            11,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "816a31f1-a74d-4291-a74f-094ed49d9ac8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "2 cases of hematolysis were recorded in NCT00265759, none in NCT00866905.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            5,
            6,
            21,
            22,
            23,
            24,
            11,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "84f54029-ce4f-451f-ac13-fba93acfe80c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 1% of patients in NCT00866905 became depressed.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "48e2cf3f-10ac-4b83-a963-2ff4aec792c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 2% of patients in NCT00866905 experienced an adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "2266c345-b7d8-4ae5-8ff4-d9f4ee2fa07a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for NCT01790932",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "a42ab7aa-82c7-4597-8dad-65ac13dbe440": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for NCT01790932, if this treatment ended over 5 years prior.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6
        ]
    },
    "449b4226-c0b8-4cdb-a52c-e8ada9fedff4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for NCT01252277.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "05d5483d-2951-4f61-bb66-5c3a066e0642": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for NCT01252277.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "2bd2dd9a-4161-4178-8853-f156e57700c9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike NCT00479674, NCT01252290 does not record any instances of Anemia, Dyspepsia, Nausea or vomiting.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1c25fd69-86b4-4905-a86c-8e2fa13ae6b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike NCT00479674, NCT01252290 does not record any instances of Anemia, Dyspepsia, Nausea or depression.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "5b9953ab-fe73-4929-affd-dafcb97baaa0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been trated with bevacizumab are not eligible for NCT00479674.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            24
        ]
    },
    "7d42f6b7-2db0-4231-bd04-6317e2ac1855": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been trated with bevacizumab are not eligible for NCT00479674, unless they have also received carboplatin 2 weeks prior to study entry.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            22,
            24
        ]
    },
    "0f5921dd-89fb-4b3d-aee6-858c574068f1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 72 year old patient suffering from dementia would be excluded from both NCT01216176 and NCT03624972.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            7
        ],
        "Secondary_evidence_index": [
            56,
            73
        ]
    },
    "2dbea7ce-e4f2-41ab-a8f4-25a0dc963a38": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 56 year old patient presenting occasional memory loss would be excluded from both NCT01216176 and NCT03624972.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            7
        ],
        "Secondary_evidence_index": [
            56,
            73
        ]
    },
    "181bd13d-112f-4aac-903e-150fd87c2843": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the most common adverse event in NCT01216176.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "e178d227-e985-4fd2-95bf-13bb5ce6d692": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the only recorded adverse event in NCT01216176.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f7362496-7c6b-4d2a-9afb-9a544616b434": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy resulting in intolerable paresthesias, are excluded from NCT00629499.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "49a19129-940f-47cf-91c5-004bba4bac8c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from NCT00629499.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            13
        ]
    },
    "e39394a4-35c8-4da1-8484-c688027fb057": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for NCT02027376.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            25
        ]
    },
    "62f4770a-1bba-415a-9633-84d09d5c1d79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for NCT02027376.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            25
        ]
    },
    "de873ff5-872e-4d14-9d73-f5564370dde0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a bilateral mastectomy would be excluded from NCT00334542.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ]
    },
    "75463b3d-df34-4df5-9163-35e4626c3608": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a mastectomy would be excluded from NCT00334542.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ]
    },
    "a6e82cc9-5aa3-457a-b6eb-b42afdc88c60": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "NCT00322348 and NCT00429572 use different metrics to evaluate potential candidates' performance status.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            2
        ]
    },
    "37e5f9e7-ab2d-4382-86e6-7163d7e5e419": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "NCT00322348 and NCT00429572 use ECOG to evaluate potential candidates' performance status.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            2
        ]
    },
    "de31623c-21e6-4742-a43a-800b7edace72": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "pre-menopausal patients are excluded from NCT02455453, but eligible for NCT00429572.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "9f92db16-011d-49e1-9ebf-4cb528d50a9e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "post-menopausal patients are excluded from NCT02455453, but eligible for NCT00429572.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "1a8eab3b-58a1-4003-b574-4fdb117d7acd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 negative, PR and ER positive are eligible for NCT02455453.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ]
    },
    "5ab509be-fffb-44ce-bb05-30a89845d05e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 +, PR and ER -, are eligible for NCT02455453.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10
        ]
    },
    "83f1bbf4-e042-4c47-838e-357940df5e65": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Statement": "Patients with end-stage liver disease are excluded from NCT00429104.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            12
        ]
    },
    "e2ee631f-671b-42fc-93ab-733da9f2254d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Secondary_id": "NCT00878709",
        "Statement": "Patients with end-stage liver disease are excluded from NCT00429104 and NCT00878709.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "a3de3b52-10c6-46a5-9124-15cbd3f893db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "NCT00878709 had a total of 3 patients experiencing pancreas related adverse events, NCT02447003 had 0.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            2,
            17,
            4,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "5ca19dc8-e448-4746-b4e4-b4d2b8e1d59e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "NCT00878709 had a total of 3 patients experiencing Pancreatic Cancer, NCT02447003 had 0.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            2,
            17,
            4,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "d4274439-02de-44fc-a6b7-8997bf5feb49": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "The difference in cohort size between cohort 2 of NCT00917735 and cohort 2 of NCT02447003 makes it impossible to make meaningful comparisons.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "d5c0e2a7-3bba-4af2-8b2a-fe0f253a581e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "It is appropriate to make clinical conclusions comparing cohort 2 of NCT00917735 and cohort 2  NCT02447003, despite the difference in cohort size.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "8174245f-602d-4319-9fa6-18da48f5c03f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of NCT00917735 crashed their motorbike.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "0afd9e76-71d4-40cc-81e5-ef6cc2df12a3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of NCT00917735 died in a motorcycle crash.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "15c77140-0fdb-4cab-bd0f-db97a21bf304": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from NCT01401062.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            8
        ]
    },
    "79be37ab-9ccf-4c5d-8887-05db7b3f5444": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from NCT01401062.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            8
        ]
    },
    "cbecfd96-730b-45ec-960a-45e402d11690": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Sufferers of Systemic lupus erythematosus are excluded from NCT00847171 but may still be eligible for NCT01764022.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            24,
            32
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35
        ]
    },
    "c5ffe1b4-d894-4103-a643-2aa0faad325e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Male patients with Systemic lupus erythematosus are excluded from NCT00847171 but may still be eligible for NCT01764022.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            24,
            32
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35
        ]
    },
    "ccf01586-10ba-4018-890a-0a5b179c3618": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of NCT01764022 recorded 1 incident of thrombocytopenia.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            13
        ]
    },
    "a4696a1b-0253-43ea-937d-e5e8fb38ffe9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of NCT01764022 recorded multiple incidents of thrombocytopenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            13
        ]
    },
    "d511e7b9-61c3-47cc-b11c-0c4126c1422b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "NCT01048099 recorded 2.38% more total adverse events than NCT02502864",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cb77a9c4-6847-4a86-81b1-8cfa09c92bdc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "NCT01048099 recorded 2 more total adverse events than NCT02502864",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8d98a6d9-561e-45b9-90c4-044bc36047e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "NCT02502864 recorded the same number of occurences for every type of adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "4ae2d4db-8703-4cd3-aabe-b28c568094f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "The maximum number of occurences for an adverse event in NCT02502864 was 3.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "fd73c28f-b430-4c26-b718-8be245a89d09": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of NCT01572727 recorded more white blood cell related adversse events than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "0a03f608-a31b-4a17-824b-c9ee694f226b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of NCT01572727 recorded more optical adversse events than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "b75683b0-dd0f-4ebe-96a7-120a5822391f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were 4 different adverse events, for which 0 cases were recorded in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "a3994deb-1906-4053-b52d-53747e5f40a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "575430f3-66c8-4d5b-aadb-802a04a11ba5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of NCT00317603 must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7,
            8
        ]
    },
    "ab6ce2dd-2ade-4835-b947-71971fbf01fa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of NCT00317603 must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            6,
            7,
            8
        ]
    },
    "5ba4d9d5-4b43-45bd-a13c-04d626415a01": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for NCT02694029 are expected to be capable of holding their breath for half a minute.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "3d7ece7b-7db2-45e8-8e18-9138ec4a226b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for NCT02694029 are expected to be capable of holding their breath underwater for 30 seconds.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "70f6fc19-90a0-48d4-aaab-94410dfd0fe2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for NCT01127373.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "b3bf22f1-12b2-43c0-b64e-7d1dd6d2dc79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for NCT01127373.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "455fbb08-a30a-408e-8103-30dca0cf397c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients must have an ECOG score below 3 to participate in NCT00254592.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "b62cc68d-cdb7-416a-897a-f0d02501298b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients needing active supportive care can participate in NCT00254592.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "bb53cc41-ef61-4bac-8c50-92a493ea00bd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of NCT00086957 experienced an adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "152c805a-f250-4b8d-9167-8724d143e8fe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of NCT00086957 experienced Leukopenia and Febrile neutropenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "9ecc3d19-e4d7-4fc8-8dae-330c80961c55": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of NCT00887575 recorded more cases of diarrhea and dyspepsia than cohort 1 of NCT02491892.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8
        ]
    },
    "0528b8b6-f60d-4b09-87cd-8535013e1ac5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of NCT00887575 recorded more cases of diarrhea and dyspepsia than cohort 1 of NCT02491892, this is due to the significant difference in cohort size.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8
        ]
    },
    "bfdde258-9911-4bc8-858a-de5bc926da7b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of NCT01610284 had more than 3x the cohort size of cohort 1 of NCT00887575.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d1001260-6095-4511-a274-0d7e102b2fc8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of NCT01610284 had more than 50x the number of patients as cohort 1 of NCT00887575.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e7ec1847-0d6c-4762-afeb-36265aac53ba": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in NCT01610284 had an abrupt loss of heart function.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "294df8b7-9be1-423a-a3fb-a5083229aa59": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in NCT01610284 had a cardiac related adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "2898f087-09de-479c-beee-20e61c98dc0e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of Leukopenia in NCT00915018 occurred in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "ae23596a-0d91-41d2-9e2b-79dcbafdf661": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of cardiac problems in NCT00915018 occurred in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "83a997a2-bdae-4321-812d-27b873c96353": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for NCT00090857 must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8
        ]
    },
    "6c9e0d99-b357-461e-9537-196377b7bc75": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for NCT00090857 must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8
        ]
    },
    "65503362-004d-4a24-9ddc-3370dedc866a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients with dysphagia cannot participate in NCT01931163, but may be eligible for NCT00676793.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            26
        ]
    },
    "48f3dbb4-d8e2-4f14-bb7d-ee195a3bd0f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients suffering from vomiting are still eligible for both  NCT01931163 and NCT00676793.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            26
        ]
    },
    "d156eeaa-3d3c-44d1-9ae8-90bde168d1c3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of NCT01931163 had High blood sugar, 0% of NCT00274469 patients were recorded as having High blood sugar.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "1f006d14-ca61-4549-a6c7-67496f2d3388": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of NCT01931163 had LACRIMAL DISORDER, 0% of NCT00274469 patients were recorded as having LACRIMAL DISORDER.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "ff783c2d-93db-4051-9102-1d1a4628e5f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No more than 1% of either cohorts of NCT00274469 felt nauseous.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12,
            13,
            25
        ]
    },
    "2b3411df-60ab-4f2d-954b-4313181fa067": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No less than 2 patients from either cohorts of NCT00274469 felt nauseous.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            12,
            13,
            25
        ]
    },
    "ec46afa1-8f40-486f-89f8-be26673aa6fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from NCT00129389, but may still be eligible for NCT00304096.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            30
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53
        ]
    },
    "7ac4fcef-408e-405f-86ff-cff29b518973": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from NCT00129389 and NCT00304096.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            22,
            30
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53
        ]
    },
    "bd6a14a2-8013-4bc5-acbf-7b716a74bd9c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Statement": "A minimum bodyweight of 50kg is required to participate in NCT00304096.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            14
        ]
    },
    "54ced7a4-2f54-4467-a891-f2f822f68372": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Secondary_id": "NCT00876395",
        "Statement": "A minimum bodyweight of 50kg is required to participate in either NCT00304096 or NCT00876395.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "546b614d-15de-49b1-bbf6-e9d529136824": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "Patients suffering from Ulcerative colitis are excluded from NCT00876395.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            15
        ]
    },
    "d73a4cf3-b9a5-4934-bbd7-0d634cbd1672": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Secondary_id": "NCT02287675",
        "Statement": "Men suffering from Ulcerative colitis are excluded from NCT00876395, but eligible for NCT02287675.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7424097d-75dc-4f52-84f8-810e765b70e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is obligatory for entry in NCT02287675.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "f6c82611-9925-41d4-9551-e697f6afca8d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is optional for entry in NCT02287675.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "77dffce1-66d7-475d-b0c9-3256ee7b71b5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was one case of hemorrhaging in NCT02139358, and no recorded cases in NCT02574455.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "f1f565e6-596b-4bbf-abe5-845718611ce7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was 16.67% more cases of hemorrhaging in NCT02139358 than in NCT02574455.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "86b25484-78fa-4362-8ba1-388d65379179": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than a quarter of patients in cohort 1 of NCT02574455 experienced an adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "4b5c00dd-c59d-4dca-aa7e-46b6c0f09835": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than 1/3 patients in cohort 1 of NCT02574455 experienced an adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "c44d0680-7507-44fe-bbd7-3f908b3ac3c6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR equal to or above 1.5 is mandatory for participation in NCT00915603, it is not necessary for NCT02511730.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "517a4e11-ff79-4135-ae78-bfe9cd75cbc2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR of 1.35 is enough for participation in NCT00915603 and NCT02511730.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b6d8dfa2-4cf8-42cb-9f37-9e1a3bd90355": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are eligible for NCT02511730, but excluded from NCT00193206.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "4c57c7ba-56c9-440d-8c1e-7b68550e1cfb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are excluded from NCT00193206 and NCT02511730.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "24fc9ea8-bcc0-4153-ba84-b4241bb62b71": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "NCT00193206 records a total of 7 patients suffering from various infections.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "c8c023a9-ea43-46ce-b243-6eea682cec0a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "NCT00193206 records a total of 7 different types of infections.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1b21712e-22e6-4df5-a540-ac50c95c7fbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of NCT00856492 recorded no deaths and no cases of Enterocolitis infectious.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "c0fb814b-8b5b-40c6-8615-3bb56820a8d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of NCT00856492 recorded no deaths and no cases of Anemia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "7ec328ef-74ce-4ad6-acc7-2c6178ef9e12": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A total of 3 patients in NCT02630693 suffered a life-threatening reaction to an infection.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "25b33037-70dd-4840-8955-38bca77ef8dc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A 30% of patients in NCT02630693 suffered a life-threatening reaction to an infection.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "2e4be17d-0b7e-4b39-9470-11e76bd389d5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 and 2 in NCT00454532 experienced adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "069a5712-ca4d-48bc-aba2-fe08f5f346f2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 in NCT00454532 experienced adverse events, but more than 45% of patients cohort 2 did experience adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "c4f3e806-0e33-46ea-8037-9909bb69f426": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in NCT00546104 suffered from a blood clot blocking their blood vessels.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "e4bec596-5dbc-419d-9075-3528dcfb954f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in NCT00546104 suffered from a blood clot blocking their trachea.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d6136067-b747-45db-b315-a737540a74b1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for NCT03096847, but may be eligible for NCT01840163 as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "145ae57d-4dee-4791-b3d1-8d45bf1c625c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for NCT03096847, but may be eligible for NCT01840163 unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "65de2541-a6b0-4388-a8f4-2277bb8bce5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "NCT01840163 and NCT02005549 do not exclude patients with non-melanoma skin cancer.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "fcac25c9-2876-4364-ab7d-9c0d8569a8f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "NCT01840163 and NCT02005549 do not exclude patients with concurrent systemic antitumor therapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "fcf692d4-bf66-48fe-b61e-f3085e1715c3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with stage 3 Cervical carcinoma are excluded from NCT02005549.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "43d4b7c8-62de-46b0-96bb-5b64728346c8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with Cervical carcinoma in situ are excluded from NCT02005549.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "979d361c-7cfe-4b4e-80ca-f3545abfae71": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast cancer has spread into both the skin and the chest wall are eligible for NCT02748213, but not NCT00290732.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "0bab4ab1-7014-4dfc-8d72-266d87e9438f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast tumour is 0.1 cm across or less are eligible for NCT02748213, but not NCT00290732.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e43f41b0-9729-4ec8-a57c-73f91a441b2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "1 patient, in cohort 1 of NCT02748213 was recorded as having an overactive thyroid gland.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "33e01bb8-f938-4fe4-ba75-ba14d732e45f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "2 patients, in cohort 1 of NCT02748213 was recorded as having an overactive pituitary gland.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "bcf862b3-14ac-40dc-bf84-f76d2b5a78f9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with a QT interval longer than half a second are excluded from NCT00482391.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            29
        ]
    },
    "7b875b5f-e0f2-48aa-b464-8c1dc427e5d0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with No QT prolongation are excluded from NCT00482391.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            29
        ]
    },
    "0cc10975-6b91-46ca-a35b-a76546a18bc5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for NCT01730729, even if they are able to receive intravenous (IV) alimentation.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            24,
            31,
            30
        ]
    },
    "056eeea1-049c-42f3-a44a-595555e7e6af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for NCT01730729, unless they are able to receive intravenous (IV) alimentation.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            24,
            31,
            30
        ]
    },
    "cea9874a-f22f-4eb4-83d1-c17a168cb204": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "NCT02445586 reported more cases of Haematemesis, but NCT00789581 had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "639ad8ba-91b4-4f96-a6fb-3e59942158ff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "NCT02445586 reported more cases of Haematemesis, but NCT00789581 had more cases of Sinus tachycardia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "b0d48b39-128c-4bb1-ab53-ee8c5e5fa7bd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in NCT02445586 experienced adverse events, and there was not a single patient in either cohort of NCT02115984 that did not experience an adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "15122a4f-81ca-4a28-85d5-0036d7dc31da": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in NCT02445586 experienced adverse events, and 100% of patients in NCT02115984 did not experience an adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "dfa30932-1473-46c0-ad0d-c1c2918f65e0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in NCT02115984 experience a Herpes related adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1edcab86-a81c-4a2e-966b-6389549e0e37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in cohort 1 of NCT02115984 experience a Herpes related adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f39d0e66-8fa9-4b00-ba40-8a491444ed8d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only types of adverse events recorded by both NCT00728949 and NCT02301988 is Diarrhoea and various pains .",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "ff8ffd50-fa9d-4a0a-818c-a93731059f4c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only type of adverse event recorded by both NCT00728949 and NCT02301988 is Diarrhoea and Abdominal pain.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "40e645eb-22b6-4083-9901-691a7b66e137": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of NCT00728949 which recorded at least one case.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "e5d9b9ca-ec89-484c-90b1-d1477c39575c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of NCT00728949 which recorded at least three cases.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "6684e757-1d02-467f-a4d9-3fd023dcace4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of NCT00024102 received a Packed red blood cell transfusion.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            18
        ]
    },
    "00ffe537-5d2b-44b0-8c54-04995d1ea817": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of NCT00024102 received a Plasma transfusion.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "d9cc5b0a-7150-4fda-8706-e8cd893c85fe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "NCT00171314 recorded more total occurences of cardiac adverse events than NCT02896855.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "db021da5-b729-474a-b019-c164f8cfe4f6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "NCT00171314 recorded more total occurences of gastrointestinal adverse events than NCT02896855.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "839e6a1f-dfef-40ba-9af1-53e9cb7f0065": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in NCT00171314, for which no occurences are recorded.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "6cad137d-a9a9-49be-8ce9-9502e05a590f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in NCT00171314, for which one occurence is recorded.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "39dc5b91-992a-4b15-b3c7-570f3df11072": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of NCT02273973 suffered from Erysipelas than Bacterial diarrhoea.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11,
            12
        ]
    },
    "2a733b5a-38de-4b8a-a65d-b77df5d10ed2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of NCT02273973 suffered from Erysipelas than diarrhoea.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            11
        ]
    },
    "814fabdb-7c3b-4454-8075-c7e23e95f591": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Thrombocytopenia in NCT01498458 than in cohort 1 of NCT03176238, no robust comparisons can be made due to the significant differences in cohort sizes.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5d448ff5-576f-4123-9cfc-5f0b1480d79a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Enterocolitis in NCT01498458 than in cohort 1 of NCT03176238, no robust comparisons can be made due to the significant differences in cohort sizes.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "66058a0c-2cb1-497f-82ee-490d48e0f0b0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For all adverse event types in NCT01498458, at least one case was recorded.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6bb3b40b-5424-4eef-a30b-d361cb3d7d18": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For some adverse event types in NCT01498458, there were no recorded cases.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a8418168-5e7a-4763-8f59-ba61930a8ef3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Less than 20% of patients in cohort 1 of NCT00357110 had Varicose Veins.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "9e888d5c-8273-4769-bc96-c3cdea77caf8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Only 6 patients in cohort 1 of NCT00357110 had Varicose Veins.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "df980f70-a1f2-42a3-b013-240ca8d59ada": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of NCT01560416.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "1cf045cd-8e35-47cf-a9ef-d50d565e02ad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of NCT01560416.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "2a4b65b0-3b4e-4075-ac85-e0eddb27b35a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of NCT00148668 recorded the same number of patients with Neutropenia.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c5742239-5589-4b17-89d1-e3627706098f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of NCT00148668 recorded the same number of patients with Febrile Neutropenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e62630ef-407e-4a2d-ba02-1e9984c958ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of NCT00320710 which occurred in more than 5% of patients.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "865390b8-95da-4d19-9c31-a580e8345882": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of NCT00320710 which occurred in more than 0.5% of patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "f1c4e215-1d00-46ee-aba1-17a87f975627": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "At least one patient in NCT03066947 suffered from Gastroesophageal reflux disease.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "ef0c006e-d9d6-4a16-aa71-a651e317bf3f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "Less than 1/4 patients in NCT03066947 experienced adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "3b8db182-7791-4b34-a73e-1b63ef937991": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4% more cases (1 more case) of Dyspnea than Dehydration in NCT01127763.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            6
        ]
    },
    "910d0d6f-e31f-4820-a8c3-3ef19b6bfeb6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4 more cases of Dyspnea than Dehydration in NCT01127763.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            6
        ]
    },
    "27e7510c-2f52-4e6c-9a0a-1bc224f2fdcb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in NCT00544167 occurred once.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ccae36aa-4b16-4407-9579-209db24fd709": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in NCT00544167 occurred more than 8 times.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "6027ae9a-06ec-48af-a4ba-02dcb5d4a241": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in NCT00679211 presented a fever, in addition to either a cough or a sore throat.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12
        ]
    },
    "554750f2-4cbb-4470-87db-26298f51ef61": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in NCT00679211 was diangosed with Influenza.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            12
        ]
    },
    "8f9e82c4-93bb-4612-8efd-49eff4974097": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than eukopenia observed in NCT00091442, but less cases of Febrile neutropenia than Neutropenia.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            3,
            4
        ]
    },
    "51a83f45-0f96-4776-85ba-dc0e0f479cfd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than leukopenia observed in NCT00091442, but less cases of neutropenia than leukopenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            3,
            4
        ]
    },
    "340e9448-47c1-4c49-abe4-11a4f730d17f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of NCT01998906.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            4
        ]
    },
    "ad9801db-9577-4092-9219-59d4f9c55167": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of NCT01998906.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            3,
            4
        ]
    },
    "8205fa8b-8350-40e9-b43f-e25974071897": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with ERBB2 positive tumors are eligible for NCT00741260.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "333631dc-27c9-4de1-a13f-29e275ced5a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with HER2 positive tumors are ineligible for NCT00741260.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ]
    },
    "5297e0f0-78cf-4108-8089-be91a098d3aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from NCT00836186 on the basis of race or ethnicity.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "2840d44d-407b-4f24-8b92-5c2707fc70f2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from NCT00836186 on the basis of gender or ethnicity.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "3564ef31-c859-4c74-85f9-a5d0baed6ed5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7
        ]
    },
    "4cb2d813-cc1e-4cb8-abed-4fca67e3ec52": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7
        ]
    },
    "251f0b54-527f-417d-828a-6e8968c2c201": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Less than 0.25% of patients in cohort 1 of NCT00130533 suffered from Hyperbilirrubinemia.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "fb6448e7-d20a-45ff-9d42-746e7d8efdb7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Nobody in cohort 1 of NCT00130533 suffered from Hyperbilirrubinemia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ]
    },
    "967e380c-a882-4075-9cea-1523e7ed15e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "All of the adverse event cases in NCT00074152 occurred in patients from cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "efab4bc2-98a2-4823-a144-177476dee05c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "Only 2 of the adverse event cases in NCT00074152 occurred in patients from cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "8c2d61cc-ad31-411a-958a-fd9ab22b794d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were no pain related adverse events observed in NCT00179309.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "596a77af-38b4-46ae-8653-81a2222609ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were 2 cases of severe back pain observed in NCT00179309.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "7aebe5f1-a828-49f1-a650-f2ab60627fe8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from NCT00825734; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            87,
            94,
            95,
            108,
            117,
            118,
            119,
            120
        ]
    },
    "902cb3ac-2670-4fa3-ba3a-4317abc4daab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from NCT00825734; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            87,
            94,
            95,
            108,
            117,
            118,
            119,
            120
        ]
    },
    "fad2fafd-fd7e-463f-a7e5-de06d9552cda": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for NCT00058058 do not need to meet a specific life expectancy criteria.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            19,
            9
        ]
    },
    "fb8002ce-c391-4eaf-a793-c3cae4d3f1a3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for NCT00058058 must have a life expectancy over 6 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            19,
            9
        ]
    },
    "d6551509-9597-4b3f-9b89-fa2afc35a6af": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There are no recorded cases of thrombocytopenia in NCT02015676.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "bcacd7a7-677d-4f9a-af81-5d0d5415f2e4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There is 1 case (1.45%) of thrombocytopenia in NCT02015676.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "c9c6e622-8ba1-48e1-904e-842525541475": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "One patient in NCT02187744 suffered from sepsis, due to the presence of an implanted device.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "ffaf36bf-7c91-4e21-a5ec-9777a71e1d73": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "sepsis, due to the presence of an implanted device was a common adverse event in NCT02187744",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ]
    },
    "1f31504f-8a0f-43d7-a7e3-cc787906b319": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients diagnosed with intradural tumors are excluded from NCT00405938.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10
        ]
    },
    "880f9dd1-f299-405e-9325-db66b45f2c46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients intracranial metastasis may be eligible for NCT00405938.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10
        ]
    },
    "36b2b643-b9af-439c-b60a-1fcec1361b9b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT01008150",
        "Statement": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from NCT01581619, but not from NCT01008150.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43
        ]
    },
    "4113f99d-9f68-4ac5-a476-4075164280da": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Statement": "histologically confirmed invasive ductal breast cancer would result in exclusion from NCT01581619, but not from NCT01008150.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            10
        ]
    },
    "8165e4ae-f10f-4181-a39d-ba104d595874": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total NCT00375427 recorded only 1 more case of Mucosal inflammation than NCT01008150.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            1,
            16,
            3,
            18,
            5,
            20,
            7,
            8,
            9,
            24,
            25,
            26,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "0aa53c84-3ecc-47f5-bc55-8b61f9b09164": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total NCT00375427 recorded only 3 more cases of Pyrexia than NCT01008150.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            1,
            16,
            3,
            18,
            5,
            20,
            7,
            8,
            9,
            24,
            25,
            26,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "4dfd8583-7f38-4f9e-ba39-4ac0f7f73f29": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteoporosis are eligible for NCT00375427 but excluded from NCT00579826.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "c670da7f-bcf8-4c51-b93e-06e130c9474c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteonecrosis are eligible for NCT00375427 but excluded from NCT00579826.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "e21e24a5-8087-4fc5-8bb1-cc839932b898": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of NCT00579826 cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            8,
            10,
            11
        ]
    },
    "0e679031-29c0-49b3-b785-6aefd5433960": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of NCT00579826 cannot be currently receiving for treatment rheumatoid arthritis, experiencing poorly controlled migraines, receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            6,
            8,
            10,
            11
        ]
    },
    "bb8ee3dc-5008-46e9-944a-b8fd73ff1637": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, could be eligible for both NCT00356148 and NCT02322814.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            22,
            15,
            33
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "273b7adb-308c-45d3-aa56-0a6991bc6558": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both NCT00356148 and NCT02322814.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            22,
            15,
            33
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "2553a450-de22-4b83-bb42-55d89adc83b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in NCT00356148, but only adults can be eligible for NCT01856543.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "010aa40b-b692-418d-99b9-ec4e8f53fb55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in NCT00356148 and NCT01856543.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "0e41db07-199c-419c-881b-6a5831243692": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of NCT00365599 and NCT01856543 there was only a single recorded case of Myocarditis and Pericarditis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "6a030b1a-e9e6-4af1-8faf-8ffd8e3bb4b1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of NCT00365599 and NCT01856543 there was only a single recorded case of Myocarditis and Thrombosis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "2ee2da3d-aa8e-4012-9020-959b8b82dc4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for NCT00365599 but excluded from NCT01771666",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10,
            12,
            15,
            25
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "83732d5c-c9c1-4f7f-9dd2-7d1c78a3744c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for NCT00365599 but excluded from NCT01771666",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10,
            12,
            15,
            25
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "abffbd12-4142-4923-9a31-02a5cf0c2753": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG <=1 are eligible for NCT01256567 and NCT01771666.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b6da352e-ec17-42ed-ab6e-20b0136af3f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG of 2 are eligible for NCT01256567 and NCT01771666.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2c6c7f67-645c-4d65-938c-e820836baa33": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in NCT01256567 was Febrile neutropenia (42.86%), whereas in NCT01926886 it was a decrease in Ejection fraction (4.95%).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e7744c90-36d7-49be-9547-2b25e6fffc6a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in NCT01256567 was Febrile neutropenia (14.29%), whereas in NCT01926886 it was a decrease in Ejection fraction (4.95%).",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7c14b9b2-65cd-4ceb-b052-aba6dea18079": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Nausea or Anaemia in NCT01926886.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d2f9c05f-a7b6-433e-85b8-54712453dd79": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Vertigo or Anaemia in NCT01926886.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7e15ed8c-4e71-400f-951e-7e4ee09fabda": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "NCT02019277 and NCT00863655 recorded three of the same types of adverse events",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a33f6e14-7264-4ef6-bfb1-3160d143a6a6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "NCT02019277 and NCT00863655 recorded none of the same types of adverse events",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "c6ef6d39-b4ab-45bf-bb2d-c925c0570aa5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of NCT00863655 compared to cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            12,
            13,
            14,
            15
        ]
    },
    "e3a742df-6dc9-4307-bea1-44e5a3598125": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of NCT00863655 compared to cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            12,
            13,
            14,
            15
        ]
    },
    "74137694-f8e1-404b-9d5a-d502fa51b027": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "NCT01237327 and NCT00030823 do not have any overlapping inclusion or exclusion criteria.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            13,
            21,
            22,
            23,
            13,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            47,
            52,
            47,
            54,
            55,
            56,
            47,
            58,
            59
        ]
    },
    "851388a1-561b-4ae4-8c7a-ec7a953662d2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "NCT01237327 and NCT00030823 do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            13,
            21,
            22,
            23,
            13,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            47,
            52,
            47,
            54,
            55,
            56,
            47,
            58,
            59
        ]
    },
    "439dc5f4-b410-456c-a40c-fdad58c7e573": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV breast cancer may be eliglbe for NCT00030823.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            2,
            11
        ]
    },
    "3738ac65-5bcd-4151-a8a4-a19617af9e4f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for NCT00030823.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13
        ]
    },
    "246819e9-8b12-4be4-b70e-c719549c556b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "NCT00645333 records several immune system related adverse events in its patients, whereas NCT00006110 does not.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "3032397f-befb-4a24-b91c-f4f686a8eff0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "NCT00645333 records several central nervous system related adverse events in its patients, whereas NCT00006110 does not.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "3628b0fa-f018-4c68-93e0-bbefc3eb86b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "NCT00464646 records several gastrointestinal adverse events, whereas NCT00006110 doesn\u2019t record any GI adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9
        ]
    },
    "a03b4e2d-4885-4ec1-8697-62960b6f0add": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "NCT00464646 records only gastrointestinal adverse events, whereas NCT00006110 doesn\u2019t record any GI adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "370fae61-246a-4ee0-8221-d0600359ee70": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for NCT00464646.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            15,
            16,
            17,
            18,
            19,
            10
        ]
    },
    "fdbdd8d4-b69f-4fc6-a220-4e6529b371e8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for NCT00464646.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            15,
            16,
            17,
            18,
            19,
            10
        ]
    },
    "2dfeee35-7ea0-40b9-b74b-3e7d2d9c35ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with cancer in situ of the cervix are eligible for NCT00903162 and NCT01674062.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            12
        ],
        "Secondary_evidence_index": [
            6,
            10
        ]
    },
    "dea8c008-b843-4fae-a3c3-2a42e3dff9f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with BCC are excluded from NCT00903162 and NCT01674062.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            12
        ],
        "Secondary_evidence_index": [
            6,
            10
        ]
    },
    "4a39fa62-8a29-481d-b57a-249d109aacf3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in NCT01674062 was observed vomiting blood.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "f3c27e4c-24a5-4d2d-b49a-5414840d641c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in NCT01674062 was observed suffering from Enteritis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8b5550b1-5986-46e5-8326-b74daa5cf1a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of NCT01439282 recorded more than 10 times the number of adverse events as cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "09e30872-1b25-442e-883d-f02c4cd4a4ba": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of NCT01439282 recorded 20% more adverse events than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "a8541c07-67a7-48fa-a9d3-d9808d51e024": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in NCT01828021 and NCT01326481 did not have any of the same adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "2a66e69a-7679-48c4-9c73-45e5dcdcba5c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in NCT01828021 and NCT01326481 did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7556d979-032c-4522-9fed-6393de041392": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from NCT01326481.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            18
        ]
    },
    "110603db-7f9b-4f34-a7a1-3e295d6220aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for NCT01326481.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            18
        ]
    },
    "44e0b931-19a0-4427-b9e6-3e51298fca92": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for NCT01527487.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            32,
            49
        ]
    },
    "0b2f2c4c-49e2-46c8-a590-056fcff8117c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for NCT01527487, as Psychological illnesses are not permitted.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53
        ]
    },
    "2b04ffda-8ed7-4ee6-9bb4-ee5520b8cc1d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both NCT01299038 and NCT00248170.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            6,
            10
        ]
    },
    "ea621412-2fd9-425b-b368-bac8837a42a1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both NCT01299038 and NCT00248170.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "1d1e8680-b38f-4806-bcf6-5ed051da6dc0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from NCT01299038.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "f8d864dc-9c95-40af-a9ee-c648d09387b9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has a known history of Hepatitis. However as he is over the age of 18 is still eligible for NCT01299038.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "a54b743a-516c-40fb-b715-a2b64abfb69e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "NCT01015131 records instances of Rectal Hemorrhage within its patient cohort, whereas NCT00312208 records Vaginal hemorrhages.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "b8b59683-a516-473c-b474-9bcd5c3dc9da": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "Both NCT01015131 and NCT00312208 record instances of Rectal Hemorrhage within their patient cohorts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f268c187-7341-4a80-827a-3b4b9df9911e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of NCT00312208.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "fe5a0d98-65c2-4486-8732-0ffef2f29a38": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and  Leukopenia were only observed in cohort 1 of NCT00312208.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "c4726d18-29a1-4cdf-89ac-500e57e86353": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in NCT01752907.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "a5b0b866-e14b-4852-9d4a-6d4736807e89": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Secondary_id": "NCT01940497",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in NCT01752907 or NCT01940497.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "ce3d829d-00ae-427b-ba9c-e7e9de8009ef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were more allergic reactions observed in cohort 1 of NCT01940497 than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "2853017f-b54e-4a9e-8913-7545dfa65aff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were 3 more allergic reactions observed in cohort 1 of NCT01940497 than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "6427d4cf-b90f-4f51-b426-e931f8570963": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Statement": "The majority of patients in NCT00182793 experienced an adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "30904b3f-8a22-412b-937d-193aff6169fc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00509769",
        "Statement": "The majority of patients in NCT00182793 and NCT00509769 experienced an adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8af08173-526e-45d9-ab21-79752e36da5f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "1 patient in NCT00509769 had toxic hepatitis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "1a7f8626-f30f-4af7-806b-3ebfa7d8c268": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "3/112 patients (2.68%) in NCT00509769 had Diabetes insipidus  ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "fb4afa6a-7511-409d-a4b2-e1fc81e2c7a0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across both cohorts of NCT00284180 a total of two patients had low levels of oxygen in their body tissues.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "a0d9ec2a-cdb6-4989-a24a-10419607b739": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across all three cohorts of NCT00284180 a total of two patients had low levels of oxygen in their body tissues.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "1d1d2bf6-73c7-4b49-a75f-4b416b999b18": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorts of NCT02132949 and NCT01111825 there was only a single patient with a deficiency of granulocytes in the blood.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "f7404dfc-6214-45c3-8c81-1d3ac60d7674": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorst of NCT02132949 and NCT01111825 there was only a single patient who suffered heart failure.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "1f9dd5b6-cbf1-4e11-a345-8d5a98c125f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of NCT01111825.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "3444719c-6f6c-499b-8136-12c28cf27987": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, oedemas or Febrile neutropenia within patient cohorts 1 and 2 of NCT01111825.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "50810875-f93a-4f7e-8338-7112020f503d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 12 adverse event types recorded in NCT00992225, occurred more than once.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "255a9724-b484-4191-bd4f-ff8385551768": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 16 adverse event types recorded in NCT00992225, occurred more than once.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "1d0d2069-35c2-4906-9c47-ffe621aca876": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event is observed in patients from cohort 1 of NCT00759785.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a879389a-288c-44d3-8264-419a02c8f6fd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of NCT00759785.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "67fac3c7-9079-4b2d-b3ee-d815f6856c0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had an oophorectomy in the last month would not be eligible for NCT01094184.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            7
        ]
    },
    "8f6861ed-79e8-4312-9a0d-4cb7c11cd244": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had a Joint injection in the last month would not be eligible for NCT01094184.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "1a62b95d-e60b-4461-8205-8f8bcbe6899d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Statement": "Patients must have already participated in a specific clinical study to participate in NCT00971945.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "b3d3a813-3d3b-4d57-bb83-26f3f26fc17b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT01027416",
        "Statement": "Patients must have already participated in a specific clinical study to participate in NCT00971945 or NCT01027416.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "a43ccab4-e6d2-46bb-93ba-3f9fe44e1068": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for NCT01027416, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            8
        ]
    },
    "05c5145b-0b68-4dc1-abfc-20eef368207e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for NCT01027416, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            8
        ]
    },
    "fdd5ed22-f3a6-4923-9507-d88b5a012c2b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is the same number of cases of Diplopia in NCT02049957 as anemia in NCT01506609.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "de1075e0-4024-4148-b14e-f9bd75d8be79": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is are the same total number of patients in NCT02049957 as in NCT01506609.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "b5da522f-cb39-48e0-a16f-9610ab172024": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for NCT01506609.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d3a02f75-4d50-482e-96e0-41eb43e81cda": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Secondary_id": "NCT00656019",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for NCT00656019, but are eligible for NCT01506609.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "aec306c3-909d-4416-a4e6-6290772b7d15": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from NCT00656019.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ]
    },
    "227087a7-7296-46d1-b90f-b6c62b3ce523": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Secondary_id": "NCT00328783",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from NCT00656019 and NCT00328783.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e6d4db95-7499-44cf-b8a0-3b1ed021896b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with a COPD diagnosis through spirometry are ineligible for NCT00328783.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "e23efcae-86b7-4e91-ba5a-c06ad0df6325": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with an FEV1 of 80% to 120% are ineligible for NCT00328783.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "45e71ac7-c429-4f4f-a42b-733cccf1d063": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At least 1 patient in NCT00022516 suffered from a radiotherapy induced adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "70ae732f-4034-49ae-beb9-4978d7913565": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At most 3 patients in NCT00022516 suffered from Neutropenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "5c0cbe2d-07bc-4b03-af23-14ec6244892b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both NCT00853996 and NCT00365417 patients must satisfy all the following conditions; alkaline phosphatase  < 2 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            13,
            14,
            9,
            10
        ],
        "Secondary_evidence_index": [
            17,
            18,
            20,
            23
        ]
    },
    "82a67143-4a26-4b99-beb2-de273996b154": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both NCT00853996 and NCT00365417 patients must satisfy all the following conditions; alkaline phosphatase  < 2.5 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            13,
            14,
            9,
            10
        ],
        "Secondary_evidence_index": [
            17,
            18,
            20,
            23
        ]
    },
    "fc4a05a8-011e-4f4e-9bcc-5f48e7cff2b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for NCT00853996.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "d9f209f5-2730-45a6-a9f7-568f5891198e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model , and no Family history consistent with hereditary breast cancer, are eligible for NCT00853996.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            8
        ]
    },
    "959acda8-70ca-45a2-8de1-6823a5272cd5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Statement": "Less than 5 patients in NCT01095003 experienced Earache.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            4,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "8b3c0869-a383-4605-8025-1014a3fdc360": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Secondary_id": "NCT01702571",
        "Statement": "In total more than 5 patients in NCT01095003 and NCT01702571 experienced Earache.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            4,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "5175f457-f3e8-42be-bbb8-60732db694db": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and  unresectable Locally Advanced Breast Cancer are eligible for NCT01702571.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "e6d7498b-7afe-4862-ad77-0a95fe8744f7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and unresectable Breast Cancer are eligible for NCT01702571, unless it is metastatic.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "1ef8d8f6-83b2-4de9-b3a5-101a00aebd92": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in NCT01011946 must have a bilateral breast MRI prior to study entry.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            7
        ]
    },
    "b8c629e9-314b-444b-9a46-77224ef1b602": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in NCT01011946 must have a bilateral breast mammography prior to study entry.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "f8223f28-7cc0-481f-be7f-b906b2e58349": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": " Patients with metastasis in four or more axillary lymph nodes are eligible for NCT00050167.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "79577606-70b3-4fe5-93f6-7cc636330ab8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": "Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for NCT00050167.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "708074c7-57f1-4e01-b359-dde25679ebc3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed Diuretics are excluded from NCT01351376.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            18
        ]
    },
    "9e070e0f-18fa-41ce-979e-af7506004b04": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed laxatives are not excluded from NCT01351376.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            18
        ]
    },
    "e5ed29c0-dc9d-4ce9-ab25-649f07e16727": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "NCT00281697 does not record any pain related adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "f52668dc-2a7f-4682-ae20-7fb9f1ed414e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "NCT00281697 does not record any cardiac related adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "7c3d536f-1e3c-4d38-ab4c-9451ab30fadb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "A patient in NCT01705691 suffered from Kidney stones.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            14
        ]
    },
    "d358165b-e1d4-4e65-a666-494ff2517968": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "The majority of patients in NCT01705691 suffered from Kidney stones.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "bdd40340-d967-4e98-8d6a-b1da71afe9ce": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both NCT01966471 and NCT00981812.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            5,
            12
        ]
    },
    "9d4f35fa-70e9-416c-bd8d-920cffcd02c0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both NCT01966471 and NCT00981812.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            5,
            12
        ]
    },
    "f92207bf-75c6-4a3f-8890-90a6fb6fa55c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure in the last 2 years are excluded from NCT00981812.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            8
        ]
    },
    "49b763ea-3917-4b36-b361-985dd1f3f3fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from NCT00981812.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "38f192a4-6e4a-4e96-9816-2c681b5b9f80": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were no adverse event in NCT00894504 which occurred more than 71 times.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8110d842-fbd7-4c65-93a9-df0dd1b95e66": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were only 3 adverse events in NCT00894504 which occurred more than twice.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "c94cd1aa-f8d6-461b-a984-f161b2ae7cbe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "Several adverse events which occurred in NCT02149524 were not heart related.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "38804a7f-c7cd-4a42-bae7-d046b9437e8d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "None of the adverse events which occurred in NCT02149524 were not GI related.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "09e83e7d-c6e4-49d9-9d53-74e0d10cc0dd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "NCT01466972 recorded one patient with congestive heart failure, NCT01446159 did not record any.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5,
            13,
            5
        ]
    },
    "8d43a56b-5c22-4501-aa3e-2802cf54ab9d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "NCT01466972 recorded one patient with congestive Cardiac failure, NCT01446159 recorded more.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5,
            13,
            5
        ]
    },
    "b6048d4d-01d4-4254-9aa3-c18aa0b2563a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "NCT01446159 only had a total of 6 patients in across both its cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "21135338-c8a2-4a1d-a876-a7b9c4e78d0b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "NCT01446159 only had a total of 66 patients in across both its cohorts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "4830b933-3d2e-4490-9246-f0984a2c0bec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There were no MRSA infections in either NCT01201265 or NCT00493649.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "3ac45e1e-1d4e-4add-b622-5aa639affab6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There was 1 MRSA infection in cohort 1 of NCT01201265 and 4 in cohort 2 of NCT00493649.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "dd689cfc-fd9f-4a1c-b977-6ebf3f5327de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Statement": "1 patient in NCT01201265 was affected by Sepsis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "d6d0d137-0c24-4dbb-b88f-f71d712bfcc2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Secondary_id": "NCT00932373",
        "Statement": "1 patient in NCT01201265 was affected by Sepsis, and several were affected in NCT00932373.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "70606298-fbbf-4470-8fda-1db836186a9e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade III peripheral neuropathy or above are eliminated from participation in NCT00932373.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            10,
            16
        ]
    },
    "a74051db-6198-4fc7-af33-71f9225b0d34": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade I peripheral neuropathy or above are eliminated from participation in NCT00932373.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            10,
            16
        ]
    },
    "b5725d28-b913-442b-ad0c-5c0abae4e846": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for NCT00952692 must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            27,
            28,
            38,
            43
        ]
    },
    "c0734afb-c837-45c7-a80e-616bede80c20": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for NCT00952692 must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61
        ]
    },
    "cdf0e8a5-1d81-487b-a9b7-a6604ed2fb0c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "Two different types of tachycardia occurred to patients in cohort 2 of NCT01565083.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            22,
            23
        ]
    },
    "9681c1b9-ef74-4aa3-9d7f-f66cf2ad375e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of NCT01565083.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            22,
            23
        ]
    },
    "27e5ea8f-e255-4315-ad6a-3a1e6f57a1dc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer, aswell as not having Dysphagia.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            8,
            12
        ]
    },
    "5106dad0-919c-4dc5-9991-d63ad27fcdfd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer, aswell as not having Dysphagia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            8,
            12
        ]
    },
    "7d4c0099-b03f-4e4f-be17-e9bac3db845f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "NCT00899574 uses different inclusion criteria for its cohorts, NCT01007942 only uses one set on inclusion criteria for all cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "f3a2aa4d-f534-4d82-9f35-ad28aca5506a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "NCT00899574 and NCT01007942 use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "0c41c5a3-7181-41f0-afcc-360a605ea5ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "Febrile neutropenia was in excess of 5 times more common in cohort 1 of NCT01007942, than in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            12,
            16
        ]
    },
    "2ee1cc41-3eb5-4723-9619-753b03c30b71": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "There were no adverse event in NCT01007942 which affected more than 10% of a particular patient cohort.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "2f28d1e8-264c-4322-b87a-b46d05dcd909": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for NCT01097642.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            3,
            4,
            5
        ]
    },
    "14a74367-67f0-40b1-be5d-183b67f5b210": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for NCT01097642.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3,
            4,
            5
        ]
    },
    "bb7cde09-d36f-4d59-9a39-37424ab076db": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from NCT00756717.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "df72b5ee-cd0b-44cf-a3e7-d67ece1cab79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for NCT00756717.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "5b487b40-6ea0-49ec-9230-ef4f36f7a618": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in NCT00688740 and NCT00191815 is Neutropenia with a total of 3 cases across all cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "f8a7808a-518e-47f3-b28c-2d2a2c832b08": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in NCT00688740 and NCT00191815 is Neutropenia with a total of 3 cases across all cohorts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "edb5265a-316d-492f-aa91-8e7707df6d47": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in NCT00191815 committed suicide, however there was one such case in NCT01301729.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e10a9b65-c81c-4f65-929f-7900d6fec547": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in NCT00191815 or NCT01301729 committed suicide.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "f95d8c3b-36a2-4b40-8188-86de1a73c593": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 respiratory adverse event was recorded across the duration of both NCT02129556 and NCT01301729.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "ce2f178d-d123-4f22-bc4a-5bfc23e6c39d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 type of infection recorded across the duration of both NCT02129556 and NCT01301729.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "fa2d2d7b-91be-4937-8236-7ad1b37d7e2f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of NCT02129556 had a much higher mortality rate than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10,
            13,
            23
        ]
    },
    "c28bb9d5-c450-4398-9f3d-22b7ffbbb49b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of NCT02129556 had a much higher number of deaths than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10,
            13,
            23
        ]
    },
    "8c29454e-c06e-4dc2-8950-b9ce2b00cf9c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There are no cases of agranulocytosis in NCT01419197.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "ff70f974-d2fd-40ed-8f46-229c4c984606": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There was one patient in NCT01419197 who suffered from a significant decrease in the number of granulocytes in their blood.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            17
        ]
    },
    "c48058b9-8805-44a6-bded-c2176844db39": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia in cohort 1 of NCT01491737, and 0 cases of heart failure.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            5
        ]
    },
    "c7a21845-c3d3-453c-a333-915a9b89b62e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of NCT01491737.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            5
        ]
    },
    "cdde8c15-1d39-426e-b8e5-fdc7305bad5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of cardiac tamponade in NCT00574587 or NCT00777049.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "5d33dd10-547c-4715-90c3-bc918bf819b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of Myocardial ischaemia in NCT00574587 or NCT00777049.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "70e02276-cac8-4619-9afc-b4654c28a60c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "Most of the cases of CHF in NCT00777049, were in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            14,
            20
        ]
    },
    "fb609511-3fa2-4203-be0c-52359a37a0f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "All 4 of the CHF cases in NCT00777049, were in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            14,
            20
        ]
    },
    "408063fd-b874-4028-bb5f-c27c3ffef1d6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in NCT00206427 had a fungal infection of the mouth.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "ae005980-2a85-4d54-b052-5e0d72fba797": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in NCT00206427 had a vaginal fungal infection.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "c93ad33b-3ba0-4494-92f7-670e7e3424f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Neutropenia was the most prevalent adverse event in NCT00670982.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "85d53b11-e167-4fdc-99e9-a0d4f8440391": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Acute coronary syndrome was the most prevalent adverse event in NCT00670982, other than Thrombocytopenia .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "4de4db11-8ad9-4411-96ad-7c8751e09ab7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in NCT01250379 had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5,
            7,
            9,
            10,
            11
        ]
    },
    "81567db6-bbfb-4153-b575-a008d7caf04b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in NCT01250379 had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8,
            5,
            7,
            9,
            10,
            11
        ]
    },
    "3703e845-8cb3-46c1-bec7-a3469e529380": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to NCT00768222, NCT02102490 did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b54cc86d-9327-48ea-bb15-cfcbc933dddf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to NCT00768222, NCT02102490 did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "9da8545f-28e6-4404-8e93-3f47f3d65f0e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in NCT00768222.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            4,
            8,
            9
        ]
    },
    "667172bd-7d1e-4237-bfe3-782d84d99cb0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in NCT00768222 due to her age.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            4,
            8,
            9
        ]
    },
    "7f53010f-6680-493c-987c-272c64af0c78": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG of 3 are excluded from NCT00581256.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            8,
            14,
            17
        ]
    },
    "65cc3a1f-a999-4a33-95e8-998335f74e28": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from NCT00581256.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            8,
            14,
            17
        ]
    },
    "fd9aec07-ee6f-4719-ae49-37cc378323fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer are eligible for both NCT02419807 and NCT00777101. However, only patients with stage 1-2 breast cancer are eligible for NCT02419807, and patients with stage 3-4 are eligilbe for NCT00777101. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "6801f96b-7803-40b6-bb29-8dd08aab5a56": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer stage 1-4  are eligible for both NCT02419807 and NCT00777101.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "6c938f7f-50fc-4d66-b00d-c56701a1b40d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no completed suicides in either NCT00777101 or NCT00559845, however there was one attempt in cohort 1 of NCT00559845.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "b45361f3-e133-4b5c-aa34-ad90b65cdea9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no depressed patients in either NCT00777101 or NCT00559845, however there was one suicide attempt in cohort 2 of NCT00559845.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "78344a63-48d9-463f-a036-e2a176327d68": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in NCT00426556 than in NCT00559845.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "01258e97-b4ea-4f61-9b87-7d8d3b6dfe67": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in cohort 1 of NCT00426556 than in cohort 2 of NCT00559845.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            14,
            15
        ]
    },
    "d75d2091-6f84-4dcf-81fe-4c0685cf10f1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in NCT00426556.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "b9673446-7e14-46c2-9aaa-aad4f4de30ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in NCT00426556.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "dc47f0bf-ad75-4857-ba8e-2709f4593a12": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was the same number of anemic patinets in both cohorts of NCT00567190.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            12,
            14
        ]
    },
    "3c83608f-5d08-4e71-b0d3-d7e551d4c7ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was exactly the same proportion of anemic patinets in both cohorts of NCT00567190.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            12,
            14
        ]
    },
    "20ef9913-401a-4140-80e5-3edffc4ce93c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in NCT00885755, but at least one was affected in NCT01075100.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "50bfd7e5-546b-4752-a3a3-e7cfc6b6c7b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in NCT00885755 or NCT01075100.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "8a70034c-e1ef-4641-a31c-33310b74b1d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Statement": "No mental health issues were observed in NCT01075100.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "07308522-1472-4305-903a-26ebeccd0917": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Secondary_id": "NCT00290758",
        "Statement": "several different mental health issues were observed in NCT01075100 and NCT00290758.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "cded9ba5-e98f-463e-b076-4a40852c44ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one genitourinary adverse events recorded in NCT00290758.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "bba79316-cf35-460f-b91d-d829e2994d09": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one GU and three GI adverse events recorded in NCT00290758.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "1222163f-4be7-4cfa-8ed6-9989a949ef4e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 NCT00528567, is larger than the cohort size of NCT01196052.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "c679f88d-81ab-4725-abc5-3d52a33e81e4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 NCT00528567 is more than 1000.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "ed66478a-eb5d-400d-9dbd-5cb64cc404a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in NCT01196052 must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "73a9ee4d-805a-4850-a6df-10e63043e30a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in NCT01196052 must be willing to undergo cyclophosphamide-based chemotherapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "c88e1b2e-db9f-4021-98d0-e50496803cf5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both NCT00297596 and NCT00908791.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            21
        ]
    },
    "ec5e9976-c4b7-4126-a451-34c901b380b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both NCT00297596 and NCT00908791, unless they have an ECOG>2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            21
        ]
    },
    "bed575d4-134d-4f79-ab00-6f40bfa4ae94": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 weeks before study entry are eligible for NCT00297596 but excluded from NCT00580333.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            8,
            10
        ],
        "Secondary_evidence_index": [
            8,
            9
        ]
    },
    "2971375a-62d4-418b-bc36-9d9dd9ac6e2d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for NCT00297596 but excluded from NCT00580333.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            8,
            10
        ],
        "Secondary_evidence_index": [
            8,
            9
        ]
    },
    "7fcb97a2-f7ae-4229-8ac8-125ed2be4d2e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy exceeding 3 months to particpate in NCT00580333, there is no mimimum life expectancy define for NCT00934856.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            3,
            12,
            13,
            6,
            15,
            16,
            17
        ]
    },
    "79842bcd-7cf6-4a25-8326-4835ca531bd7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy less than 12 weeks to particpate in NCT00580333 and NCT00934856.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            3,
            12,
            13,
            6,
            15,
            16,
            17
        ]
    },
    "2b51fec5-2baf-4c0a-81dc-fb89e93e27a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of NCT00934856, there were at least 2 patients with a fever.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            1,
            2,
            16,
            17,
            5,
            6,
            7,
            8,
            9,
            10,
            24,
            25
        ]
    },
    "a063f6f7-af1b-4661-ba23-15b8024771b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of NCT00934856, there was at least 2 fatigued patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            1,
            2,
            16,
            17,
            5,
            6,
            7,
            8,
            9,
            10,
            24,
            25
        ]
    },
    "45731aa9-9d4e-4ca9-b97e-3ce58bda9e2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of NCT00080301, than in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            13,
            20
        ]
    },
    "630042c9-ba82-4a30-817d-f2c711dbfdaf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of NCT00080301, than in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "1077fbbc-1472-4974-8016-2f595c931fcb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of NCT00471276 than cohort 1 of NCT00951665.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "19c5efec-ecdf-407b-ba3d-ba1c356d68f3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of NCT00951665. than cohort 1 of NCT00471276 .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "70f26477-aaa5-4776-ad8d-e81852f531e2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Nausea and Death are two of the most common adverse events for patients in cohort 1 of NCT00951665",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "1396bd82-788c-41ba-8a2a-fd3156c0e3ea": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Most patients in cohort 1 of NCT00951665 died of unknown causes.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "485e4e5a-13ec-495b-a50e-5ebc3b75cb8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10x more patients with Left ventricular systolic dysfunction in NCT01026142 than in NCT00846027.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            12,
            19
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "bb5079be-145c-47ed-8b41-473d80bccf5e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of NCT01026142 than in NCT00846027.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            12,
            19
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "f4b45df7-ca27-46db-84f1-07dc54bfa215": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for NCT00846027 occurred more than once.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7507b488-1e6c-4919-a9c6-894d65fd42f8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for NCT00846027 occurred less than twice.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "bff3efc0-4b6f-4c3c-966c-c189825b2af1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of NCT00451555 recorded exactly the same number of each type of adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "ffa27355-6423-4199-86e5-e2654706025f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of NCT00451555 recorded exactly the same percentage of each type of adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "6650af5a-f850-4cba-85a2-82649bcbdf2b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 3 patients in cohort 1 of NCT00875979 experienced any adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "6ea9249d-c36c-4fdc-87b1-673fb38a1ba8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 60+ patients in cohort 2 NCT00875979 experienced any adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ]
    },
    "becf41b6-96a1-4db5-96a9-3ab01e4065fa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia or Arrhythmia observed in patients participating in NCT00403130.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "e3c46503-9949-4780-b5ae-7f8bf074171b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in NCT00403130.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "0ef5bd91-11d5-4fce-984b-182cc3f1491a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile bone marrow aplasia in NCT00929240.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "394e0ff2-23c7-49f1-abf9-efc5e177b662": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile neutropenia in NCT00929240.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "2b7bad6a-393e-46b1-8f3d-c1f6c0dd84af": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There was a dental adverse event in NCT00717405.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "97c4871a-ba7c-46ef-9a7a-ad39906c9780": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There were several patients who contracted Pneumonia in NCT00717405.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "316e948a-1e7e-4c8f-bd7e-5c99c500afab": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of NCT01416389 had more cases of urinary infections and lumbar fractures than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10,
            11,
            14,
            24,
            25
        ]
    },
    "10d73eac-c0f2-4f15-835d-acdc3ac99a20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of NCT01416389 had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "75b9fa7b-df22-4894-a302-60aeb7a86fa3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in NCT00811135 than in NCT00483223",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "23de1ebc-2a30-480c-a4da-1de83d94c156": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in NCT00811135 than in NCT00483223",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4ee41ff6-987b-4cf2-96fb-3f4b01b2a0e0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in NCT00811135 did not experience Left ventricular dysfunction.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "d4b24900-c9eb-48cd-b3f5-92a1ef2f1c81": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in NCT00811135 experienced at least one adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "e68c0e27-1b52-43d7-a3e3-e5b42bd93159": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF greater than or equal to 60% are eligible for NCT00976989.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "3f48d29c-ad78-416a-9bdc-4d0153ac106f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF equal to 53.5% are eligible for NCT00976989.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ]
    },
    "753fb97b-6b24-4729-88fb-89ec45ba2754": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for NCT00568022 but excluded from NCT01120184.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "33c4a129-5a5e-4dbb-97f8-64cd1aae2c4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for NCT00568022 but excluded from NCT01120184.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "e4818ff5-e3fb-4ec3-8a2a-da00acfed3da": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of NCT01120184 suffered from a coagulation disorder.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "8c55db3c-ada2-4ea4-b005-aa6961dfede4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of NCT01120184 suffered from a Hemophilia, a rare coagulation disorder.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "fd208a9d-f778-4876-b29d-808ada7d8d1e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "More than 3 patients in NCT01421472 suffered from adverse events associated with a low number of white blood cells.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "1cce8b64-1783-4d57-9ba0-6d5e67867413": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "Over 9 patients in NCT01421472 suffered from adverse events associated with a low number of white blood cells present in the bloodstream.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "f46b0cc4-7cd1-43be-8a8f-cbe5357d52d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "less than 1% of either cohort of NCT01492101 was effect by either Pancytopenia or Coagulopathy.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5,
            11,
            15,
            16
        ]
    },
    "1b309766-0a6e-417d-9824-dc53004db3b3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "There less than 1% of either cohort of NCT01492101 was effect by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5,
            11,
            15
        ]
    },
    "7e3a46e4-34a2-42ee-9d87-f9457bd15998": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "NCT00950300 recorded a patient with chest pain, whereas NCT00615901 observed a patient with abdominal pain.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "2187feb5-2639-451e-84e7-59507fc5b31c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "NCT00950300 recorded a multitude of patients with chest pain, whereas NCT00615901 observed only one patient with abdominal pain.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            10
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "95f211ee-e7b2-4314-9795-010c41e63fee": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "NCT00615901 recorded more seizures than NCT00829166, despite having less than one tenth the number of patients in its total cohort.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "d0bbe1ef-adf4-41d9-bbe1-93df75ae3c07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "NCT00615901 recorded many more seizures than NCT00829166, despite having less than one tenth the number of patients in its total cohort.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e9833d4d-3629-4d8f-bb05-22a432ae082e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from NCT00829166.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            12
        ]
    },
    "fdde3cb1-ba53-4606-bc07-e250062c4245": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy >0 are excluded from NCT00829166.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            12
        ]
    },
    "8c5abbfe-bc22-4e9b-8212-be74cf6c0f6b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate blood, kidney, and hepatic function are required to participate in NCT02536339, however this condition is not specified in NCT00213980.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            7
        ]
    },
    "6370cd63-8b40-47e3-8f56-73a91a2bd6e0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate hematologic, renal, and hepatic function are required to participate in NCT02536339 and NCT00213980, however, patients with severe loss in cognitive function are still eligible.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "b0269c12-7798-43fc-a6e4-ca8862713ef6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "At least one type of respiratory illness was observed in patients from both NCT02536339 and NCT00371345.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            11
        ]
    },
    "a1529f12-c327-4e13-a37b-2d1d3d8a7c77": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "Respiratory illnesses were observed in most of the patients in NCT02536339 and NCT00371345.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "b5d50da4-7672-4cf0-8733-525c59d65b3f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There is no overlap between adverse events obeserved in NCT00371345 and NCT00475670.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "a88226a0-c21c-4b80-9a85-4bd0a3e9c515": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There only overlap between adverse events obeserved in NCT00371345 and NCT00475670 is the several case of Sepsis which occurred in both trials.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "079aa2ef-1d40-4f89-a3d7-d6279b7d07bf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of NCT00475670, there are more cases of every observed adverse event in cohort 2. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "b192d6c0-f85c-476a-8949-42b66101cc49": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of NCT00475670, other than sudden death, there are more cases of every observed adverse event in cohort 2. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "e5362b9c-4833-4b10-80ff-0ada026323e0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions in NCT00545688.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            6,
            18,
            19,
            9,
            10
        ]
    },
    "48dd06df-05c4-46c5-836d-02c72555bec4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in NCT00545688.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            6,
            18,
            19,
            9,
            10
        ]
    },
    "9d217374-14cd-4a21-b0eb-868688fe3c68": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo in NCT00546156 or NCT00546156.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "00fb1585-43c1-4dd7-9b1e-b7d5a44f687b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo, Abdominal distension or Neutropenia in NCT00546156 or NCT00546156.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "7df45036-21df-4208-8c20-7744667bfcf8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "3/4 patients in NCT00398567 did not suffer any adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "1a0504cc-054c-48ae-b7ab-92bf3203842c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "80% of patients in NCT00398567 did not suffer any adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "1c65f513-b6fe-4209-87b5-319f5b0a329f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of NCT02924883 experienced adverse events, than in cohort 1 of NCT00559754.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "238efd11-d06e-4314-b48d-9d0f99c25274": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of NCT02924883 experienced stomatitis, than in cohort 1 of NCT00559754.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "eb62b7f0-df29-4023-aa91-0dd725afbe69": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In NCT02924883, all cases of  Enteritis, Vertigo and Cardiac failure occurred in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "950e8fa7-276a-4977-b789-3097cd51a16e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In NCT02924883, all cases of  Enteritis, Vertigo and Anaemia occurred in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "05459a76-fead-4315-af1f-89ba5891a6ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients wanting to participate in NCT00325234, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            7,
            8
        ]
    },
    "eeae2ffc-17d3-4080-8761-c10e73cbe6ef": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients under the age of 18, wanting to participate in NCT00325234, must discontinue any Antitumoral hormonal treatment prior to study entry, and have a life expectancy of more than 3 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            8,
            13
        ]
    },
    "4008f829-2b8f-47df-a662-a33d728a71c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for NCT01028352.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6
        ]
    },
    "956e7f0f-ca9e-46f4-8415-3dd269a6d682": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for NCT01028352.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4,
            5,
            6
        ]
    },
    "fe86334c-d0a7-458b-b54f-db94d30b4efd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were 0 patients with Dysphagia or Fever in NCT01596751 and NCT00193050 cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "bd5fbac9-3f89-4667-835e-e9938f4f1333": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were at least 15 patients with Dysphagia or Fever between the NCT01596751 and NCT00193050 patient cohorts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "7b3b02d3-85bd-4654-bbfa-5172c9843b80": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in NCT00193050.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            11,
            13
        ]
    },
    "2216c94c-d778-4c0a-aeb5-6fd9a20c200a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Secondary_id": "NCT00232479",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in NCT00193050 or NCT00232479.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            11,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "8588c6d9-e7cd-4b8c-8a0d-dc1d864da305": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Only patients with HER2 positive breast carcinoma are eligible for NCT00232479.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "bd4d0d01-2ddc-49f4-aee8-1b5449a83f4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Patients with HER2 positive breast or colon carcinoma are eligible for NCT00232479.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "ee6d4ef0-aaed-4be3-9ea7-08e2ed9858c7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in NCT00191854",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "6e05c1fc-db31-4bd9-88af-c67e7a66d844": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients must have a one bi-dimensional, measurable indicator lesion to be included in NCT00191854",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "fb56a373-5699-4bc1-9ce5-e34cc7a0f756": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in NCT00404066.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            28,
            29
        ]
    },
    "e0668e5b-b949-4cbd-9914-3e246603c025": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in NCT00404066, unless treated with herbal medicines.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17,
            22,
            28,
            29
        ]
    },
    "e4fd0b1e-e2e8-45cc-9ac6-9dce5947401f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events occurred in more than 1% of patient in cohort 1 of NCT00448591.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "545bcd35-91c4-446f-afbc-513b80fc7098": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of NCT00448591.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "add5f080-13b9-46c3-96cb-dfb2acc710b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Statement": "Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in NCT00149214.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5
        ]
    },
    "b41f22b6-2e9e-4223-a861-978366fcc45d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Secondary_id": "NCT01004744",
        "Statement": "Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in NCT00149214, but not for patients in NCT01004744.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            4
        ]
    },
    "8f6af42e-3aa8-43ea-bc56-493601c75ee6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in NCT01004744.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "f4bcd3fc-9cfa-4c94-b095-3ac8535bad56": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in NCT01004744.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "92cf1100-c6e4-41e8-834c-404bcb6fcd81": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Secondary_id": "NCT00256243",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of NCT00121836 or NCT00256243 will not be made to take part.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            11
        ]
    },
    "0392e38a-dae4-4b49-a317-7df4d663945f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of NCT00121836 will still be included.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "683cfdbd-b45a-4b64-94c3-47e24d8b54b1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "Patients wanting to take part in NCT00721630 must be at a specific location, this is not necessary for NCT00256243.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "ea057f19-1e27-452b-a4fa-e464b14d09a0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "NCT00721630 and NCT00256243 are both taking place at the Memorial Sloan Kettering Cancer Center.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "00476c78-92d7-4e52-bb74-a8d5a2341941": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "NCT00721630 and NCT00364611 recorded the exact same number of cases of nausea.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            7
        ]
    },
    "8b8b2ff3-6b97-4470-81d6-bcac05458708": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "NCT00721630 and NCT00364611 recorded the same proportion of patients experiencing nausea.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            4
        ],
        "Secondary_evidence_index": [
            0,
            7
        ]
    },
    "b99df7c9-9afe-4a71-a4b9-c622ec4b3fa7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with wounds that havent healed within five to eight weeks are ineligible for NCT00364611.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ]
    },
    "14416eeb-ccab-454c-acf9-5cedb06aa525": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with clinically significant grade 3 PVD are eligible for NCT00364611.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18
        ]
    },
    "a3e08ad0-111b-4fc5-9cb8-a72ec128203a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have an infiltrating breast carcinoma to participate in NCT00127933 or NCT00201760.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "a29eca12-6bff-4e27-aa4a-7c25c8668a8f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have a triple negative infiltrating breast carcinoma to participate in NCT00127933 or NCT00201760.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "94e7a5a6-2117-411e-9a3e-a6d16292b576": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "NCT00127933 recorded one patient with a catheter-related complication, whereas in NCT00191789 none where observed.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "ceb8139b-c284-4ce8-90a1-f53f402cb0a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "NCT00127933 recorded at least one patient with an infection, whereas in NCT00191789 none where observed.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "7ebfd985-fcf9-46c3-b39a-e87df5ac96c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In NCT00191789 there was 1 case of jaundice.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12
        ]
    },
    "10b276d4-ffc9-4353-95f5-fcb4a6ad496c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In cohort 2 and 3 of NCT00191789 there was only case 1 of jaundice.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "80db29ea-7f21-4cf2-af1f-7333f9819aec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "Patients in NCT00201851 and those in NCT00679341 did not share any of the same adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "53e493bb-bac1-4d4b-a95b-81e6022516a0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "The only adverse event observed in Patients from both NCT00201851 and NCT00679341, was Endocervical cancer.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7c75ab52-6bbc-4529-a293-55b15fec04f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming observed in NCT00201851.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "217328d9-d4eb-4e3c-b20b-adc531aa0f97": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in NCT00201851.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4dc4665b-20bf-4fad-a189-22478b4f8f14": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in NCT00191451 experienced a variety of Oesophageal and cardiac adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "c84a8c7f-5d2b-4218-903f-bce475b09493": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in NCT00191451 experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "f12758f5-10ab-423b-a10b-2b530c6b42ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several cardiac adverse events recorded in NCT00333775, but not a single one in NCT00201864.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "f1d8b651-df8c-407a-8f58-3ed765474a00": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several coagulative adverse events recorded in NCT00333775, but not a single one in NCT00201864.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "faee20d9-9161-4c6e-83b9-89b68a450387": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in NCT00201864 had blood calcium levels far above normal.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "f6578b53-3e36-4171-810c-c17001147f83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in NCT00201864 had a WBC count far below normal.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "076abfbc-7df0-4aaf-8ce7-ae47ccf79642": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 7 patients in NCT00444587 were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            6,
            8
        ]
    },
    "7969b4b2-93b9-4144-ab46-fb1a3ff7fa1a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 2/93 patients in NCT00444587 were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            6,
            8
        ]
    },
    "aab29c19-4bb9-4b08-b62d-c64a8a254752": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had a heart attack, she is excluded from NCT00494481.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "2a38dde9-2314-4bc7-bee5-4e3f92e5ca48": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had fell down a flight of stairs and fractured her hip, she is excluded from NCT00494481.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6a9bb95f-fedc-4bda-9c91-cd50cf72a420": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for NCT00201773",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            6
        ]
    },
    "3d9e7cf5-108e-45db-9f7e-e631d272ac45": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for NCT00201773",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            6
        ]
    },
    "54a41192-769e-4e21-99ea-27d73e88222f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the NCT00193063 patient cohort, 3 different types of infections are observed. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "819e8b64-08fe-4baa-b433-0c58d61a464a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the NCT00193063 patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "ae116157-1de1-445d-ab5c-7250950ac87f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "NCT00243503 and NCT00448279 observed a different number of adverse events in their patients.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "8131899c-5d89-40f4-b759-311ccdd31cd9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "NCT00243503 and NCT00448279 did not observe any of the same adverse events in their patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "c23acf4c-2aa4-41d5-92ed-ee5e4a75ab91": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were more adverse events in cohort 1 of NCT00448279, than in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "58d276b1-7b32-4ee8-8fff-2d9f77552d1d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were 5x more adverse events in cohort 1 of NCT00448279, than in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "43a4744b-523f-4889-8691-1454e505221e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in NCT00391092.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2,
            12,
            14
        ]
    },
    "c08dafc9-2321-4567-8b7c-e3a16a391182": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in NCT00391092, and only one case of anemia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2,
            4,
            12,
            14,
            16
        ]
    },
    "09a3b17c-769d-4af2-b64e-cc97f2cc3ed1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for NCT00089479 but not NCT02964234.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "43b2d04b-4862-4888-90f9-4c84e84ac1e4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white british origin. she is eligible for NCT00089479 but not NCT02964234, due to her age.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b44e4079-5e90-4198-b2fe-0c68f4f0bf7e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Statement": "Patients eligible for NCT02964234 must live in the USA.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "28deb41a-d197-4629-85a7-d1bbceef5339": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Secondary_id": "NCT00246090",
        "Statement": "Patients eligible for NCT02964234 and NCT00246090 must live in the USA.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "58829e99-090c-45f7-9ff9-dfdd946bb525": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of NCT00246090 15% less total adverse events than cohort 2 of NCT00266799.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16
        ]
    },
    "46565da8-655b-4896-9631-e54917aa5d0a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of NCT00246090 0.0015% less total adverse events than cohort 2 of NCT00266799.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            15,
            16
        ]
    },
    "a4b0933e-071c-4d57-8745-2e419eae9411": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of NCT00266799 had Acute coronary syndrome.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "227282bc-9d96-4167-9056-4b07f81374ba": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of NCT00266799 had ACUTE VESTIBULAR or acute coronary syndrome.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "799fc49c-13f9-4153-80c2-8fa40015abf4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Statement": "NCT00365365 only recorded one type of acute adverse event.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "8610e1d5-31c1-43f3-91e6-1bfb9c1b2a8d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Secondary_id": "NCT00005908",
        "Statement": "NCT00365365 and NCT00005908 only recorded one type of acute adverse event.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "931ab269-6ddc-4853-b53a-29ecdb17ff83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There was only one patient cohort in NCT00005908.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "ed7928ab-5fdd-4b9c-8ae4-9f54802edc57": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There were 8 cases of pharyngitis in cohort 2 of NCT00005908.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "64b6b74d-a3bf-4a39-a913-9a2e80fae27a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 32 patients in NCT02340221 had Diarrhoea.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "4c52d774-3e66-4493-87e3-2cf253eeea75": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 89 patients in NCT02340221 had Supraventricular tachycardia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "4bbee3cf-2821-475d-bd17-f49d1df3a871": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "NCT00259090 studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1
        ]
    },
    "a84660fb-91cb-48ca-a8c8-51568481e388": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "NCT00259090 studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ]
    },
    "54c5738e-58ac-4879-91c1-94441c5c8326": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in NCT00077857.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            5
        ]
    },
    "0f10d9e6-4da7-4bb0-96d2-cf827c20dbee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have three or more target lesions and more than 1 regiment of chemotherapy to participate in NCT00077857.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            5
        ]
    },
    "e470de8d-e86f-4876-86ca-2e5becae45b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for NCT01904903.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "627be8ee-e798-4f82-add7-9c265361e6e6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for NCT01904903 and NCT01663727.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "6e2d92db-6edb-4643-b399-5d514333868c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "There is no maximum or minimum age defined for participation in NCT01663727 or NCT00072293.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            16,
            17,
            18
        ]
    },
    "a52c22fe-e782-48b0-9d9d-8de723ffde31": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "Patients must be between the ages of 13 and 76 to participate in NCT01663727 or NCT00072293.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            16,
            17,
            18
        ]
    },
    "e5422252-99d2-465f-8e6b-517a33cc4ccc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for NCT00072293.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            12
        ]
    },
    "9a04672d-dc0b-474a-bde7-4b4243f4391a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a palpable breast lesions and axillary lymph nodes are eligible for NCT00072293.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            12
        ]
    },
    "7f36d025-5d6e-4656-b7cd-2f12d4312a8c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "1/7 patients in cohort 1 of NCT00452673 suffered dose-limiting toxicities.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1e2ed451-c25d-495d-8e34-3f107bc13288": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "7 patients in cohort 1 of NCT00452673 suffered dose-limiting toxicities.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "f9d2ce73-3495-4d5e-93e9-76b425036db3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The minimum Progression Free Survival for patients in cohort 1 NCT01997333 was 1.6 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e0d2b169-b1f2-4643-a031-1716dc26a2e6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The maximum Progression Free Survival for patients in cohort 1 NCT01997333 was 1 year.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "aa0d8abd-8f49-4e0d-aecd-83e264b5190a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "NCT00593827 and NCT02425891 both measure PFS of their patient cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4a9ddd69-2fc7-4441-80d3-1bf88683027a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "NCT00593827 and NCT02425891 both measure PFS of their patient cohorts and use the same time frame.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5806fd60-b84b-4112-bcdd-2a9b260fe591": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative BC are eligible for both NCT00593827 and NCT00478257.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "0a2408f5-e072-4124-b0e1-797bcc2894ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative MBC are eligible for both NCT00593827 and NCT00478257.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "537afca1-c546-45aa-8f98-9a74c17beb99": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in NCT00478257.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "0483b0a7-bd8a-4578-a451-b8f72e4f948a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in NCT00478257. However, being pregnant is required.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "1043bde2-5b72-4542-ba29-33d77fab2f2c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from NCT00627978, as this would complicate the evaluation of neurologic and other adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18,
            19
        ]
    },
    "d4623a53-3a18-47ff-8c3e-570e27eada41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from NCT00627978, as it would prevent them from giving informed consent to study entry.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18,
            19
        ]
    },
    "a6420daf-7386-4340-a430-2152b0274f8a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00b5l and total bilirubin > 1.6 x ULN are eligilbe for NCT00101400.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12
        ]
    },
    "ac0d87e5-3f10-41fb-ba09-9acf6a96b63c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00b5l and total bilirubin < 1.2 x ULN are eligilbe for NCT00101400.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12
        ]
    },
    "90581810-ab54-4318-bfd6-7933327d9b74": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in NCT00217399, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5,
            8
        ]
    },
    "de5c9d30-9458-4ff8-aa7c-f9cd4ca26041": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in NCT00217399, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5,
            8
        ]
    },
    "28966aad-00d4-4699-824b-4db856887084": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "Cohort 2 of NCT00303108 produced marginally better results than cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "101166a1-91ec-4029-a7a9-97f4f885a8c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "The Cohort of NCT00303108 which received D+C and Taxane Na\u00efve, produced marginally better results than the other cohort.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "9667bb8c-95ca-49b8-9a0b-1392f9ad288f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in NCT00076024, was 191.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "eb205a05-9cf4-4eb6-b8c1-20e058944c1f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in NCT00076024, was just over a year.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "25c04d53-56f0-4820-8d44-7a3e5d2ad32d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from NCT00045032, but may be eligible for NCT00416572.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "740a077c-bb1f-4aec-8faf-dd1f815b0108": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from NCT00045032, but may be eligible for NCT00416572 if they are a UK resident.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "8cc6551c-5351-4bc2-81d9-cb640e0efc0f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients suffering from ovarian or lung cancer are excluded from NCT00416572.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            13
        ]
    },
    "29671a7c-134a-4875-a6e9-e8738c67b9f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients with a prior malignancy of skin cancer are excluded from NCT00416572.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13
        ]
    },
    "b03860fd-956f-4363-9979-22736c3e0a85": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP in cohort one of NCT00534417 is just under 27 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "1f0c4723-80f8-4e1c-afc9-ec9be27c1bda": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP for patients in cohort one of NCT00534417 is NA.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "80887e80-3f27-4e61-9750-4e7d6b9060d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Statement": "In NCT00410813, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "c3ac7425-6e6f-4ae8-957e-68067290596d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Secondary_id": "NCT00617539",
        "Statement": "In NCT00410813, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in NCT00617539.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "afc1ac96-6b8c-457f-8b46-020f8dff47a9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases are still permited to enter in NCT00617539.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2653b8b8-c4e1-490f-a5fe-5f7ce5c6c8e8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Presence of Extracranial metastases is part of the exclusion critera for NCT00617539.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f6dc6925-4d7c-48bc-9810-f75d3277b037": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to taxane is obligatory for patients in NCT01908101.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0479dca3-a8a8-4abe-906f-36c85ca07783": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to doxatel is obligatory for patients in NCT01908101.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "addb6a6e-8065-43cd-b092-ea1c954ac12e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for NCT00316199.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "3bc38592-7afe-4669-8b1b-0a8110ef4343": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for NCT00316199.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "375b3395-5662-424d-bd9b-d5a72fc289b8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "NCT00191269 did not use PFS to evaluate the performance of its interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "59488476-8f7f-4ae4-919b-d27499a5aa84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "NCT00191269 measured the Number of Participants With Disease Progression (PD) or Death, to evaluate the performance of its interventions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "501b8fd1-8d6b-415e-9398-c62dd1a3405d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "NCT00399529 and NCT00754325 both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d5c77765-e349-47dd-a07a-3ac718bf6de3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "NCT00399529 and NCT00754325 both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d7c03c79-e5fe-4fd3-8ee0-8f288f8a0cb0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for NCT00399529.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ]
    },
    "168696dd-a686-4c17-92f8-d953a4a2eab7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement, are eligible for NCT00399529.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ]
    },
    "edcd2cef-6677-4bf5-a8d4-dfea4428d469": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either NCT00167414 or NCT00334802.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "1c9e83cb-aa9c-4cac-bfac-9cd4dff9bd2e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either NCT00167414 or NCT00334802. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "53eed363-245c-4403-8112-5be3dce80ce0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients do not need to have a known hormone receptor status to participate in NCT00167414.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "827b1818-30a0-44d3-9cc5-2af90cc9f4e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in NCT00167414.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "269e564e-d800-4ddf-8c10-825bcd9cf226": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of NCT00022672 with a PFS exceeding one year.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "618a1e24-cbed-433f-895f-8b67276168af": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of NCT00022672 with a PFS exceeding 6 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "6821bbc1-df79-41da-b564-257031703ab6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause was higher in cohort 1 of NCT02555657, compared to cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "a9a71812-0898-4dcd-bf54-da8c858eeb55": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of NCT02555657, compared to those in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "1eec583e-96c0-42c9-8008-979c9945c2ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of NCT00370552.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "902862fe-4635-4e57-b0b7-1ba7a0092781": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of NCT00370552 than in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "c9ba4c00-e730-43f4-9def-835eb515ae00": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "More NCT00004888 participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "49488f34-a359-49d3-aa7a-7e4ce4646681": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "Most NCT00004888 participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ]
    },
    "8bd46eb1-140c-4e6b-9db3-701f67b8669e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "NCT00696072 uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for NCT01855828.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c18fa695-2b49-450a-a165-18c6d38e1811": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "NCT00696072 uses Overall Survival (OS) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for NCT01855828.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3a8f0fc4-13ec-4b22-95ff-f39eaaa6187b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "20 patients treated with Dasatinib and Letrozole in NCT00696072 had a Disease Free Interval (DFI) Greater Than 2 Years.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "6d71a512-97c0-4e1f-8673-025b0c580f32": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "Most patients treated with Dasatinib and Letrozole in NCT00696072 had a Disease Free Interval (DFI) Greater Than 2 Years.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "1ba92efc-fe14-43e9-8343-acc3946c5592": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of NCT00337103.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "b8f1410f-1926-48fd-b7e4-dfaea21470e7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "Several patients in the Eribulin Mesylate group in NCT00337103 survived less than a year.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "837e7625-df54-499b-8580-a63a662b52c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in NCT01151046 had a much lower Median PFS than the MM-121 cohort.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "69694f8a-34c4-4a79-9afd-4070a4eab3c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in NCT01151046 had a much lower Median PFS than the MM-121 cohort.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "621c97ef-9aa4-471a-90ab-d663c4b153fe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Statement": "Patients of any ethnicity can participate in NCT00097721.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "0916743b-c8bc-48ee-b079-b1e0c40fcd1d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Secondary_id": "NCT00896649",
        "Statement": "Black women cannot take part in NCT00896649 or NCT00097721.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "726a7795-c54b-48df-b076-19a5f951b1ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in NCT00896649.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "4b5a4024-1351-4060-a212-5675922bf01e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in NCT00896649, neither is Adequate organ function or a particular racial or ethnic background.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "72f41eda-4614-4228-8226-19503e87bc93": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in NCT02463032.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            15,
            9,
            17
        ]
    },
    "88d646f0-681f-4464-8a26-b3f365eba980": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in NCT02463032.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            15,
            9,
            17
        ]
    },
    "e0a02a8d-fe1e-4d3f-b296-4c862154897d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "The Ixabepilone 40 mg/m^2 group in NCT00633464 reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "efa36777-0f11-47df-8d77-999efebedf2d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "Cohort 2 of NCT00633464 reported worse results than cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "9121f961-3c3f-41a4-8b64-766645e3dfe4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0  bilateral  breast cancer cannot take part in NCT01816594, but may still be eligible for NCT02222337.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0dd8c02d-518b-4111-8347-748abfe07807": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0 breast cancer cannot take part in NCT01816594, or NCT02222337, unless they present LVEF below 50% ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "00f9af3e-4593-474d-9e55-06441b8f20fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for NCT02222337 must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "dbba7285-d786-470f-bb63-cae469be3fbb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for NCT02222337 must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a0908bb5-f8d8-40d3-ad18-19368be2f51d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60% of Subjects in NCT00270894 were able to Complete at least 85% of the Planned Dose on Schedule.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "f9a06631-00f5-4595-90a6-1be6113783f9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60 patients in NCT00270894 were able to Complete at least 85% of the Planned Dose on Schedule.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "46efe1a2-9b75-4508-88a8-983dfd3f19ad": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "NCT01743560 and NCT02435680 use non comparable evaluation metrics, and significantly different time frames.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8925cb97-d598-49d9-b9bc-76c6e9c59cef": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "NCT01743560 and NCT02435680 use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "11646daa-b652-4773-a13a-e2b442b3cc84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of NCT01743560 none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "f5babb7f-1aea-4af2-a104-bb4ec2a4d9e2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of NCT01743560 the majority of patients had Stable Disease, none of them had complete or partial response.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "1e4a4a75-c344-4cbb-b521-79916ff83cdc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "2 of the patients in NCT02069093 were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "daa03591-7939-438f-942d-5c939f18597f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "All of the patients in NCT02069093 had minimal Stomatitis symptoms and a normal diet.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4ac0d32e-3812-451d-bf37-6fae8dc3c7db": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from NCT01827163.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "41f84ba7-b30f-4999-bb75-ee690d9d00ae": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for NCT01827163.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            14
        ]
    },
    "57bf3d9a-6db2-4e22-bdda-911d7ede1b8b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients with BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both NCT00438100 and NCT00662025.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e8c15959-2ddf-4259-a06b-e8c5273171ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients must have BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either NCT00438100 or NCT00662025.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "03e4fffc-40d0-456d-b9dc-4e88921aaa6e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 NCT00662025 Participants had a confirmed disappearance of all target and non-target lesions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "ba89a0a0-938a-4ac9-a1e6-3c667c91ded3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 NCT00662025 Participants had a confirmed disappearance of all target and non-target lesions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "dda2ae94-c61e-4a1b-a594-117c61270d46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Only Black women are eligible for NCT02692755, as long as they do not have uncontrolled or symptomatic brain metastases.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            10,
            11,
            12
        ]
    },
    "77d82ae6-f270-45ed-be8d-40b3fd54195e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Asian, white british and white irish women are eligible for NCT02692755, as long as they do not have uncontrolled or symptomatic brain metastases.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            10,
            11,
            12
        ]
    },
    "fc6013df-d5ee-4d7d-b360-0be5a3dd24cb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Statement": "Any patient can enter into NCT04396665 as long as they are willing to provide Informed consent and are capable of using the internet.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "69b2aeff-0ce8-414b-8458-9d64b63dbf27": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Secondary_id": "NCT00493636",
        "Statement": "Any patient can enter into NCT04396665 or NCT00493636; as long as they are willing to provide Informed consent and are capable of using the internet.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ]
    },
    "4d456c05-4ccf-4662-baac-2b319a15e1f3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of NCT00493636 had a longer median, maximum and minimum pfs than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            7,
            17,
            9,
            19,
            11,
            21
        ]
    },
    "b51d7fea-76d4-4f52-8fd7-8b1a0a170b30": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of NCT00493636 had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            7,
            17,
            9,
            19,
            11,
            21
        ]
    },
    "ced74407-3ddf-446a-a735-27e1c0090c6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 of NCT02513472 produced better Objective Response Rate results than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "2343a45e-9f0d-4ca5-8395-42cc2e066a66": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 patients in NCT02513472 surivied almost twice as long as those in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "c39700fb-d1c0-4228-a43a-2bd08215ec46": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women are eligible for NCT01176916, and Premenopausal women are eligible for NCT00186121.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "4173e9d0-53e7-4a12-abae-9a4829c9a622": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for NCT01176916, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for NCT00186121.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "54ed3071-df78-4ab8-b1f0-287de75748ac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for NCT00186121.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "1e35e4be-c28f-4320-a71e-f49e8f641d1e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for NCT00186121.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5
        ]
    },
    "815ba569-8dbb-43ea-a673-f525848fcec1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for NCT00981305, as long as they are over the age of 20.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "d23fa494-3f17-4cce-adc5-ad2e4a5fb4f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for NCT00981305, as long as they are over the age of 20.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "c8f27969-2de7-4eb9-99de-74f9f38a38fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "NCT01808573 Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "4089be0d-5390-427b-aa81-49e43aa4c8c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "NCT01808573 Patients receiving Neratinib Plus Capecitabine had a PFS  much longer than the study time frame of 38 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "70075982-e0fe-4b41-b9ba-81c0751416b4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "NCT00706030 studies the interventions impact on target lesions and NCT00171704 measures changes in Bone Mineral Density, the results from these two studies are therefore not directly comparable.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "461357b2-e377-41f2-af66-09759ac3b75f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "participants from both cohorts of NCT00706030 had a drastically lower CNS Objective Response Rate than those in NCT00171704.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2d0c4cfe-6a6c-41ba-be8f-50c93aff0e64": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "Most patients in the Letrozole group of NCT00171704 had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "07315610-9607-48e6-afa3-105945fe0d99": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "All patients in the Letrozole group of NCT00171704 had a decreased Bone Mineral Density of the Lumbar Spine after 3 years.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "2b4201c9-36e3-40f6-b088-eda8ebacc4e4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in NCT02260531,than in the ER+ and/or PR+ group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            7,
            9,
            10,
            11,
            23,
            14,
            25
        ]
    },
    "c9810bb0-dd96-4da5-b76b-3c3a57297abf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in NCT02260531, than in the ER+ and/or PR+ group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            7,
            9,
            10,
            11,
            23,
            14,
            25
        ]
    },
    "7f7e7e8b-864e-4eed-88e9-c026fb4438a3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There were twice as many patients with DLT in cohort 2 of NCT02622074 than in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            19,
            20,
            27
        ]
    },
    "c01dcbb8-aa04-49de-b10e-779e4b0e9276": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There was 38% more patients with DLT in cohort 2 of NCT02622074 than in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            19,
            20,
            27
        ]
    },
    "516a6fcb-0a67-45ea-bdbd-94bef6b44f3f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of NCT01827787 had a much lower ORR than the HR+/HER2- cohort.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            6,
            7,
            15,
            9,
            17
        ]
    },
    "ee238d64-e0bb-49da-985c-a0398199d9a4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of NCT01827787 had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            6,
            7,
            15,
            9,
            17
        ]
    },
    "55575476-10b0-456f-9b1d-b915857d4ca5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for NCT02073487 but are excluded from NCT02658734.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "6fe036d6-6ce3-404a-be3e-1f7223721a16": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with any of the following drugs; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for NCT02658734 but are excluded from NCT02073487.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "10ee0450-8a2a-4da3-a563-2e3fce80a0cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for NCT03371732 and NCT02073487.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "b35e817a-d073-4342-a2f1-d492b4dfc645": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for NCT03371732 and NCT02073487.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4bc45602-f2eb-496b-af52-64cb2e2bbaa2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "patients with Karnofsky Index  = 72 are eligible for NCT03371732.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fb0d14c6-2757-4396-ad0e-a8b541a1a85a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "Any patients with Karnofsky Index  < 80 are eligible for NCT03371732.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7da66993-2714-410c-8810-1cd0c76a4f32": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Secondary_id": "NCT00943670",
        "Statement": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both NCT00943670 and NCT02279108.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "f326822a-3521-4702-a3b8-663477817fab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Statement": "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from NCT02279108.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "acfc55ab-64da-4c85-aeec-0f4c1f757c51": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in NCT00943670 was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "c3b80419-fe28-4bbf-a36e-5adf5d6c1ed2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in NCT00943670 was at its highest on Day 1 of the third cycle, before T-DM1 intravenous (IV) infusion.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "1afe1e2e-2001-4926-bdce-062b11549a49": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Statement": "The majority of patients in NCT00054132 had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "bcb66b29-cb5a-4cd5-81c6-c80f7e1dfb3d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Secondary_id": "NCT01421017",
        "Statement": "As NCT00054132 and NCT01421017 use very similar outcome metrics, we can easily compare and contrast across their results.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "cb3b7f83-d337-472e-bea3-2b038ba138b1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "NCT01421017 studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fe435e67-3f52-41cf-9fd8-291cfef14a80": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "NCT01421017 studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS), 9 weeks after the start of treatment.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f27b5f75-dd2d-4183-bdfb-f36ed0d02242": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In NCT00450866 a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "80c284c5-cd98-48fd-9c51-82d27f087b00": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In NCT00450866 group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "ccd845bd-e4e3-41d9-b039-d0e5332333f7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for NCT00121992, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-3, N0 and M0 breast cancer.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12,
            13,
            14,
            15,
            19
        ]
    },
    "d1ef94af-04b3-4a65-b8d3-8c3d2f7f9247": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for NCT00121992, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-4, N1 and M1 bilateral breast cancer.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12,
            13,
            14,
            15,
            19
        ]
    },
    "e0c6bf4d-a071-48ee-9ac4-f91229d52ea7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "Both men and women of child bearing potential must use adequate methods of contraception to be eligible for NCT03197389.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            16,
            17,
            18
        ]
    },
    "1010ea3b-d251-4ab3-a419-f6eaf0f1b168": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for NCT03197389.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            16,
            17,
            18
        ]
    },
    "46614834-690a-4be5-a429-972cacb37d9c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at least 60 beats per minute are eligible for NCT01847001.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a961d37c-0024-496b-9485-05f8b6953bf0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at most 50 beats per minute are eligible for NCT01847001.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "edb9350e-6927-492a-bd6b-21078af2ca8a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are not able to take part in NCT00612560.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "421762ad-accc-46cb-bff1-dbbae73bb266": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are able to take part in NCT00612560, unless they are can read and write in italian. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ]
    },
    "4005f8fd-eaa4-4e0f-9480-d86a90355259": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of NCT00393939 than for the Docetaxel group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "1818314c-76fc-446d-b5ae-1a017dbbb136": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of NCT00393939 than for the Docetaxel group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "9def67a2-6f35-41bd-b6b2-a65cfb056ea0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of NCT00503750 must have recently undergone either an echocardiography or a MUGA scan.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "e7cb971a-3270-445c-93da-60d76a970640": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of NCT00503750 must have recently undergone either an echocardiography.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6
        ]
    },
    "771cab41-8c17-4836-a491-e982eb806045": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in NCT00450723.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "4d405cce-f5d5-4605-8056-21fa80df59bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in NCT00450723.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "a7633b8b-fcd1-4933-8e48-bff71c0d376b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients must be doing less than 2 hours of physical exercise per week to participate in NCT01340300, however, this is not a requirement for NCT00671918.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            8,
            18,
            19,
            20,
            21,
            22,
            10,
            24,
            25,
            26,
            27
        ]
    },
    "bd945c25-276e-40a9-899f-0de72f508441": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in NCT01340300, however, this is not a requirement for NCT00671918.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            8,
            18,
            19,
            20,
            21,
            22,
            10,
            24,
            25,
            26,
            27
        ]
    },
    "70d84185-0920-4efc-bcd6-9f6e35eb1aed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) are eligible for both NCT00571987 and NCT00671918.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            12
        ],
        "Secondary_evidence_index": [
            0,
            9
        ]
    },
    "8edf0935-3e42-4a9b-9ce2-1e2fe6dc37da": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) or Melanoma are eligible for both NCT00571987 and NCT00671918, and are able to participate in these trials alongside other drug trials, up to a maximum of 3.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            7,
            12
        ],
        "Secondary_evidence_index": [
            0,
            9
        ]
    },
    "37874d1a-2adc-4c61-9ff6-2f2a89c220b1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "occupational exposure to ionizing irradiation will not disqualify a patient from entry to NCT00571987.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "d98eb6ee-6eec-4f39-ad5b-5529a14a3e07": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to NCT00571987.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ]
    },
    "7ce52221-f373-4e9a-9838-065fcf72e33c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism are excluded from NCT02683083.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "90c49130-d18f-48a8-820b-34957dbb8d68": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism and diabetes mellitus are eligible for NCT02683083.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "3616a8be-758c-4329-8274-cb9adbfef1d4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "The majority of breast cancer patients in NCT00548184 treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "d07cb664-c595-42a2-8eea-41f316d77ad8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "64 of the study participants in NCT00548184 receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response, or better, after 12 weeks.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "5eb52403-e078-429b-94c0-cc03fdefb9dc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in NCT01305941, meaning their cancer is Histologically-confirmed as being HER2-positive.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "329e7b81-ec0e-4d4b-9279-d9f88e02ac24": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in NCT01305941, meaning their cancer is Histologically-confirmed as being triple-positive.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "f995dc72-238d-48eb-91fe-f31994bb3ccf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to NCT00717886.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5,
            6,
            7
        ]
    },
    "73d45c72-e28a-42e4-9e14-5067bbbed465": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to NCT00717886, patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "bd8adb71-545a-40b8-93b9-9f5dc181ee07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of NCT02915744 was less than one month.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "a6f4cfe6-6f53-4847-b8f3-9329ab8bcf1e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median Overall Survival (OS) of Patients between the two cohort of NCT02915744 was less than one month, the patient with the longest OS was in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "22fe022c-4be8-4c17-a03a-7c2877217bd4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of NCT00244881 participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "61662e0a-9b33-4f28-9e7a-0789a96ab3dd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of NCT00244881 participants had an increased level of CECs after 42 days of treatment.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "4026d527-35f7-4110-b6ae-82f7c75118b2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "NCT01648322 has a shorter time frame than NCT00436566.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f058b82e-6959-4485-bb5a-c50d978d9418": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "NCT01648322 has a shorter time frame than NCT00436566, both of these studies employ the same units of measure in their evaluation.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            9
        ]
    },
    "b9e8e745-fb15-43c0-a6ee-2e627d5ae86d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in NCT00436566 suffered from Congestive Heart Failure (during active treatment).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "9cbbbcc8-1218-43c9-bbfb-7355886a84b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in NCT00436566 suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c5662862-3f91-4130-bba6-fe4eb9d983e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 1 prior treatment with trastuzumab to be eligible for NCT00317720.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "172bd82d-34cc-406c-9a5a-de553dc898fa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 3 prior treatments with trastuzumab to be eligible for NCT00317720.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            2
        ]
    },
    "f7de9a45-02c0-4896-9830-0fd92da98f1e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan for before entry for both NCT03273426 and NCT01985971, for NCT01985971 patients will also need to have a brain MR and PET imaging, after study entry.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            6,
            2
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "27bc0321-c0a9-49e6-8a8d-e9cc4a3440d4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan of the spine for before entry for both NCT03273426 and NCT01985971, for NCT01985971 patients will also need to have a brain MR and PET imaging, after study entry.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            2
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "d8e1ccb8-8544-4d68-ae9c-ef28ea508bfe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with Concurrent serious uncontrolled medical disorder may be eligible for NCT03273426, but are always excluded from NCT01091168.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            4
        ]
    },
    "c56feb40-ee78-4119-8acb-a14cbd0fb7e3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with dementia or schizophrenia may be eligible for NCT03273426 and NCT01091168.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            4
        ]
    },
    "a3f8f378-7ab2-4ff2-bc31-aa5e206bd500": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of NCT01091168 had a median Overall Survival of less than a year.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            11,
            12,
            13,
            14,
            15,
            9,
            17
        ]
    },
    "b6f6890f-e7d3-4e22-ba9c-54edc23a7ce0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of NCT01091168 had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            11,
            12,
            13,
            14,
            15,
            9,
            17
        ]
    },
    "67be6148-18b6-4c20-88b2-d47c36304639": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Statement": "Every patient in NCT01097460 suffered at least 1 Treatment-emergent adverse event over a span of 2 years.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "4ee47bbd-dc47-427b-a0fd-8a9895ce2b6e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Secondary_id": "NCT01009918",
        "Statement": "Every patient in NCT01097460 and NCT01009918 suffered at least 1 Treatment-emergent adverse event over a span of 2 years.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "f5d5992b-1339-4a00-8213-7f73684b69f9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Secondary_id": "NCT01688609",
        "Statement": "There are no racial criteria for entry into NCT01009918, but there are for NCT01688609.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            17
        ]
    },
    "b025f417-3603-4ccb-b4c9-4136ca609165": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Statement": "There are no racial criteria for entry into NCT01009918, however there are gender criteria.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "dd0d388a-4a97-480c-8eed-cfcf3490851f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer, with Primary tumor > 2 cm in diameter to participate in NCT01688609.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "16ae68ae-7390-447e-80c4-be994f442fb2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed PR+ invasive breast cancer, with Primary tumor > 2 cm in diameter TO PARTICIPATE in NCT01688609.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7eb3a632-5096-4ce3-9888-ec8a735b8079": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "antibiotics within 10 days prior to beginning is acceptable for patients entering NCT00418457.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "7d2ae0f1-1ef2-4483-b5da-34ef31403a07": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering NCT00418457.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "8039edef-8a98-4f78-8e88-3ae3da686e4f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Pre and Post menopausal women can enter NCT00982319, as long as they do not have prior hormone replacement therapy.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "94a73f25-0e92-4bca-9121-9b250ac713e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Only Post menopausal women can enter NCT00982319, as long as they do not have prior hormone replacement therapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3d66637e-553f-4ebc-8aab-f49e877479c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in NCT01381874 had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "6b7e50cc-8f68-46cf-a92e-0868f629b4d6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in NCT01381874 had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "9fb16e7e-6d65-4da1-baaa-838c24d565b6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in NCT00369655 had a Confirmed tumor partial response, No patients in NCT00091832 were evaluated for tumor response.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "51b6f5da-f4f1-4125-8b0e-49091d8a7c92": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in NCT00369655 had a Confirmed tumor partial response, in contrast thirty patients in NCT00091832 had partial tumor response.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "93bbee94-af96-475b-ac50-b56c7e79d08e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "Both cohorts of NCT00091832 in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "c436fef5-6018-4fc6-b6ab-11821e91fe43": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "cohort 1 of NCT00091832 had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur).",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "5742b0c1-810e-49bd-9b4c-31de34493c2c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59% of Arm A of NCT00477464 achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8f5fd2d6-2ffb-4be5-b5fa-5257390aeed8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59 patients from Arm A of NCT00477464 achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e40b6499-5467-4495-8d89-2b1a47e36fda": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Statement": "There are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to NCT00005879.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            13,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            41,
            64
        ]
    },
    "1a804dcc-280e-4612-bbe4-c8ce99b2897b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Secondary_id": "NCT01217385",
        "Statement": "The only criterias for entry to NCT00005879 and NCT01217385 is that patients must be female, over the age of 21 and british.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            13,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            41,
            64
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "50f4622e-7ae9-474e-8be0-e92d70fb5077": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not allowed for patients in NCT01202591, however, NCT01217385 may accept patients despite this.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "6c75184c-ed88-404c-9525-6ce0b59bab18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not explicitly banned for patients in NCT01202591 or NCT01217385.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ],
        "Secondary_evidence_index": [
            6,
            7
        ]
    },
    "59b74c71-c886-456b-a105-02add235aa1b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in NCT01202591 suffered adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "f031ea66-6738-4a82-bce4-4a02191ed139": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in NCT01202591 suffered life threatening adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "657db03c-3a03-4791-a77c-c26171c4bd60": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "NCT02041429 and NCT00068588 use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b4ffc1c9-a218-4f4f-bac5-e1516c8c357b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "NCT02041429 and NCT00068588 use the same outcome measurements, same drugs and the same cohort sizes.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "39bdbf62-834f-45ea-b0c5-d5aa807451e3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "We cannot compare results between the two Arms of NCT00068588 as there were no patients in cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "d5d3c695-450d-47cf-b44c-a8beaa737116": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "between the two Arms of NCT00068588, cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "87d8fedc-bec1-453b-950e-4cb6b4a6a83f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for NCT02756364 patients must have had ineffective aromatase inhibitor (AI) therapy before study entry, ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "ae3fedae-65c9-45dc-9166-5163551c6b4b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for NCT02756364 patients must have had aromatase inhibitor (AI) therapy before study entry, resulting in complete tumor response.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            9
        ]
    },
    "428d4e90-65c0-47c7-9840-fe5e25734703": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from NCT00436917, as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            39,
            40,
            41
        ]
    },
    "bbc93e65-753b-41d1-94ec-d273c53c49dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from NCT00436917, as these would interfere with the necessary CT and MRI scans for the study.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            39,
            40,
            41
        ]
    },
    "edeeff34-fe2e-406d-9289-73e50a3457a3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The NCT00676663 placebo group performed worse than the test group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "8cef638b-8778-49f3-a810-6e5b985cb3c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The NCT00676663 placebo group performed much better than the test group, as a lower PFS is ideal.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "ad7ee01c-8b36-4542-a820-d68e46fa62ec": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "On average patients from both arms of NCT03252431 experienced Grade 4 Neutropenia for the same amount of time.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            9,
            17
        ]
    },
    "c9568d2f-334f-457e-b736-60fc886e8917": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "patients from both arms of NCT03252431 experienced Grade 4 Neutropenia for the same amount of time. There was no recorded difference whatsoever. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            9,
            17
        ]
    },
    "a3cff507-f159-4551-af38-5d1d9284dd91": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of NCT00373256 included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "20914c47-2f6b-4d36-9eb5-6ed62abc62ab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of NCT00373256 included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the mean PFS for this group was just under 7 and a half months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            7,
            8,
            9
        ]
    },
    "cbd67adf-65b5-4e9f-bb7e-9923ecfa3646": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of NCT00820170 the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "51175ee7-5a8b-40ff-9b58-1fc26bef6c74": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of NCT00820170 the MTD of paclitaxel is approximately is 120 mg.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "ce467379-6078-47a3-bf91-0c7d33cc96f7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "NCT03366428 and NCT00295620 employ non comparable outcome measures.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "3375000f-aadd-4690-a3dd-de4593d3a118": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "NCT03366428 and NCT00295620 use similar outcome measures, evaluating how long patients survive after treatment.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e97a09db-d283-49d7-97ba-887a9e5e02c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "3/49 NCT03366428 Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "9626e7a8-936f-45ce-9b0c-55f018c82d2a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "0/49 NCT03366428 Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of <60ms.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "5ab519c0-f716-4f81-8dfc-1629ba887b4c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to NCT02872103, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for NCT02995980.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "23a9228a-b400-4e0c-95c1-ed9c6f5bf15c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to NCT02872103 and NCT02995980, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "e6d81eea-fbda-49ea-be53-5a7b1a23076a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for NCT02995980.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3,
            4
        ]
    },
    "a1e33a17-5f5e-40e4-ac59-903abba4733a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for NCT02995980.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3,
            4,
            5,
            6
        ]
    },
    "10ee5364-4506-453d-a6bf-941318f4a39e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In NCT02447328 11.1% of patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients had Unexpected adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "91f0aaf0-5c2a-4441-a9a2-04294fd081a4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In NCT02447328 11 patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients passed away from Unexpected adverse events.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "938e8a5d-623b-4540-8be3-1d4325aa1699": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "NCT01004172 and NCT00802945 both evaluate response rates, however NCT01004172 studies CNS response, whereas NCT00802945 studies tumor response, additionally, they test different treatments.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8a6ee377-ee0c-40ac-968d-31f5060e614b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "NCT01004172 and NCT00802945 both use tumor Objective response rate to measure the effects of their different interventions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e60f5cc3-bf20-4b26-9d4a-375674cc5454": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of NCT01231659 has a higher ORR than both the NKTR-102 14 Day cohort of NCT00802945 and the NKTR-102 21 Days cohort.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "cf0e65a3-efc6-4098-b1d8-8b28b2f21ca2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of NCT01231659 has a higher ORR than both the Everolimus + Letrozole cohort of NCT00802945 and the trastuzumab cohort.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a492bb1d-55bb-40c7-8548-f0ad45d00b6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 40% of NCT01231659 participants achieved either complete response (CR) or partial response (PR).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "4a166773-31c6-4168-abfd-1ad621875151": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 20 NCT01231659 participants achieved partial response (PR).",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "480955b2-867e-4098-8020-55ba2cb83f20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "NCT00096356 results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "7b76af36-9e05-4155-9172-653bdbe52d90": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "NCT00096356 results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "4810151d-a4da-4a4b-b3dd-5d6698a1d94d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "NCT00191152 and NCT00073528 study the Progression Free Survival (PFS) of their participants, however they use different Units of Measure.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            9,
            10
        ]
    },
    "a3a97147-cb32-40eb-a552-eefdf37deea4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "cohort 1 of NCT00191152 had a much longer median PFS than cohort 1 of NCT00073528.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "fd404a6a-8bf9-4f03-8114-ebe9fe02ea73": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression NCT00191152 was over 11 months  in the Docetaxel Plus Capecitabine group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "86df8cd0-e8db-41fb-b556-524e0c5b92fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression NCT00191152 was over 21 days  in the Docetaxel Plus Capecitabine group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "081c745b-b690-429d-8c03-30b46ab53250": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of NCT00338286 had a Progression Free Survival over 1 year.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "e7cffa7d-0945-4555-a638-ed7bc468d72b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of NCT00338286 had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "ebc01ce1-1445-4ac6-b9fe-7bf6eef3666f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "NCT00073073 and NCT01325428 do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "cdfd9532-95f9-4bc5-b8e6-a349821075fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "NCT00073073 and NCT01325428 do not require participants to be of a particular ethnicity, sex, height or to be able to speak a specific language.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "081002b9-5271-42ee-a005-52b91f52e336": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There are no placebo or control groups in NCT00073073 or NCT00054028.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2c618813-6013-4658-935a-5ba105cc02a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There is no placebo or control group in NCT00073073, in NCT00054028, Suramin acts as placebo.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c9227520-b91b-4721-ac37-23ed7b24903a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both NCT00054028 and NCT02162719 at least partly administer their interventions intravenously.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "dd4f85fd-d8e4-45a3-9967-039cf722e01f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both NCT00054028 and NCT02162719 at least partly administer their interventions orally.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7f9bd2ba-5ada-4186-afad-89c45f2a6e35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Statement": "NCT02162719 does not investigate the effects of its intervention on patient tpCR.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2e60e482-dbe5-4ed8-bf1c-5ddf0101b4be": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Secondary_id": "NCT02131064",
        "Statement": "NCT02162719 and NCT02131064 investigate the effects of their intervention on patient tpCR.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cb89ab63-fbb4-4ae1-868a-dc07de4f58c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "over 100 participants in the TCH + P group of NCT02131064 achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2bd6cb66-d47e-4dc2-a10d-9060dd96b877": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "less than 60 participants in the TCH + P group of NCT02131064 achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ff7a9c4e-8a9b-4312-be9b-4ccb11d55a20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of NCT01605396 had a median PFS of over 5 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "73978563-05bf-4771-8c92-2dcb38474acf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of NCT01605396 had a median PFS of over 38.43 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c1c42d16-236e-4d4b-b734-8e94c4055bbe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Progression Free Participants (After 16 Weeks of Treatment) in NCT00708214 were in the Afatinib 50 mg With Letrozole group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "efdc812f-8673-44b0-8419-3d670163c39c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Participants with disease progression (After 16 Weeks of Treatment) in NCT00708214 were in the Afatinib 50 mg With Letrozole group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "4d7b6e49-c3bd-415f-92bb-953a9899eee0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "NCT00082433 results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "39de9bcc-1c9c-41df-b5ed-8d83fce34044": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "NCT00082433 results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, triples patient OS, compared to Capecitabine alone.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "2b69576d-dd5a-4e58-9e9f-ede767f09292": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in NCT01572038 receives 3 different drugs, whereas in NCT00826267 patients receive 1 of 2 possible drugs.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cdc64ef1-899e-4f53-a8c2-415461683d3e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in NCT01572038 receives 3 different drugs, whereas in NCT00826267 patients are given supportive-expressive group psychotherapy instead.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9a604271-3a3c-492c-9c6b-5e3452641bd1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of NCT00826267 receive different quantities of different drugs.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1e6fe456-d84f-49b3-829f-dc2a188c1048": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of NCT00826267 receive 50mg of different drugs, administered orally from Day 1 to Day 21 ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "bc31bdb6-0ab4-4f4a-9975-a3b4f0ece08d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "All patients in cohort 1 of NCT01401166 had a Preferred Method of Drug Administration.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "31e46c7e-b081-41b0-9d01-467b694b5c4a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "several patients in cohort 1 of NCT01401166 Preferred oral tablets as a Method of Drug Administration.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "323d8c6e-b693-4962-a3b7-5b3d376213c4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of NCT01566721 is less than 1%.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "1162ed4c-7be3-466e-a51c-68bf6a701b05": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "More patients in cohort 2 of NCT01566721 had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "51f17844-c9c6-4036-a12c-7f6dbec8d6f7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least one participant in NCT01125566 receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "6f44a406-6a97-486a-9f2b-0735cd179be7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least 400 participants in NCT01125566 receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "ce3b9f93-604f-4b38-b694-657fc6988745": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in NCT03584009 administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            15
        ]
    },
    "36b9d187-7d28-4dd4-a914-09ca2a90a121": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in NCT03584009 administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            15
        ]
    },
    "9e2f7eb9-84e3-481b-bbb2-ae84d043aefd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "NCT00445458 and NCT00950742 measure the DLT of their respective interventions, using the same time frame.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8bddc052-c5ad-44ef-b648-3a867d9c1933": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "NCT00445458 and NCT00950742 measure the DLT of their respective interventions, using the same time frame and the same unit of measure.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5c210040-1679-45f0-87d0-d4859a4be23c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100% of participants in the Afatinib 30mg + Herceptin group of NCT00950742 suffer Dose Limiting Toxicities.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "55b5101e-1a0b-4b55-b3fb-b0f1999f604a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100 participants in the Afatinib 20mg + Herceptin group of NCT00950742 suffer Dose Limiting Toxicities.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e0f33605-12e4-4ae1-b1c6-15087bb964bf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "NCT00325598 has a much longer duration than NCT02441946.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "c0ecc876-0c72-4317-9a4d-41ccc94f0992": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "NCT00325598 does not have a defined end date, whereas NCT02441946 lasted 2 weeks.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            3
        ]
    },
    "9d7779c5-407b-4035-8807-4b39b94b9534": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is no difference in results or cohort size between cohort 1 and 2 of NCT00325598, the increase in Gy has no notable effect.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            9,
            10
        ]
    },
    "011d9679-3605-4f18-9acb-881de40c9837": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of NCT00325598, the increase in Gy has a huge effect.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            9,
            10
        ]
    },
    "81dc6c6c-809e-4784-ac38-f04a661c4053": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "NCT02286843 is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "aadab9c7-451e-47f4-8e73-2d94a61d0358": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "NCT02286843 is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5170ee8d-1ba1-4632-9a53-2598d73b39a7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "NCT01422408 is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "bc7c9383-3417-416c-bf18-fe070645b6a0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "NCT01422408 is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "90c75a67-7de3-404e-86f3-d9b4fd7150aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "NCT00171340 results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "2084c575-503e-4666-b5b8-db6d9b1b6945": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "NCT00171340 results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a smaller, but still positive change in Bone Mineral Density (within a certain patient demographic).",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "e15aa386-1bad-424a-8fb3-5bc4ca22fb2d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of NCT00431067 participants achieved Objective Response (OR).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ee14c250-a2df-47f3-8375-f12160ea3446": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of NCT00431067 participants achieved partial response (PR).",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8d9b9089-37d3-44c6-b5dc-b3a44d2e0929": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of NCT00291577 to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7fd0e376-c718-4269-99ca-d83d15f0a49a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of NCT00291577 to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5a32767a-d290-4b3c-aceb-2ce7682039eb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "NCT00687440 had a higher percentage of patients with at least partial response than either cohort of NCT01307891.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "74a9efa3-4141-433b-a364-03180f0c8b8c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "Results from NCT00687440 and NCT01307891 indicate Abraxane + Tigatuzumab produce better ORR than Caelyx, Docetaxe and Trastuzumab.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "fbecaafa-3eb6-4c66-a2ac-4167bacc4c50": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Tigatuzumab group of NCT01307891 has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "d9cf10a8-79a6-4860-abf5-c1da658a240b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Capecitabine group of NCT01307891 has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "d0f1bb9d-7546-4409-b644-94ba7599cfe1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in NCT00319254 and the longest recorded PFS was in NCT00435409.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "aff4f051-38a4-4f9b-93b9-eac1e0e26362": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in NCT00319254, at only 5 days, and the longest recorded PFS was in NCT00435409 at 78 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "0c317c55-9595-4381-9ddf-f150c37a93e6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "NCT00319254 did not use overall response rate, tumour response rate or preference score as its outcome measurement.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ce915393-8784-4688-9d4a-324525198b72": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "NCT00319254 did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ae0cd890-ecb8-4810-9052-e1ffbcf83842": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f8c807bb-fb7a-43b3-a77c-2a3d7ec70779": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0fa43757-0d79-4334-b0a9-758840da18ae": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort B of NCT02186015 with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "782f26a3-7d0a-4e47-85e0-8bf986ff8741": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort A and B of NCT02186015 with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d2fdc4f9-fdf9-4c07-9865-ce4712267903": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of NCT01925170 undergo a Mammography, whereas patients in cohort 1 of NCT00324259 receive 6 mg Estradiol, and no Mammography.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2442a759-32d1-4a88-bb06-2ee3e5dee679": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of NCT01925170 undergo a Mammography, whereas patients in cohort 1 of NCT00324259 receive 6 mg Estradiol as supplementation for the Mammography.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2124d0b3-4c77-4f62-bd71-56b6edf16316": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of NCT00324259 had one more patient with Stable disease than cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            12,
            13,
            23,
            24,
            25
        ]
    },
    "df6c789f-a6b0-4657-8b44-42711e7d3641": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of NCT00324259 3 more patients with Complete response than cohort 1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            12,
            13,
            23,
            24,
            25
        ]
    },
    "5d8d5789-e495-4c8a-a98c-fd58ff25dccd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in NCT00900627 receive the same drug treatment, but different doses.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ba7c918e-aaab-49c3-bc9d-e44caa244397": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in NCT00900627 receive the same drug treatment, but group 2 gets double the dose.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7d6b9b32-2e47-410b-9f8e-295d0345d33f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in NCT00509587 receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "49f7ee2c-98e6-4909-bc9a-deaeeb9d5ce9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in NCT00509587 receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3cd62ee5-9cc6-44e7-bf57-baf245ee5478": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Patients from NCT00246571 receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "26e572c4-ba0c-4345-bcec-bfcdfc8e1826": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Renal cancer Patients from NCT00246571 receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "646020e1-e31f-44e0-acd1-e2d9e4be1c5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Statement": "16/179  patients in NCT00550771 Experienced Cardiac Events, with the majority of those coming from cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            10,
            17
        ]
    },
    "9c45a678-b014-49db-a6a4-c10af11479ed": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Secondary_id": "NCT00143390",
        "Statement": "over 20% of patients in NCT00550771 and NCT00143390 Experienced myocardial infarction or arrhythmia, with the majority of those coming from NCT00143390.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            10,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "29b68227-4366-4108-8a41-4de851f66bb6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In NCT00143390 There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "5045a2da-c540-4d30-a5bf-f724e898ec77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In NCT00143390 There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "29a94505-7a5f-4b0b-8eb5-a82d474e6377": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "NCT00446030 and NCT00975676 have no overlap in the drugs they use for their interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a77ea2bf-4e44-4c9c-96d1-223d1699861a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "NCT00446030 and NCT00975676 have no overlap in the drugs they use for their interventions, however they both have placebo groups.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5e3aa395-3c7c-41ab-8c42-b68e39f9187d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "NCT00975676 does not explicitly state the dosage of Triptorelin for either of its patient cohorts. On the other hand, NCT00632489 gives details of doses used for LBH589, Capecitabine and Lapatinib.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            6,
            3,
            9
        ]
    },
    "721ac203-a01e-4611-aedb-3add4c306223": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "NCT00975676 uses the same dosage of Triptorelin as NCT00632489 uses for Capecitabine and Lapatinib.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            6,
            3,
            9
        ]
    },
    "24d4635b-a566-4619-b9e1-b647a38846a4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "NCT00632489 uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            6,
            3,
            9
        ]
    },
    "b067a614-5053-4c8e-ae8d-195a49e2b451": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "NCT00632489 uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            6,
            3,
            9
        ]
    },
    "6baed271-afaa-44c8-b926-1baf362da45e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "NCT00383500 is not testing a drug based intervention, it is testing a Medical device called the Flexitouch.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "943f5a04-5771-4b1a-8074-3f80f934b0be": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "NCT00383500 is not testing a drug based intervention, it is testing a Medical device called Manual Lymphatic Drainage.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3bfc0034-5445-47ae-86b8-6b21b1362b8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Both patient cohorts of NCT01302379 had a median Insulin change from baseline lower than -15%.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            9,
            17
        ]
    },
    "610bc570-7954-473e-87fa-70e05e63fa62": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Only one patient cohort of NCT01302379 had a positive median Insulin change from baseline.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            9,
            17
        ]
    },
    "67a39142-2a7f-419c-8205-d34f4edb4ba9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in NCT02162667 had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "28b23369-cd71-40a8-b82d-543fe31a11e2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in NCT02162667 had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "2c4c3d92-38aa-4ce1-b41c-99339c79425e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Single IV Infusion of ZA 4 mg group of NCT00399802 had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "62a8d91c-2a51-4b9e-9be9-12f916441989": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Lapatinib group of NCT00399802 had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "9cdecbe5-b6cf-4070-ad70-87c10c3cebff": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "NCT00470847 participants will not receive any Lapatinib post WBRT.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "334bed0a-ec04-4bbc-9bcb-67690e573c15": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "NCT00470847 participants will receive either Lapatinib, WBRT or Herceptin.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f69aaa9c-00f3-4f20-ad58-3af8e82b7510": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "NCT01289353 and NCT00429182 share at least one drug in their chemotherapy regiment.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3
        ]
    },
    "f4ffba4f-21ac-4b52-ab04-ab40f15b9f2b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "NCT01289353 and NCT00429182 both administer bi-weekly oral Carboplatin to their test groups.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            3
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3
        ]
    },
    "61a25083-06f8-44e8-a60d-9d64126c6912": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "NCT00429507 and NCT00429182 give their patient cohorts Stem Cell Transplants on the first day of the study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "37880891-304c-426a-b30d-6d2eb8b8daf8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "NCT00429507 exclusively uses radiotherapy in its intervention, whereas NCT00429182 gives its patient cohorts Stem Cell Transplants on the first day of the study.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "84bbfe0f-241d-470a-9963-d00a9461199f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike NCT00038467, NCT00429507 does not administer any medication orally.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "39a88eec-8848-470a-b3ed-06901be6e744": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike NCT00038467, NCT00429507 does not administer any medication orally or intravenously.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d558cc6f-d931-4183-bd6c-92c94dfe6a9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in NCT00038467 each receive different oral medication, either Tamoxifen or Exemestane.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cc3f85b1-1b5a-4b9d-9da3-347045b60d08": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in NCT00038467 each receive the same doses of different oral medication, either Tamoxifen or Exemestane.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e368bf99-49a2-4476-8383-122503193f1b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "NCT01104584 does not use trastuzumab, Tamoxifen or Exemestane in its intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "18faa61d-4db2-4bce-84be-33e7c67c017e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "NCT01104584 participants receive either 50mg/m2 trastuzumab, Tamoxifen or Exemestane.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e89f0e18-7316-4f10-bc9b-f90f959f6338": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in NCT00748553 receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "6c6b6ef0-40e0-49b2-9293-3bfe6496829d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in NCT00748553 receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "eb048c37-5720-40bc-bd49-7478f90e64c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "At least 8 participants in NCT02581839 had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e2fa48cc-f0a0-4420-b717-aa2e6cf53888": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "All participants in NCT02581839 had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 16 weeks.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "52e7d33b-c3c7-4cc8-9b08-3d0a534fcef2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "Most patients in NCT01268150 treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "f4d1556c-a232-41dc-adc6-985085c4ba73": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "The Eribulin Mesylate group in NCT01268150 had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ecf6e20d-18e4-460a-a7fe-b3a1a4033a80": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "NCT01570036 and NCT00021255 monitor the DFS of their patient cohorts, however NCT00021255 reports the % of patients with DFS >= 5 years whereas NCT01570036 reports % of participants with DFS >= 2 years.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8a539e82-375b-4480-9a44-f85ff5974451": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "NCT01570036 and NCT00021255 monitor the %  of their patient cohorts with DFS < 6years.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2b02f04e-827b-42e6-a38a-592ed8c3f924": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of NCT00021255 recieves Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "268821b9-8f66-44fd-b43a-f28d72cb2092": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of NCT00021255 recieves Doxorubicin only during cycles 1-4, and then Doxorubicin, cyclophosphamide, Herceptin and docetaxel during Cycle 5 of the study.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "f92ebc7a-d58b-4b87-94a1-4cf5fae01823": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of NCT00195013 is a placebo group, NCT00620373 does not have a placebo group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "85674a35-e2ac-4c9f-9400-0a7aafa5cd1c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of NCT00195013 and NCT00620373 are test groups. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "85a3f312-d81b-49db-a9ca-2c9fea75beb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "NCT00620373 tests two different breast imaging modalities, namely X-ray and gamma imaging.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3d9d1e6e-c36a-4e09-ac11-85226f441424": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "NCT00620373 tests two different dental imaging modalities, namely Mammography and gamma imaging.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9ce8d8d0-00bd-4636-ae55-fb98656c00b3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Statement": "Patients in NCT00313170 treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "d1e449ec-6e4b-4755-8e0f-3fb44fd9ab2d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Secondary_id": "NCT00305448",
        "Statement": "Patients in NCT00313170 treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "7427bfb7-5abc-4ecf-a1ec-5f8e668b4e9e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 4 patients in both cohorts of NCT00305448 achieved either complete response (CR) or partial response (PR). ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "b08067a0-76d0-407c-b70d-9a62e347de87": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 11 patients in both cohorts of NCT00305448 achieved either complete response (CR) or partial response (PR). ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "bb2f017a-35e2-4760-95c8-79bc1217f98c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of NCT01953003, will be administered medication orally and intraveinously.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            4
        ]
    },
    "af2e6e9c-78e3-4fbc-8155-3643561dffb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of NCT01953003, will be administered medication topically and intraveinously.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            4
        ]
    },
    "187c0dc0-4788-4159-ab8b-47238b55babb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in NCT00291135 is half as long as in NCT00291694.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2181a3a9-2664-4ebb-b923-bfdf8a166003": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in NCT00291135 is half as long as in NCT00291694, but twice as frequent.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1bcca0cd-fd0b-41d5-b4ee-d91a8197095d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "NCT00291694 does not specificy the route of administration of its intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b3497eec-ccf8-46d0-be24-230a43dae764": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "the route of administration for both interventions in NCT00291694 is a topical skin cream.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "22907cc7-2a14-4f92-8f2f-b1932701eeb4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "NCT00821964 participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "47ffbb4c-decf-453e-ba7b-b7a5e19c76c5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "NCT00821964 participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7f07f5c1-ce26-467b-92ad-8215f08bcf2f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of NCT00240071 survived over 200 days without documented disease progression.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "990f7620-ccec-4484-9996-676ad9c6777d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of NCT00240071 died in under a 100 days.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "f543d64f-2b69-4118-b519-f156df1a6dfa": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "NCT01923168 and NCT00577122 do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "ebb4537b-bd45-4ed7-aff3-fa13e6d1f232": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "NCT01923168 and NCT00577122 both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "66339fbc-280b-4689-bccc-cb71fadbae38": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of NCT01923168 require participants to take 300 mg alpelisib once daily.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d97aa931-9bbf-49c6-bb1e-26a04d97dc42": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of NCT01923168 require participants to take a total of 150 mg alpelisib every two days.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "3b69133c-a31a-4716-b5aa-61da664d85b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Statement": "Only patients in cohort 2 of NCT00880022 undergo Trunk compression.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            2
        ]
    },
    "dbd403a2-d59d-4084-92e3-18e2b9313bb5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Secondary_id": "NCT00916578",
        "Statement": "Only patients in cohort 2 of NCT00880022 undergo Trunk compression. However all patients in NCT00916578 are treated with Trunk compression.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2452b39e-e89d-4630-96dd-6a57498c770f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "NCT00916578 is testing a combination of chemotherapy and radiotherapy.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5b0e6c16-2383-4590-98d4-1d6d37776214": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "NCT00916578 is testing a combination of capecitabine once daily with radiotherapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "959d7e46-019e-4797-8cc5-d371d493a945": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in NCT00841828 had lower percentage of participants with pCR compared to cohort 1 of NCT01959490.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            10,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "15c332bf-b948-4930-bd1f-584729fa903d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in NCT00841828 had lower number of participants with pCR compared to cohort 1 of NCT01959490.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            10,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "a09b911b-dba1-4be4-847e-aa799c0e2a6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only one participant of NCT01959490 did not achieve Pathological Complete Response.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "846c5be9-3166-4fe6-ab88-9a6b1167bcc9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only 20% of participants in NCT01959490 did not achieve Pathological Complete Response.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "99dabf7b-6b92-45c8-84de-fb467d82ebf0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in NCT01042535 was 800 mg.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5d1fc18b-3ddb-4184-8715-1dee079c9b2f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in NCT01042535 was 800 mg.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "a5d7d2f4-60fa-4062-b9b2-73f3f8359c07": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "NCT00106002 participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "bbf34867-019e-403d-95c2-94293ec3c645": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "NCT00106002 participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "132debac-fbda-4a9c-a4c0-061ebf94c67c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "NCT00791037 and NCT00606931 do not use the same route of administration for their interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8397af59-5c8f-4aae-8a05-df3a2515da4e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "NCT00791037 and NCT00606931 both use vaccine based interventions, however this is done in different intervals and for a different duration of time.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "981107e1-da81-4d31-b470-3b6aa7d1721f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "NCT00606931 tests positron emission tomography as a technique for guiding a medical procedure.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "41f889e4-f1dc-4dd3-87cb-e76c08991064": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "NCT00606931 tests MRI scanning as a technique for guiding biopsies.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f93f55ae-adb9-403f-bc6d-e844433fe2c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike NCT03210220, NCT00290745 has no control group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "0e1697c1-2212-465d-badb-5df728b17060": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike NCT03210220, NCT00290745 does not test Gonadotrophin-releasing Hormone Analogues or medical devices.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "945d4471-9715-489a-9d06-3598aa395074": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "There is no radiotherapy or educational part of the intervention used in NCT00290745.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "df84d7c5-c22b-4fd4-8767-6f4e6441ad86": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "in NCT00290745 participants from different ethnicities receive different interventions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "c0a2d894-f9e3-4b85-83ac-5efbdaa48d25": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of NCT02518191 is the control group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "3be91bf9-0be0-4e5a-b386-18577c9f48bb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of NCT02518191 is the control group, as the Eligible patients with breast cancer treated with GnRHa every 28 days.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "ee190267-5b7b-49d3-bac9-50ccaa9852b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "NCT01277757 is not testing a novel Physiotherapy or radiotherapy intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "223101d5-b173-4368-a8aa-dd2734c5426a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "NCT01277757 is not testing a novel Physiotherapy or chemotherapy intervention.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c2d8e30a-5453-43ef-a4bc-5254f258aa38": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of NCT03765996 receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "24956e1a-c987-42bb-9482-2e80dcd7174b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of NCT03765996 receive taping to anastomosis regions., but no  Complex Decongestive Physiotherapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0cc58d4f-b56a-40b8-9016-a2472d24643b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In NCT01106898 Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients. Whereas all NCT00262834 participants receive the same treatment.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "12e2f5ae-73cd-4746-80e2-15f03a3f6c1c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In NCT01106898 and NCT00262834 Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "07e66980-5873-4269-b3ae-98527c2f3edc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of NCT01106898 patients had Recurrence-free Survival < 3 years.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "4c4ae73b-c970-4dc9-9050-0b89cbabb1bd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of NCT01106898 patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "e7befc05-20f6-4505-9d66-507ef738b838": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in NCT00537771 and all participants of NCT00354640 take 1 milligram of anastrozole PO QD.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "bf4801c6-3b98-4850-bcf4-b7bcf903c7ff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in NCT00537771 and all participants of NCT00354640 take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            5
        ]
    },
    "ae344626-8957-4d7c-931f-0a8fd8abb9e9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of NCT00354640 receive 4 times as much simvastatin as anastrozole.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8f0fd384-8240-46b5-847d-6d191e7d4dad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of NCT00354640 receive higher doses of anastrozole than of simvastatin.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "873d5086-9097-4afd-989b-d7e47f607522": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "NCT00368875 results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "e9d00903-3b0b-4bb7-a1c2-2ba6981e223a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "NCT00368875 results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2 .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "43af4b51-d5b7-445c-b47f-102fb1a247ec": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The most common Chevalier grades for patients in NCT00206518 treated with Taxotere/Docetaxel were 3A and 3C.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ]
    },
    "87be4b0b-4907-474c-b104-75c92a764e50": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The least common Chevalier grades for patients in NCT00206518 treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ]
    },
    "166194dd-3395-4bba-af3f-5a7b94b7de8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "3/4 participants in NCT00699491 suffered from Dose-limiting toxicities.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            13,
            22
        ]
    },
    "7cf8aafc-dd55-476b-9671-0f9ae117aab2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "NCT00699491 results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            13,
            22
        ]
    },
    "06412613-8762-4a9a-a943-2f502d01b1d8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of NCT00463788 than in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "418cb5a8-d3f0-4555-a99f-e09805ff6485": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of NCT00463788 than in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "ccb5cbc7-d96e-46a3-8b92-341650feb4f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of NCT00119262 both had 3 patients that suffered from Congestive Heart Failure.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "8f08c711-0c9a-49f0-bf80-4d0f51dc5f36": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of NCT00119262 recorded a different number of patients that suffered from Congestive Heart Failure.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "14546993-b642-4c6a-b3de-c954433c895d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Doxil and Trastuzumab were used in the NCT00331552 intervention, but not in NCT01738438.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "97bd5ea2-5735-443a-a13d-e319ec8465c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Cabozantinib and Trastuzumab were used in the NCT00331552 intervention, but not in NCT01738438.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0324ffad-61e0-4a20-8c9c-8792154b2a61": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " trastuzumab was used for the interventions in NCT00331552 and NCT01306942.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e83d2815-cc42-47e8-8019-24bc16905c09": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " The same dose of trastuzumab was used for the interventions in NCT00331552 and NCT01306942.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5cfccd6e-6fcd-464d-9a13-eb2d3999e82e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in NCT01306942 received more Dasatinib than those in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "30518f24-1c4a-4abf-a500-0b09f3e8287e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in NCT01306942 received more Dasatinib and Paclitaxel than those in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6ddd0bae-76d0-43ea-986b-bb47fccb4a16": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in NCT00572728 will not be made to take Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously like those in NCT02472964.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "ca50d32e-1555-4bdd-a18f-6d549fc9d1db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in NCT00572728 and NCT02472964 will take Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "606c3a3e-1de4-4032-941f-8563502180c4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "NCT02472964 studies tumours response, whereas NCT00089661 investigates changes in Bone Mineral Density.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "907302d4-540d-4850-8e36-97688682b850": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "NCT02472964 studies changes in tumour diameter, whereas NCT00089661 investigates changes in heart failure rate.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fa3ff811-536b-4999-b124-f9b521e63170": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in NCT00089661 had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            6,
            13,
            8,
            15
        ]
    },
    "af79c8b0-82fe-4ba3-bf7b-bd0f8a8bf4bd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in NCT00089661 had an increased Rate of Acute Toxicity , whereas those in cohort 2  did not experience any Acute Toxicities.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            6,
            13,
            8,
            15
        ]
    },
    "665f4895-b966-4adc-b25f-6a94544a6133": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "NCT01727011 and NCT01420146 interventions involve a variety of scans, such as CT, PET and dosimetry ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4c5232aa-218a-4ccb-8c2f-eb4412173aa8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "NCT01727011 and NCT01420146 interventions involve a variety of scans, such as CT, PET, MRI and dosimetry ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5a16f84b-e6c4-4915-951f-358f485fdb54": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "NCT01420146 and NCT00077376 are both single arm clinical trials.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2298583f-8470-4303-a1c9-90cf140b8279": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "NCT01420146 and NCT00077376 both have a control arm, and several test arms.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a29d9138-9feb-49ef-9385-c5f08a2226b4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "NCT00077376 investigates a novel chemotherapy treatment, whereas NCT01256008 is testing a type of psychological therapy.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b19f0300-4380-4d0c-917b-9f26c5f906b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "NCT00077376 investigates a novel radiotherapy treatment, whereas NCT01256008 is testing a type of psychological therapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5bed8e54-d2b7-4c38-8fe2-6dd15ca3776a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "NCT01256008 is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast NCT00300781 studies Neratinib, a type of chemotherapy.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "337ad1d6-daa9-4967-aeed-cccd8848f3b6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "NCT01256008 is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast NCT00300781 studies Trastuzumab, a type of chemotherapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6cb064b8-cce6-4618-9b31-5ca75271b442": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of NCT00300781 are assigned an intervention depending on their prior treatments.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ef20b521-d1df-4565-b21f-5cb38864ece5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of NCT00300781 are assigned an intervention depending on their hormone recpetor status.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "921167f5-aa7e-4add-968d-9066ae5caf9c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "NCT01390064 has more patients cohorts than NCT01017549.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3
        ]
    },
    "c14b0e97-4bb0-4089-8145-3161139656d0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "NCT01390064 has 5 more patients cohorts than NCT01017549.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3
        ]
    },
    "ff48f282-9303-4677-9863-b0b51f34ef87": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Statement": "The both Cohorts of NCT01390064 receive their treatment via Subcutaneous administration.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3
        ]
    },
    "c8271f53-20fc-4994-ac65-02ceb077d39e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Secondary_id": "NCT00485953",
        "Statement": "All Cohorts of NCT01390064 and NCT00485953 receive their treatment via Subcutaneous administration.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "caba12e6-90c6-4dbe-9606-10b5e2049a74": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in NCT00068601 and the Placebo dose in NCT00485953 are not specified.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3,
            8
        ]
    },
    "6e6ab7c8-69f9-4660-834d-ddd0bd152434": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in NCT00068601 is 150mg once every 4 weeks and the Placebo dose in NCT00485953 is 12mg QD.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3,
            8
        ]
    },
    "e5e95c63-58a1-41d8-86eb-74bd4e6384bf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "NCT00068601 and NCT01684215 do not employ the same route of administration for their interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a83bcfff-4a14-48bd-8e86-0d7719ab12b1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "NCT00068601 and NCT01684215 both use subcutaneous injections as the route of administration for their interventions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3,
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d2153e49-3d0a-4912-b06a-5682d665aaaf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In NCT01684215 there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "1dc57712-4fff-4aaf-a391-6267226b44b6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In NCT01684215 there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in NCT01684215 suffered grade 4 or above thrombocytopenia.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "1dc43232-e81a-4fba-b373-db60976b815d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "16 participants of NCT01129336 are considered to be censored. NCT01945775 used the same outcome measurement, but had no censored patients.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "aec200be-f4f1-4f85-b7f4-4102391b4f58": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "More than half the participants of NCT01129336 are considered to be censored. NCT01945775 used the same outcome measurement, but had no censored patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "e17fa99c-e474-4b74-904c-47e96b7edabe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of NCT01945775 was over a month shorter than the Median PFS for that group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "73043042-0614-4d8b-ab2d-8f33dfd3f28c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of NCT01945775 was over a month longer than the study duration.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "233ff4c7-eb66-4384-97bb-fd4e8762c541": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "Recurrence-free Survival, used as the outcome measurement in NCT01806259 and Clinical Benefit Rate, used in NCT00057941 are not synonymous, and represent entirely different patient characteristics. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7a0f8a8b-14b0-4eda-977f-9f4f875d0d46": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "DLT occurence, used as the outcome measurement in NCT01806259 and Clinical Benefit Rate, used in NCT00057941 are not synonymous, and represent entirely different patient characteristics. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "f303bf19-aff7-49e9-b703-9cdfbd3aa3fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 82% patient in NCT01806259 achieve Recurrence-free Survival after 5 years.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "5cd4448a-1015-4e05-8f03-759a672fe9ea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 85% patient in NCT01806259 achieve Recurrence-free Survival after 3 years.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            9,
            16
        ]
    },
    "9e001d6e-2f54-46ff-922c-859135b2ab9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in NCT00558272 was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "75d3b8e0-3fae-40f8-bf03-002af5e714e8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in NCT00558272 was a patient in the Zoledronic Acid 4 mg group, with a -73.0 % change from baseline.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "3c186221-f714-41d7-a321-93e9083ee4ca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Statement": "Cohort 2 of NCT01797120 is only receiving placebo tablets, and no other medications.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9,
            3,
            4,
            12
        ]
    },
    "c5afec0f-c5cd-43fb-a6ed-369d9634cb42": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Secondary_id": "NCT02005887",
        "Statement": "NCT02005887 and NCT01797120 both have a placebo arm and a test arm.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8,
            9,
            3,
            4,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4
        ]
    },
    "994f32b0-cc0a-4c4e-9670-55c7cbc23f93": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in NCT02005887 and NCT00050011 are receiving the same daily dose of oral Letrozole for the same duration of time.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "4c4f625d-d5e6-4c7b-b6c4-b4e93fcdd773": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in NCT02005887 and NCT00050011 are receiving the same daily dose of Degarelix injected into the muscle, for the same duration of time.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "f0490d91-2bb2-479d-94d3-818bc53f2c1e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "NCT00050011 results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD).",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            7,
            8,
            17,
            10,
            19
        ]
    },
    "ee61d638-4ddc-4051-a300-67e6b8ce8411": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "NCT00050011 results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD).",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            7,
            8,
            17,
            10,
            19
        ]
    },
    "daf17191-5a41-4c6c-99fc-69851bf02c2f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "NCT00256698 and NCT03573804 use completely different drugs and techniques for their interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c140f2eb-8b46-4510-9769-192759225d46": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "NCT00256698 and NCT03573804 use completely different drugs and techniques for their interventions, however they both require trained Radiologists on site for evaluation.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b93c163c-5f82-4110-8877-4ab56df3324b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of NCT03573804 must undergo at least one MRI during the intervention, in NCT02781051 patients must use a fitbit.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "c9bb8766-3ff2-405e-b1bb-c528d58827b0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of NCT03573804 must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in NCT02781051 patients must use a fitbit.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "811b19f7-872a-462a-a60f-45226e3d9630": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for NCT02781051 requires participants to exercise for 12 weeks while wearing a fitbit, no physical activity is explicitly required for NCT01067976.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b4399a17-5155-4b64-a464-df02e42536e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for NCT02781051 requires participants to exercise for 12 weeks while wearing a fitbit, in contrast a full year of daily physical exercise is explicitly required for NCT01067976.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "98a324b6-546b-4b8f-b514-8b01cfef263b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike NCT00941330, NCT01067976 does not provide a duration of cycles or any dosages in the intervention section.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "5a7db6a6-b759-46ea-8a7f-f4a0444b698b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike NCT00941330, NCT01067976 only provides the duration of cycles and drug doses in the intervention section.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "6f337a7c-50ee-4e53-b3bc-697d86213f07": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of NCT00941330 receive Exemestane more often than cohort 2 patients receive Cytoxan.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "717727eb-ec0d-4a06-9db5-da276566860f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of NCT00941330 receive Exemestane twice as often as cohort 2 patients receive Cytoxan.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "7a588cac-3a1f-48b7-982a-3880718ca6d8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of NCT00322374 receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "89d1085f-15d6-4213-8202-477cf5278ab8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of NCT00322374 receive a higher dose of Ixabepilone, at a higher frequency, than cohort 1, ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ea56228e-9e8c-4f59-bce2-8a45f7021e48": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "NCT00611624 and NCT00600340 administer their interventions at different frequencies.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "30e5f0f0-2c7c-4195-8b45-b909f5eeacc4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "NCT00611624 and NCT00600340 require patients to undergo a minimum of two weeks of Mammosite Therapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9bd1cb3e-7760-42ef-ac07-7891301b28d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of NCT00600340 recieves Bevacizumab at a higher frequency than cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2ca61ca4-045e-4339-bc55-0ae3697072e4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of NCT00600340 recieves Bevacizumab at a higher frequency and dose than cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "95ef0d6a-608a-4f74-9eba-5d26962af931": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "We cannot compare the doses and frequencies provided in the intervention sections of NCT01118624 and NCT01852032.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0a2df0b0-396b-4c79-b4d3-2bd3cb4354cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "NCT01118624 administers placebo tablets at twice the rate of NCT01852032, but less than half the dose.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7d9e48e7-b677-4725-83ce-da2bcaae48ed": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "Less than 5% of NCT01118624 participants achieved CR or PR.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e75d63de-76f0-499f-81cd-b2669a4e17aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "The majority of NCT01118624 participants achieved CR or PR.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a209b768-8773-4f99-8858-2ee86c1165b0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in NCT01712009 receive naproxen at the same frequency as cohort 2 patients in NCT00343382 receive Pilocarpine.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "c30ab9d2-e6b0-4548-b1b1-5cbce4811949": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in NCT01712009 receive naproxen at the same frequency and dosage as cohort 2 patients in NCT00343382 receive Pilocarpine.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "557a0c6b-0760-4337-93d1-a46b64844559": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of NCT00343382 recieves a lower dose of Pilocarpine than cohort 2 of NCT00798135 recieves of oral itraconazole.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2f9c02ea-8909-48d7-8483-37e9e4f39366": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of NCT00343382 recieves the same dose of Pilocarpine as cohort 2 of NCT00798135 recieves of oral itraconazole.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b8e16a72-201c-46a3-b514-8612b52bde70": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "NCT00798135 and NCT01209195 investigate different outcome measures for different interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8288d1f2-670b-4fcc-acfd-522db2e4a71f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "NCT00798135 and NCT01209195 both investigate Pharmacokinetics Itraconazole 500mg QD.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c18cd542-8b81-4dae-9d24-2d396a985e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 are utilised in cohort1 of NCT01209195 than in cohort 2, Paclitaxel doses are the same for both cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "f6a7fca9-2221-4c01-9fa3-bf7e3a43f33a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of NCT01209195 than in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "8e748ed8-afbe-4d95-bf9d-028dd8617557": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in NCT01720602 are administered by mouth, none of the treatments in NCT00602043 are given via this route.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            2,
            3,
            4,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "fa83c87d-85d5-4225-be7b-3667b4403d72": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in NCT01720602 and NCT00602043 are administered by mouth.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            2,
            3,
            4,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "5bc6a9b1-2be0-4a6c-a3b0-6a3dd96d3f21": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "NCT01720602 participants receive more anastrozole, letrozole and exemestane than patients in NCT00082810.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "cdb891d2-324f-405b-893e-a839d0281942": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "NCT01720602 participants receive more anastrozole, Fulvestrant and exemestane than patients in NCT00082810.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8d15bbd9-46cd-4b6b-8f10-0d07653d15db": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of NCT00082810, pariticpants receive tipifarnib more often than Fulvestrant.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ba2832c1-746f-47a4-b7b8-9e5e0e1ab4f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of NCT00082810, pariticpants receive increasing doses of Fulvestrant.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "db715d44-4687-4b09-86ae-2969055fe745": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of NCT00513292, but not in cohort 1 of NCT01697345.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f3407c7d-1260-46e9-9862-88134590348d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of NCT00513292, but not in cohort 1 of NCT01697345.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "24bbb44b-2b5c-434e-a85f-868a98d178ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In NCT00513292 the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "86a206be-b2f3-430d-94e3-f1d58f1fd45b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In NCT00513292 the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "18bcbb85-9043-4b89-b2d4-afa31231d763": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "NCT00236899 and NCT01153672 do not use any of the same drugs in their interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            4,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "bb65b1ed-a721-4299-ac1c-111e5782fe19": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "NCT00236899 and NCT01153672 both administer Paclitaxel and Gemcitabine to their patients cohorts, but only NCT01153672 utilises positron emission tomography.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            4,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "edeb9eb2-d99c-4197-9c21-e3abbd09af17": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in NCT01153672 receive vorinostat at the same frequency and through the same route of administration as NCT01432145 receive 6-Mercaptopurine.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a86b43a4-f3f0-4f48-bddc-ad1b520e4327": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in NCT01153672 receive vorinostat at the same frequency, dosage and through the same route of administration as NCT01432145 receive 6-Mercaptopurine.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9094fb5f-f6da-4a40-a6e5-5dede2ebc569": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "NCT01432145 patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2ab364c2-34e5-4926-87e3-b0fa2f49a49b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "NCT01432145 patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6516caf0-51dd-4eda-92ae-9e739abef98c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in NCT00278109, and used in only one of the arms of NCT01881230.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5366a801-0b46-4432-b49b-56ceccf9f36d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in NCT00278109, and used only in cohort 2 of NCT01881230.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "84f7c622-4a5f-4cd8-b551-8bdadb58b653": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of NCT01881230 had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "89f56c40-d694-43b7-8822-b3cc31fac189": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of NCT01881230 had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "37652bc3-3e37-4a58-9c15-9d16b9c7b8da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "NCT02536794 and NCT00712985 both administer treatments to their patients through IV.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "efe898b4-6da5-4db3-876e-8973bd059692": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "NCT02536794 and NCT00712985 both administer Zometa to their patients through IV, although in different doses.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "443cebad-d4fe-40e7-b86d-912b5013ac60": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in NCT00712985 receive a lower dose of Zometa by IV than NCT02038010 patients receive of ado-trastuzumab emtansine.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "e8f643d0-a425-4638-9b86-46bb40845117": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in NCT00712985 receive a lower dose of Zometa by IV than NCT02038010 patients receive of PI3K inhibitor BYL719  by IV.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "0de7b04a-c43d-42e2-8c82-d64d7e2cbd57": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither NCT02038010 or NCT00764322 are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0c063241-7ced-432f-bb0c-cebcf02614b3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither NCT02038010 or NCT00764322 are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c851309a-7a42-49f0-896b-09fb8a324a88": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of NCT00764322 had average increase of Endoxifen Concentration over 6 ng/mL over 4 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "6e6524c4-ae4e-405c-98d5-c7954eabf43e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of NCT00764322 had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "07791057-3c42-427a-95ec-543414849f66": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "NCT00089973 uses a 3 week cycle for SB-715992 administration.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "cd50eaca-810b-424f-9891-6ac16cd9f10f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "NCT00089973 uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7c904b24-a71a-49ab-b61d-06c9e291cff8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "NCT01539317 uses a topical intervention and NCT01323530 uses a combination of oral and intravenous treatments.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5439443e-9778-457e-bfe7-114ca10e1e81": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "NCT01539317 uses a topical intervention and NCT01323530 exclusively uses intravenous treatments.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c4bc7eb1-81d8-4d86-802e-60def5dc0864": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "NCT01106040 and NCT01323530 do not have comparable Outcome Measurements.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b07672f4-e50f-45aa-afbc-831450cfa095": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "NCT01106040 and NCT01323530 results indicate that the PFS of participants is partially linked to age, cancer grade and ethnicity.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "1ad02618-9c1f-4405-be37-c83dc5438263": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "NCT01106040 and NCT01441596 are not studying patient PFS, ORR or DLTs.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e37bebc7-e5c4-4c6a-87c3-685823185695": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "NCT01106040 and NCT01441596 are not studying PFS, PBR or DLTs.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "413f9160-1a27-42f3-a925-26c8560fa147": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of NCT01441596 may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "470fa0b1-d6fe-42e7-81c6-2e667e05b91e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of NCT01441596 may receive gradually increasing doses of Afatinib monotherapy, up to 160% of the starting dose.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "974ed497-390e-46ae-9f00-c41b8ae09a04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of NCT00425672 undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "af94badd-6361-4471-968c-37ba92e34133": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of NCT00425672 must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "8a884009-aa14-4efb-a6b2-c693b5f2c177": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in NCT00470301 is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "b4057197-4d68-446b-8d3f-ed507bb5f5a1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in NCT00470301 is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV, but only a subset of participants undergo axillary lymph node dissection.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2eece211-24b2-4449-8fd8-e7e12600b247": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of NCT01519700.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "97aa5714-6a83-403d-b8eb-34ebf3e59e67": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of NCT01519700.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "488d81b3-a281-49f7-b186-762bb2188c5e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of NCT00046891 recieves 60 mg of Ginkgo Biloba twice daily.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5478c5c6-6e69-4472-943b-9041aaad22b0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of NCT00046891 recieves 120 mg of Ginkgo Biloba twice daily.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "86731147-f137-4214-9f39-88582e12c6fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of NCT00258349 does not receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in NCT01328249 receive some.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e2b182fe-a6c5-455f-bb5b-7adb5a67044e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of NCT00258349 does not receive any Eribulin Mesylate or Vorinostat, whereas both cohorts in NCT01328249 receive some of both.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7d160edb-622b-4718-80c1-8781983d9ed4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 10% higher in cohort 1 of NCT01328249 than in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "f2245913-8116-41c9-8788-50a578d4eff8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 70% higher in cohort 1 of NCT01328249 than in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "1dfb46ac-3216-4a09-a191-c1cb0f33a757": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "NCT01516736 and NCT00733408 have non comparable results as the metrics they records are completely different.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "7c431b61-d25c-4659-aa0e-e00901e06e82": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "NCT01516736 and NCT00733408 have non comparable results as the different in cohort size is too significant.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "dc380ca8-86cb-458c-a1cb-baa6fce2952c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in NCT00733408.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "0361432c-e6d3-4a7e-9e62-4ba87636955f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in NCT00733408.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "dfc1aad5-48d8-4944-b312-1dcb696b3d08": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Less than 1/10 NCT00376688 subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "167e6256-9ae8-4b5b-a3ce-c2191856db98": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Most NCT00376688 subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "54bc610b-8f9b-4ec6-b28c-2cf1336c30aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in NCT01487954 had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4
        ]
    },
    "fd6ea7e9-e1b3-4d25-a93f-dc75937829b7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in NCT01487954 had to drink 4 cups of water, either Alkaline Water or Distilled, depending on which cohort they are in.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4
        ]
    },
    "faa15c13-a5c3-4517-9832-9a29c0f6c01b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "NCT00003404 does not have a Hypnotherapy based intervention, and NCT00711529 does not have a Radiotherapy intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "52d24336-677c-4e60-9ee0-ee98d72721cb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "NCT00003404 and NCT00711529 have Hypnotherapy based interventions, NCT00711529 also used pain medication in its intervention.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2bf8eda0-058c-4647-ad52-4c27c95eb9e1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "NCT00711529 participants are treated with hypnosis, this is not used at all in NCT02835625.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4,
            10
        ]
    },
    "9e8ab7fa-1bbf-4eae-986e-a01132e153ce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "NCT00711529 participants are treated with Cognitive behavioural therapy, this is not used at all in NCT02835625.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4,
            10
        ]
    },
    "7cba945d-0363-4c45-860f-0e92a70abb90": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "NCT02835625 and NCT00486525 do not use any chemotherapy or radiotherapy in their interventions ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "49ae1e43-846b-4348-a8b3-90397de11f1a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "NCT02835625 and NCT00486525 do not use chemotherapy, radiotherapy or mammography in their interventions ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5da2afbc-6cdc-4d0e-88c9-0a889c79799c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of NCT00486525 is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "28eaeef3-daef-406b-b698-db1fd34c21d4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of NCT00486525 is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c7e7dba6-21a5-4e98-bfab-fc3b7fe49920": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in NCT03475992 receive different interventions depending on their pre-diagnosis, whereas all patients in NCT03106077 took the same intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            2,
            8,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9cb98bea-5fb4-4bc4-aad7-d10128788762": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in NCT03475992 receive different interventions depending on their cancer hormone status, so Triple-Negative patients are seperated from HER2+ patients for example, whereas all patients in NCT03106077 took the same intervention.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            2,
            8,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d0cdeaab-3500-4529-9e14-0e4e569a680f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in NCT03106077 receive at least 150mg of IMGN853 by IV every 3 weeks.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5a8edbf6-4b05-49ee-8644-6c981db1cd1f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in NCT03106077 receive at most 200mg of IMGN853 by IV every 3 weeks.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "cc6ee63c-d256-434f-84d5-0e645d8c01cb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All NCT01928186 participants and cohort 1 participants in NCT00684983 do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, however cohort 2 of NCT00684983 receive all of these.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "83410caa-9e4c-4c84-a7f0-94c216a85031": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All NCT01928186 participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all NCT00684983 subjects receive these.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f0ad21f8-8420-460d-b4e8-625c3dffb100": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of NCT00684983 lived with the disease without it getting worse was half a year.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e5190a35-d8de-42e8-ba30-b203b6c8e489": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of NCT00684983 survived after receiving a TNBC diagnosis was 6 months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "73cb489d-2c3e-4d93-9b9b-0aaf9aa24922": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in NCT00429299 is administered trastuzumab at 4 milligrams per kilogram.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "a7c6cfa2-bd5a-4e67-b632-4ce9e7fe8d76": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in NCT00429299 is administered trastuzumab 600 mg/m^2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "154332f4-3d8e-4174-8b38-b62f670c34fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In NCT01818063 and NCT00559507 the only drugs administered orally are saracatinib and Veliparib.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            3,
            4,
            5,
            6,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "65a4bfc4-0850-45b9-9ce3-a5ff701f6c47": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In NCT01818063 and NCT00559507 the only drugs administered orally are Doxorubicin and Veliparib.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            3,
            4,
            5,
            6,
            14
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f2932fd7-24fd-4add-8dac-e3e1edf75227": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "NCT00559507 participants are given saracatinib PO every single day of the study duration.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4e1aec8a-86dc-465a-aedc-bbcbd8687f31": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "NCT00559507 participants are given saracatinib PO for a maximum of 28 days.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ac970ac3-7358-4d23-ae24-3047eaa2c898": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither NCT00382785 or NCT00784849 use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2cc281c7-e726-49aa-bc9e-7ff2a133e9ac": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither NCT00382785 or NCT00784849 use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "23296a31-f582-4352-ad03-6c9d64601908": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Breast breast irradiation is used in some form for both cohorts of NCT02104895, but not at all in NCT00784849.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6b19e002-25cb-49cc-b19f-0ec64d86cad5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Accelerated partial Breast breast irradiation is used in some form for both cohorts of NCT02104895, but not at all in NCT00784849.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "a33553cf-ad63-4a14-bb89-1430d74be7ae": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of NCT02104895 receive any medication orally or by IV.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "25bedc80-4798-46d1-8d6a-756c6da34769": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of NCT02104895 receive any medication orally, by IV or by radiation.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "99e46bb4-b0f1-41c8-8ef1-922f3b381ef3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "NCT02597452 and NCT01929395 do not use cyclical interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "67503b79-15ce-453e-a33f-2f0e9d86f378": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "NCT02597452 and NCT01929395 both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "5538266d-9e22-48bd-8e61-219e52e08cbb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "NCT01929395 only has one test cohort whereas NCT01857882 has both a test and control group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "1bc02674-fd2f-4a18-bda9-bc973f95a112": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "NCT01929395 and NCT01857882 are both utilising test and control groups in their interventions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "3e921ae4-54d7-43d5-8516-71c14ce2c33d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "NCT01439945 administers Magnesium Oxide to its patients whereas NCT01857882 tests an education intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            5,
            8,
            9,
            2,
            3,
            4,
            5,
            6,
            15
        ]
    },
    "940d9a6e-8f67-44c1-9838-44f9a0a31544": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "NCT01439945 administers 150 mg/Day more of Magnesium Oxide to its patients than NCT01857882 does.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            5,
            8,
            9,
            2,
            3,
            4,
            5,
            6,
            15
        ]
    },
    "1097f0cb-1fd2-48b4-9691-76b7059b0d84": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In NCT01439945 Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            5,
            8,
            9,
            2,
            3,
            4,
            5,
            6,
            15
        ]
    },
    "07b69886-0e7d-4886-a344-2ef7705bb496": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In NCT01439945 Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            5,
            8,
            9,
            2,
            3,
            4,
            5,
            6,
            15
        ]
    },
    "dac40008-d461-4a37-8b9f-46727c08beb4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "NCT00438659 has a topical intervention, whereas NCT01271725 has both oral and IV interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "85f5d134-7d9d-4063-bb1f-f9d456e0b476": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "NCT00438659 and NCT01271725 have a topical intervention, to be applied to the breast or face.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a10c4fbe-5896-4d22-90b7-3ef2b9f6a63f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In NCT01271725 The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "b2113967-3f59-4c48-a8d8-fc28c903dca6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In NCT01271725 The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "ad5848a1-d3fe-4af3-9f1e-2b40ca25f350": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "filgrastim is the only drug in NCT00513695 given by subcutaneous injection.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "b48eadfd-4796-404a-b045-9b6e0881d84e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "paclitaxel is the only drug in NCT00513695 given by IV.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "c5a06d38-eea8-4f83-8a7e-a2061a03f40d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither NCT02699983 or NCT00994279 require participants to practice yoga while Wearing a Fitbit activity monitoring device.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9fd5f217-a00b-4bb6-a03e-78e1799de65b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither NCT02699983 or NCT00994279 require participants to practice yoga.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "4c7aee06-d884-496d-9b11-aba1520f6e45": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "Between both NCT00994279 and NCT00545077 Bevacizumab is only administered to patients in cohort 2 of NCT00545077.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            3,
            9,
            4
        ]
    },
    "7e4d0806-b7a5-4e9c-b889-cca7e4912df3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "both NCT00994279 and NCT00545077 administer Bevacizumab to every single HER2+ patient.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            3,
            9,
            4
        ]
    },
    "b148e9b3-67e6-42f7-b415-31cbe6cf4b50": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of NCT00545077 receive Bevacizumab, but both cohorts undergo Endocrine Therapy .",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            3,
            9,
            4
        ]
    },
    "0afafeb1-f523-4cf9-a226-f9fdb737da8b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of NCT00545077 receive letrozole, but both cohorts undergo Endocrine Therapy .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            3,
            9,
            4
        ]
    },
    "dc7ef08b-08af-4417-8aa1-e4d630007dcd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On day 1 Cohort 1 of NCT00343863 receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e287938f-0d1c-4452-844b-6b4213e94bc6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On days 1-7 Cohort 1 of NCT00343863 receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0fcab6b8-074b-420b-8deb-e5fa33048f37": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for NCT02122796 does not detail the type or duration of the intervention, unlike NCT01575522.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "b1853e98-47fd-4f79-a169-23ca9dce609b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for NCT02122796 does not detail the type, dosage or duration of the intervention, unlike NCT01575522.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "3fca0040-7b44-4aa3-a6bb-c88c2a8e3e2e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "NCT01575522 and NCT00181363 are testing completely different modalities of interventions.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0f5fe491-b0e7-48d7-86be-8a937d08ba8f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "NCT01575522 and NCT00181363 are testing completely different modalities of interventions, but utilising the same 21 day cycle.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a58f9038-b094-4021-86a0-c1e1d29d1d97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in NCT00181363 is the patients position.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f7a4aced-1024-4781-bf53-8ac57637c844": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in NCT00181363 is the patients location.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "55ec49e8-b8da-4661-836c-8b02b25c432e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 1 of NCT00407888 receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "07f3f5ae-cee4-449c-bb9b-01e2d15b5367": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 2 of NCT00407888 receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "421912cc-3771-486f-8a0c-bcf761172296": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis is used in NCT00194779 and NCT02203565.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "4116b2d1-8c02-4b6c-8015-56eab22f0d31": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis and questionnaires are used in NCT00194779 and NCT02203565.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "bb46a30a-bb47-4d6e-9f29-e7bd0bec97c1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "There is a least one route of administration shared by the interventions used in NCT00194779 and NCT04080297.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "3145b34a-af63-46ed-a063-86d58b7f859c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "IV is used as route of administration by the interventions in NCT00194779 and NCT04080297.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c7e6eb11-f4e5-493d-a783-8246670f12b8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Cohort 2 of NCT04080297 receives higher doses of Q-122 than either of NCT02780713 cohorts receive of AZD9496 variants.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d43ceb5d-d66a-4a7b-bc09-3d8830ef9b51": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Both cohorts of NCT04080297 receive higher doses of Q-122 than either of NCT02780713 cohorts receive of AZD9496 variants.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8df1e5df-56fa-4201-90d8-a0ac9c72c252": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of NCT02780713 are administered the same doses of their respective drugs .",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "e5ab8727-af17-475b-a72a-43cd9fae5f47": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of NCT02780713 are administered the same drugs in different doses .",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3faa7fad-f3f7-46fd-b001-3846357d3140": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in NCT02115607 receive an Infusion of Perflutren Lipid Microspheres, whereas in NCT01823107 subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a215958e-2f13-4668-aae7-7b27f1e9c4e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in NCT02115607 receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in NCT01823107 subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c643a104-7441-4170-801c-e34e439fa04a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "11620689-3e76-4d53-b2bb-4be2aaf01691": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "398f5b43-ee18-4f10-bd7a-c76d23bd7a2f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "NCT00374322 results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            8,
            17,
            10,
            19
        ]
    },
    "fd1a9d75-54c9-44d7-83d6-95ad7cef876f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "NCT00374322 results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            8,
            17,
            10,
            19
        ]
    },
    "68bb3fbc-09d8-48f1-98b9-7e15343199d7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In NCT00375505 patients in the test group had better health outcomes than the control group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "d7a784f1-416b-4450-98ff-9379fcc2fc42": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In NCT00375505 patients in control group had a Z-score of 0.037, higher than the test group score. ",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "c68634f4-c19a-4d63-9a5a-04fd30693c99": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of NCT00338728 more Imatinib mesylate than Letrozole on a daily basis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7685028b-2d75-4566-89dc-b910c0d25410": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of NCT00338728 higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "78ad58a4-19a6-4f8b-8516-62db4d40c4cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "NCT00245219 and NCT00038103 both have control groups. ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0d4b9432-8054-4dfd-91cf-9397188b3d45": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "NCT00245219 and NCT00038103 only have test groups, so all patients are receiving novel (FDA approved) interventions.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "72536fd9-0850-40a6-a476-56d817b1df26": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of NCT00038103.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            9
        ]
    },
    "1d708e49-ad09-4684-a5f2-3a327c65311a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of NCT00038103.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            9
        ]
    },
    "706a85af-7455-4eff-a114-f148d47ed9b9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in NCT00036270 either had a disease relapse or died.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "7d548b5e-d7c1-4021-850e-749c6827588f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in NCT00036270 either had a disease relapse or died.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "6c015a52-eee5-4105-a2fc-a784d642c524": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of NCT01105650 weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "69da2b2b-b1a6-45ef-aef2-79cb429d7ef8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of NCT01105650 weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered Methylprednisolone 3 times per week for 6 doses.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "35afc147-b09b-4c02-93a1-a797111689a1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "NCT03329937 Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7505a08a-7010-471e-8f70-9e13d2ac9284": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "NCT03329937 Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 3 cycles, after which all participants undergo neoadjuvant chemotherapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "79d806d5-3405-472f-8da0-835ff60faef2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "NCT00591864 does not have an intervention section.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c3364969-3634-4cf1-81ee-441d163c59d8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "NCT00591864 patients receive Trametinib, Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8e6a89d9-e19b-4fc1-9e18-9b4c0a5bb87e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "NCT01964924 and NCT00524303 both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "6f9a2f1b-9fb1-435c-ae55-8a058e35f347": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "NCT01964924 and NCT00524303 both report Objective Response Rate (ORR) of their patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "135d4004-b9df-4746-ab20-ea0f8b6e1f2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of NCT00524303 had 9% better results than the Lapatinib arm.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "9984ea9b-b105-4aef-aa69-b11fc168b1d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of NCT00524303 reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "bdda6fea-4fc2-46ac-8fa9-c821b4f42f9b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of Event-free Survival in NCT00003199 was Stage IIIB patients, and the worst was Stage IV Disease patients.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "26b3f236-f49d-4779-ae99-41ffe9da1a51": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of PFS at 5 months in NCT00003199 was Stage IIIB patients, and the worst was Stage IV Disease patients.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "b8e5b983-3338-4856-9274-7d0365132280": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Statement": "Only one NCT00118157 patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "e634809e-555f-441a-9bb4-65681634fd56": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Secondary_id": "NCT01401959",
        "Statement": "Participants in NCT00118157 had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of NCT01401959.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1d616606-8980-475c-a99f-0701c26b3f4e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "NCT01401959 designates specific interventions to its patients depending on their hormone status, Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients, in contrast NCT00852930 assigns interventions randomly.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "151aec2f-0974-489b-9f6a-a72cad3bdf4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "NCT01401959 designates specific interventions to its patients depending on their tumour response, patients with complete response go to cohort A and all other in cohort B, in contrast NCT00852930 assigns interventions randomly.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9b25aa9c-bbc2-4553-a7b6-ba25251f94ee": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is only used in cohort 1 of NCT00852930,  neither cohort of NCT02308020 make use of this.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "83228dd9-4d94-4817-a497-dbbfb5905ba8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is in each cohort of NCT00852930 and NCT02308020, along with neoadjuvant chemotherapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "803c4583-0c78-4bae-b3ae-fd83ca96bab0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were no participants in cohort 1 of NCT02308020 with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "18eabd6a-c43d-4984-95d8-f63d0cfa38b2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were 23 participants in cohort 1 of NCT02308020 with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "5b5aa8af-3638-4a3e-ac92-b2ca7da0ed5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "8728d320-c931-4947-b8db-51fc555b693f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            16,
            17
        ]
    },
    "91ec8d1a-dab6-4c01-8e0e-5c6412d7e70d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in NCT00444535 achieved Progression-free Survival Rate After 12 Weeks of Study Treatment.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "b942caf9-0d3c-4518-b9fd-6b12a585f5ad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in NCT00444535 treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "887ae9dd-4107-4c84-8095-484f012c5326": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both NCT00558103 and NCT00390455 the test cohorts produced better results than the control groups.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            15
        ]
    },
    "f7e2c460-8edb-4cef-94e3-f303187d316f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both NCT00558103 and NCT00390455 the test cohorts achieved better overall response than the control groups.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            15
        ]
    },
    "a57df2fc-58f5-453c-a736-ad4acbcb9a3a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in NCT00558103 are administered with Lapatinib 1500 mg PO QD.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d6205f5f-318d-4a39-8470-18d2f6199b5e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in NCT00558103 are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1daa01b9-3b4b-4d26-8d23-15187268c854": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in NCT01293032 or NCT00849472 are required to undergo radiotherapy or a support group course.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "55938785-2a14-4721-8f6c-517a5071abd9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in NCT01293032 or NCT00849472 are required to undergo radiotherapy or surgery.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "391ba9b7-8d75-4ea0-b26b-4c1875a4233a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "More than a dozen NCT00849472 participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c29d32f2-bbdb-4db6-a48e-fed164cb7da0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "Two dozen NCT00849472 participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "14f26194-006f-4684-ab9b-0d503105faaa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in NCT00089999 had no tumor Response, than partial response, and 0 participants had a complete response.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            9,
            17
        ]
    },
    "d607a066-8530-4cdb-81c0-071c8e4a3dd4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in NCT00089999 had no tumor Response, than partial response, and only 3 patients had a complete response.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            7,
            8,
            9,
            17
        ]
    },
    "01a22904-c29a-42ab-838e-16045874bec0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by NCT01091428 results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "5e67c604-dba8-478c-b8ed-8d8d82a12f2e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by results from cohort 2 of NCT01091428, is 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a1599d0c-1e4c-475a-961d-86186d56f0b8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The NCT00296036 intervention is applied to the palms and soles twice daily, NCT00356811 participants are not administered any medication topically.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8bc27ec7-8b4f-4878-88f6-4397281f5682": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The NCT00296036 intervention is applied to the palms and soles twice daily, NCT00356811 participants are not administered any medication on the skin of the hands or feet, but rather onto the breast or chest wall.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f5d83a74-227b-41ca-abea-91059a4f6374": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "NCT00296036 administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "12ab6459-2353-4aeb-a290-8888da517bb9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "NCT00296036 administers the Urea/Lactic Acid Cream topically, twice daily, and the placebo is administered orally once a day.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "8da47770-0b35-461f-922f-b9f7691d80c8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "NCT00320411 participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6ac55c02-d300-4de1-ab06-d5b90f807fa1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "NCT00320411 participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ad9c34a0-d7b4-4dd6-86ba-4045052a521a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "NCT01448447 is testing a radiotherapy intervention whereas NCT03252145 is testing a novel hand-held medical device ",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "cab76ceb-36c8-461f-b9d5-72adce069780": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "NCT01448447 is testing a radiotherapy intervention whereas NCT03252145 is testing a novel hand-held medical device, which patients must use themselves to drain their lymph vessels.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "f41df174-922a-46b5-af39-d9df07457c1c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in NCT03252145 are required to injest any pills, whereas both cohorts of NCT00904033 must take a weekly tablet.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "42e55da3-1ffd-41c7-8ba7-e52985e7ecef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in NCT03252145 are required to injest any pills, and half the subjects in NCT00904033 must take a weekly tablet.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "2fe58d88-fc2d-4abe-bcc1-916f2f275648": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the NCT00904033 intervention, this is however a requirement for NCT03592121.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            7
        ]
    },
    "3a8626e8-f87b-4a0b-b56c-29ad4ec2335f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the NCT00904033 intervention, this is however a requirement for NCT03592121 where the intervention must be applied during sexual activity.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            7
        ]
    },
    "2122a4e3-c10a-430d-8159-1abc107bfb39": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "Unlike NCT01439711, NCT03592121 does not specify a specific dosage or frequency for its intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2a5579c1-94ba-4178-b0a5-b906aaab609a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "NCT01439711 and NCT03592121 both require their patients to receive their respective interventions on a daily basis.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            2,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "318af44c-4930-40bf-bc54-7167dba7fbca": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in NCT01439711 had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "0f4fb8ec-e6a0-45ad-bb3f-b4fa2c233073": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in NCT01439711 had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months, almost 1cm3 less than average.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "38cda728-832f-441c-9b0d-1c2e34c6e6fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "Both NCT02657889 cohorts reported identical results.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "0c2a82db-7099-4e49-8cb0-3fd84d567b6a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "NCT02657889 indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs).",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            7,
            8,
            9
        ]
    },
    "ea69dd88-63eb-448f-9dcb-ada77e206959": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "56.9% of NCT00347919 subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "83ac83ee-8f1b-4da3-9fe2-215fd33fa4b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "less than 50% of NCT00347919 subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "4ee91d94-b010-49f6-bdc3-05bec87ba556": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in NCT00320385, was lower than the median time for patients in NCT00075270.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "14e37705-1c3e-4bfd-940b-934ff716558b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "Both cohorts in NCT00320385 outperformed cohort 1 of NCT00075270 in median PFS.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "5fc53923-3028-436b-92aa-db30ff543370": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "NCT00075270 is testing a chemotherapy treatment whereas NCT01781299 is testing an implant.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "f644be6a-46c6-446e-a2f2-5608ec7d9d07": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "NCT00075270 is testing a chemotherapy treatment whereas NCT01781299 is testing a physcotherapy course.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "4870bfef-05b5-483c-a4ae-8d301bce98d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in NCT01781299 must undergo a minor surgery.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "a81acbe6-2bb4-4bc4-a0f1-6f7b43abcf67": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in NCT01781299 must commit to a regular exercise schedule.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "96f03572-541f-47da-8f7b-128a7ba9630e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "NCT03618017's intervention section does not describe the intervention dosage, frequency or duration.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d37d16c7-275a-4069-ab06-70b826b0833b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "NCT03618017's intervention section does not describe the intervention dosage, frequency or duration for cohort 2, however cohort 1 recieves placebo twice daily for two months.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "dd9453bf-fe8d-4fea-8c6e-65a764da507d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "NCT01905592 only defines intervention dosage for cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "11399c4f-ac8d-412b-b5d0-649296acbb3d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "both NCT01905592 cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "afa61d2f-0971-4457-989b-42e306c73a65": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy is used in all cohorts of NCT00574145 and NCT03167359.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d1ff324a-da0d-486e-968a-3a9d2ae33bd7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy and healing touch therapy is used in all cohorts of NCT00574145 and NCT03167359.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "47c2d437-28a3-4895-b689-a09e1bd68761": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Between all cohorts in NCT03167359 and NCT01385137 Omega-3-fatty Acids are only used in one cohort.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "19b339b0-9102-467d-afd8-45e56ff2080b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in  NCT01385137. but not NCT03167359.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b3169781-9213-430c-93a6-dd5ec1cb58ac": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in NCT00593346, but there is only a test group in NCT01385137.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8615b4dc-2f4e-40a7-94cc-45df4f889a0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in cohort 2 of NCT00593346, but there is only a test group in NCT01385137.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4a9a14a0-d529-4d33-b334-4e25a90c1dd6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "NCT00593346 treament last for a shorter period of time than the NCT00902330 treatment.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5dca784f-4d3b-4fbe-ab3f-20e7644e08c3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "NCT00593346 treament last for a shorter period of time than the NCT00902330 treatment, but is administered much more often.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "1f5fb94c-3c6b-4ec5-ba6c-a61cbbd41b1f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "Cohort 2 of NCT00902330 is the control group and cohort 1 is the control group in NCT00952731.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8d1b5b7e-170c-4a67-a960-97ddcadaf8e1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "NCT00902330 and NCT00952731 only have test cohorts in their studies.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "4c41dcd7-d059-4331-bc8e-8da1122ca4d7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in NCT00952731 and NCT00956813 but receive daily placebo doses.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "167c3923-a493-4799-8d79-c134cd508380": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in NCT00952731 and NCT00956813 but receive daily placebo doses PO.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "69280108-7b30-46fc-a07a-c090cccdb6e1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All NCT00956813 subjects are required to take the intervention PO daily.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "938341ef-2b42-4a24-a291-23bd6f70f3b1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All NCT00956813 subjects are required to take the intervention tablet PO daily.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2c1b47cf-ca52-4402-b0d5-4113d412703f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "NCT00376597 do not receive any intervention by IV, orally or by surgery during the study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4551b7cf-b1ca-450d-808a-db8f7257e8e6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "NCT00376597 all undergo surgery twice, first at 2 weeks and then again a month later.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "61057d56-8d26-4ba4-9660-802d1fed0b06": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "NCT03374995 subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            3
        ]
    },
    "5738b3ac-7ba7-4330-8ac8-042277cb8266": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "Some NCT03374995 subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by ubcutaneous injection.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            3
        ]
    },
    "60f2135d-ab11-49dc-a046-66f79269738d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "NCT01819233 and NCT00820222 do not test the same modalities of cancer treatments.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "97f14724-4d85-4b2d-bf4b-6d21ebf9cc93": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "NCT01819233 and NCT00820222 interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "b54fd02f-0a98-4921-b9cf-d173dbfcb7eb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All NCT01819233 participants must reduce the number of calories in their diets by a quarter throughout the duration of the study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "12349a82-7c0d-4a36-9108-142aaa149ee2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All NCT01819233 participants have the same number of calories in their diets throughout the duration of the study.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "59f6d5ed-fccd-4bc5-b4ef-03f75f2f3da8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The NCT01466270 placebo group had a better mean retention than the donepezil hydrochloride PO QD group.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            9,
            17
        ]
    },
    "c1544de6-be46-47b4-9c8c-ec998f55552a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The NCT01466270 placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            8,
            9,
            17
        ]
    },
    "17ba8cc9-049a-47cb-9c91-d54ca52b7de1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All NCT00332709 participants receive the same dose of Letrozole, only certain patients in NCT00659373 are administered Exemestane.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "1ce2810f-7038-4939-80cf-8d800e9f2b06": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All NCT00332709 participants receive the same dose of Letrozole, and all patients in NCT00659373 are administered the same dose of Tamoxifen.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "fcb2a233-bb08-4549-b9b2-19bcbbdc53ac": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "NCT00659373 has a 5 year long intervention, the duration of NCT02202252 is not specified in the intervention section.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            3,
            6,
            7,
            8,
            3,
            10,
            3
        ]
    },
    "286ae68c-9bf8-441e-a350-ed2c51896201": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "NCT00659373 has a 5 year long intervention, the duration of NCT02202252 is only a single day after removal of the drains.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            3,
            6,
            7,
            8,
            3,
            10,
            3
        ]
    },
    "9f489844-8df5-446e-854d-6612150c7872": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of NCT02202252 is the insertion of an additional negative pressure drain for patients in cohort 2.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            3,
            6,
            7,
            8,
            3,
            10,
            3
        ]
    },
    "21e2ad96-c9ab-4154-b78b-49ddadaa7d57": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of NCT02202252 is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            3,
            6,
            7,
            8,
            3,
            10,
            3
        ]
    },
    "1a8490a8-942c-4225-9d3c-aca6f6580145": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of NCT02312622 receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00b2 as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3
        ]
    },
    "16817534-ecc9-4aa4-97ba-adb56e06ae7a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of NCT02312622 receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00b2 as monotherapy once every 21 days , the differences between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            3
        ]
    },
    "1bdc2bd3-1317-415d-aba8-804abf4535df": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "NCT00911898 does not explain its intervention in the intervention section.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7e5c1919-9099-4ed0-b66d-6e0086326a66": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Secondary_id": "NCT02352779",
        "Statement": "NCT00911898 and NCT02352779 do not explain their interventions in the intervention section.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            3,
            5,
            6
        ]
    },
    "c2df6a8c-7a3e-4c30-b163-d1d753c319de": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in NCT02352779 is once cohort recieves a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in NCT00263588 is patient characteristics.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            3,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6c8d98aa-f21c-4b10-875f-4524a19f0947": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in NCT02352779 is once cohort recieves a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in NCT00263588 is patient characteristics.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            3,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "72c4e5f9-a27c-40af-8f2e-65b06376384c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "The majority of NCT00263588 subjects either had Progressive disease or undetermined CNS objective response rate.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            11,
            12,
            23,
            24,
            25,
            26
        ]
    },
    "aa1c5a14-d9ed-463d-97f7-1e96a9cc4984": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "All NCT00263588 subjects either had Progressive disease, Complete CNS objective response rate or partial response rate.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            11,
            12,
            23,
            24,
            25,
            26
        ]
    },
    "be468424-8fa7-4b11-89a4-88a8a23dd467": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of NCT01376349 receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in NCT01912612 only cohort 1 recieves Duloxetine 30 mg daily.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "6b8bc1cf-d547-41ff-8385-689032765eb9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of NCT01376349 receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in NCT01912612 only the cohort without pain recieves Duloxetine 30 mg daily.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "63f5f258-2963-46b8-8488-38c1f8d4bfe3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In NCT01912612 only 1 cohort is administered the intervention, whereas in NCT02392611 both cohorts receive the intervention, but cohort 2 recieves more than double the dose of cohort 1.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "04b40cad-e626-4c07-8494-fe699ab8f8b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In NCT01912612 only 1 cohort is administered the intervention, whereas in NCT02392611 both cohorts receive the same intervention.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "da51ceb1-f0f2-4871-b6ac-1e5985b838e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "NCT02392611 cohorts are not seperated based on patient characteristics.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "01c0b632-7ed0-4039-bd20-49efe9a444c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "In NCT02392611 cohort 1 patients must have failed or be intolerant to standard therapy, or have no standard therapy available, and cohort 2 patients must respond well to standard therapy.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "0840559c-ee7d-4756-8d21-993301f7d8f8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in NCT02556632 and NCT01869764 undergoes Laboratory Biomarker Analysis.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            4,
            5
        ]
    },
    "021a95ec-caa3-4aa5-80cd-14e813d9bc12": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in NCT02556632 and NCT01869764 undergoes Laboratory Biomarker Analysis and completes a Questionnaire.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            4,
            5
        ]
    },
    "90ba3e57-ae38-45b2-8ed3-a2ff4fcba9e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts NCT02556632 apply the topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            4,
            5
        ]
    },
    "0a2efdaf-5dcd-4d2f-8ef2-03cda5c693d3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts NCT02556632 apply the same topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            4,
            5
        ]
    },
    "522c11d9-7cf9-4a17-8d88-dbae870758ee": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither NCT02176083 or NCT0306117 use chemotherapy or radiotherapy in their intervention.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            4
        ]
    },
    "c33fe47f-dd04-4ca1-8419-dde6e82545df": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither NCT02176083 or NCT0306117 use chemotherapy, adverse event management courses or radiotherapy in their intervention.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            4
        ]
    },
    "58e4306b-6d7e-46c9-b69d-24a9fb95c0f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of NCT03098550 does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of NCT03061175 has the same intervention for the full study.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "a7cb0d1e-c2f8-4934-b1a4-13ca1b99cc08": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of NCT03098550 does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of NCT03061175 recieves a consistent dose of Daratumumab for the full study.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7454c063-88c5-4ce7-aac0-a52912a03d1a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results section indicates there were no patients in NCT03098550 with 0 adverse events.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "efc7e50a-fe04-4e7e-8efe-6d11381f0c92": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results from cohort 3 of NCT03098550 were inconclusive.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            8,
            15
        ]
    },
    "59fec4e4-9ff6-42cd-bde1-fe0893670619": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in NCT02595372 treated with High Dose Omeprazole did not have Pathological Complete Response.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e2912650-e004-42b4-ac73-77bb756b855b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in NCT02595372 treated with Minocycline Hydrochloride did not have Pathological Complete Response.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "b04181c3-b07b-4dc6-9d2b-66fbe42ecf10": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of NCT02667626 and NCT02297412 are control groups.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "ea50679c-97b6-4913-bb96-618a9ac3841d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of NCT02667626 and NCT02297412 are control groups, receiving a placebo tablet PO BID.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "84bdbd0d-3692-4ee2-92b8-1d10d56fa9f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "NCT02667626 is testing a web-based educational tool and NCT01669343 is testing the effects of using Adjuvant Letrozole on Post-menopausal Women.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d9cba978-a012-4bb3-bac9-82727598e751": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "NCT02667626 is testing a web-based educational tool and NCT01669343 is testing a medical device on Post-menopausal Women.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "c0b0d07e-2b24-41c6-8395-e7202d491148": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "NCT01669343 and NCT00146172 do not have the same duration of intervention administration.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "53c981a4-0270-4e3c-9b82-ed75d845f944": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "NCT01669343 administers letrozole for 28 days, whereas NCT00146172 administers is intervention over 4 cycles of 21 days.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "765da70b-970b-4104-8098-a3fa412440c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of NCT00146172 recieves less than 60% of cohort 2's dose of LA-EP2006.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d82d98fb-7487-42ad-a891-cd7f8140b4e2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of NCT00146172 recieves less than 60% of cohort 2's dose of Neratinb.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ecd06eb0-b791-415f-a457-415c7304200d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Neither cohort of NCT02006979 need to perform low intensity exercise prior to each cycle of anthracyclines.",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "bdae74cb-408e-4366-90f4-11764ce5def7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Only one cohort of NCT02006979 needs to receive manual lymph drainage prior to each cycle of anthracyclines.",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    }
}